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I. Abstract  
Zinc is integral for β-cell function in glycaemic control. Intracellular zinc concentrations 
are regulated by buffering and membrane transportation mediated by the ZIP (14 
paralogues; SLC39A) and ZnT (10 paralogues; SLC30A) families of transporters, which 
flux zinc into and out of the cytosol, respectively. The predominantly β-cell-specific 
paralogue ZnT8 (SLC30A8) uptakes zinc into granules, where it is essential for normal 
insulin maturation and exocytosis. Deregulation of zinc and its transporters is associated 
with β-cell dysfunction and Type 2 Diabetes development: the non-synonymous 
polymorphism rs13266684 in SLC30A8 confers differential zinc transporting efficiencies 
and is linked to disease risk, and many type 2 diabetic patients and animal models of 
diabetes present with hypozincaemia. We hypothesised that ZIP transporters are 
coordinated with ZnT8 to mediate β-cell zinc content, phenotype and function in response 
to the hyperglycaemia and hypozincaemia present in Type 2 Diabetes. We used a 
systematic approach to identify Slc39a1 in rodent, and SLC39A6, SLC39A7, SLC39A9, 
SLC39A13 and SLC39A14 in human and rodent as potentially biologically important for 
β-cell phenotype and function. We showed that both prolonged stimulation and 
extracellular zinc depletion, representative of hyperglycaemia and hypozincaemia in vivo, 
respectively, lower the zinc content of MIN6 β-cells and disrupt expression of multiple 
Slc39a paralogues and zinc-responsive markers for β-cell identity. Moreover, we 
demonstrated that ZIP6 and ZnT8 are involved in maintaining β-cell zinc content, 
survival and identity in response to zinc depletion, and identified potential co-regulation 
of ZnT8, ZIP6 and ZIP9 by the major β-cell transcription factor PDX-1. Critically, these 
data show that ZIP6 and ZnT8 are involved in maintaining β-cell zinc homeostasis and 
that stresses present in Type 2 Diabetes induce loss of β-cell zinc, which may alter cellular 
phenotype and reduce survival. 
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1. General Introduction 
1.1. Diabetes  
Diabetes comprises of a heterogeneous group of metabolic disorders characterised by 
long-term hyperglycaemia and impairment of carbohydrate, lipid and protein metabolism 
[1]. In 2015, there were a total of 415 million diabetic sufferers and this is forecast to 
increase to affect >1 in 10 globally by 2040. Diabetes represents a leading cause of 
morbidity and mortality worldwide and is estimated to account for 2.5 to 15% of 
healthcare budgets, depending on local prevalence and treatments available [2]. 
 
1.1.1. Classification and clinical diagnosis   
The majority of diabetic cases can be classified into two etiopathogenic categories, 
together accounting for ~99% of incidences: Type 1 diabetes (previously insulin-
dependent diabetes mellitus or juvenile-onset diabetes) and Type 2 diabetes (previously 
non-insulin dependent diabetes mellitus or adult-onset diabetes). Type 1 Diabetes, which 
accounts for 5-10% cases, is an immune-mediated disorder whereby cell-mediated 
destruction of insulin-secreting pancreatic β-cells causes absolute insulin deficiency and 
requires exogenous insulin to normalise plasma glucose levels [3]. Type 2 Diabetes, 
which accounts for 90-95% of cases, results from inadequate β-cell insulin secretion in 
response to increased insulin resistance at peripheral tissues, despite β-cells remaining 
largely intact. Other categories of diabetes include gestational diabetes, which describes 
glucose intolerance arising during pregnancy, and maturity-onset diabetes of the young 
(MODY), which arises from monogenetic defects in pancreatic function [1]. These are 
listed in Table 1.1.  
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Table 1.1. Genes involved in monogenetic forms of diabetes. HNF4A, hepatocyte 
nuclear factor 4A; GCK, Glucokinase; HNF1A, hepatocyte nuclear factor 1A; PDX-1, 
pancreatic and duodenal homeobox 1; HNF1B, hepatocyte nuclear factor 1B; INS, 









Transcription factor involved in pancreatic 
development and function 
GCK 
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Transcription factor involved in pancreatic 




Transcription factor involved in pancreatic 




Transcription factor involved in pancreatic 




Transcription factor involved in β-cell development 
and insulin gene transcription 
INS <1% Insulin hormone 
CEL <1% 
Digestive enzyme with role in cholesterol ester 
digestion 
PAX4 <1% 
Transcription factor involved in pancreatic 
differentiation and function 
 
 
Clinical presentation and disease progression vary substantially between individuals 
suffering from all diabetic categories and classification depends on clinical presentation 
at diagnosis, prompted by symptoms including polydipsia, palpitation, dyspnoea, 
frequent urination and blurred vision [5]. Diagnostic tests are based on the haemoglobin 
A1c criteria, which measures glycated haemoglobin in the blood, or plasma glucose 
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criteria, which measures either fasting plasma glucose or plasma glucose two hours 
following 75g glucose oral uptake (oral glucose tolerance test) [6].  
1.1.2. Type 2 Diabetes  
Type 2 Diabetes is a multifactorial disorder attributed to complex pathological sequences 
of environmental and genetic factors. Prediabetes describes the state of impaired fasting 
blood glucose concentrations and/or glucose intolerance, resulting in peripheral insulin 
resistance, with Type 2 Diabetes developing in the subset of individuals who fail to adapt 
and regain glycaemic control [7]. Recent rises in type 2 diabetic incidences are attributed 
to population growth, aging, urbanisation, high calorie diets, increased prevalence of 
obesity and decreased physical activity [8]. However, genetic contributors are 
additionally important for disease development. Estimations for Type 2 Diabetes 
heritability range from 30-70% [9, 10], with concordance rates predicted to be 76% 
between monozygotic twins [11]. In the US, a total of 30-50% of diabetic adults do not 
meet individualised targets for glycaemia, blood pressure or lipid control despite 
structured management plans, accredited to underlying genetic factors [12]. Abnormal 
serum statuses of trace elements including zinc, magnesium and manganese are 
additionally associated with disease state and may contribute to onset and progression 
[13]. 
Type 2 Diabetes can lead to potentially disabling macro- and micro-vascular 
complications. These are characterised into two groups: short-term metabolic acute 
complications (including hyperglycaemia and ketoacidosis) and long-term chronic 
complications (including diabetic nephron-, neuro- and retinopathy, coronary heart 
disease, peripheral vascular disease and cancer), largely resulting from accumulated 
organ damage caused by chronic hyperglycaemia. Type 2 Diabetes therefore represents a 
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much larger burden for the healthcare system than simply disease treatment and to the 
economy as a result of lost productivity [14]. 
1.2. The endocrine pancreas  
The endocrine pancreas consists of aggregates of cells known as the islets of Langerhans, 
which account for ~2% of the human adult pancreas [15]. Islets are oval in shape with 
diameters of 100-200µm and consist of ~1000 endocrine cells: interspaced insulin-
secreting β-cells and glucagon-producing α-cells surrounded by non-β-cell mantles 
containing somatostatin-producing δ-cells and pancreatic polypeptide cells [16]. 
Together, insulin and glucagon regulate plasma glucose concentrations: insulin promotes 
glucose uptake at peripheral tissues and glucagon stimulates hepatic glycogenolysis and 
gluconeogenesis [17]. 
1.2.1. Pancreatic β-cells and insulin secretion 
β-cells comprise ~50% of human islets [17] and have an estimated turnover of three 
months [18]. β-cells synthesise and secrete insulin primarily in response to extracellular 
glucose [glucose-stimulated insulin secretion (GSIS)], but also in response to other 
hormones, neuronal inputs, nutrients and the incretins glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is secreted from the 
distal bowel and colon enteroendocrine cells, and GIP from duodenal K cells of the 
proximal small intestine, each in a nutrient-dependent manner to potentiate β-cell function 
and viability [19]. Inability of β-cells to respond appropriately leads to secretory 
dysfunction and systemic hyperglycaemia [20].  
GSIS is initiated in a transcription-independent manner within minutes [21]. High 
concentrations of extracellular glucose stimulate β-cell glucose uptake via the low affinity 
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glucose transporter 1 in human or glucose transporter 2 (GLUT2) in rodent [22]. 
Cytosolic glucose is phosphorylated to glucose-6-phosphate by glucokinase [23], which 
is synthesised into pyruvate via the process of glycolysis. Pyruvate is metabolised by 
pyruvate dehydrogenase to generate acetyl-CoA. Acetyl-CoA enters the tricarboxylic 
acid cycle in mitochondria to create adenosine triphosphate (ATP) [24]. Elevated 
ATP/adenosine diphosphate (ADP) ratios hyperpolarise ATP-sensitive potassium ion 
(K+) channels (KATP channels; KCNJ11), causing membrane depolarisation. 
Depolarisation activates L-type voltage-gated calcium channels (L-VGCC) to facilitate 
calcium ion (Ca2+) influx, and subsequent exocytosis of insulin secretory granules [25]; 
approximately 60% of the β-cell surface participates in granule fusion [26]. An overview 
of GSIS is depicted in Fig 1.1. Although islet structure is not imperative for β-cell 
function, insulin secretion is higher in islets compared to equivalent numbers of single β-
cells. Connexin36 gap junction proteins between β-cells allow stimulated cells to 
hyperpolarise adjacent electrically coupled cells to increase overall magnitudes of Ca2+ 
signalling and insulin secretion [27, 28].   
Insulin secretion occurs as a biphasic response: an initial spike initiates after 5-6 minutes 
followed by a rapid decrease (first phase), proceeded by a prolonged increase over ~60 
minutes (second phase) [29]. Glucose further primes time-dependent potentiation of 
insulin secretion whereby glucose exposure enhances secretion in response to additional 
stimuli in a KATP channel-independent manner [24]. The secreted insulin is first 
transported through the portal vein to the hepatic system to mediate storage of excess 
glucose as glycogen. Increases in plasma insulin in the liver activate glycogen synthesis 
[30] and inhibit transcription, the activities of key gluconeogenic enzymes [31] and 
lipolysis [32]. Deletion of hepatic insulin receptors (IR) in mouse results in glucose 
intolerance and insulin resistance [33]. The remaining insulin is transported through the 
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bloodstream to target tissues where IR binding initiates signalling cascades to stimulate 
glucose uptake [34]. 
 
 
Fig 1.1. The series of events underlying GSIS in β-cells. Glucose is taken up into β-
cells by GLUT1 in human or GLUT2 in rodent and is metabolised to pyruvate via the 
process of glycolysis. This leads to increased activity of the tricarboxylic acid cycle in 
mitochondria, which increases cellular ATP. Elevated ATP/ADP ratios inhibit KATP 
channels, resulting in cell membrane depolarisation and subsequent opening of L-
VGCCs. Influx of Ca2+ triggers insulin granule exocytosis and insulin/Zn2+ co-release 




1.2.2. Pancreatic β-cell mass  
Adult β-cell mass is plastic and can be adjusted in response to physiological and 
pathological states to maintain equity between insulin supply and demand; failure to 
expand appropriately results in hyperglycaemia and peripheral insulin resistance. In non-
diabetic obesity, islet number and β-cell proportion increase, however these parameters 
decrease during diabetic onset and islets show disorganised structures [36]. A previous 
study showed that post-mortem islets from type 2 diabetic patients present with a 22% 
reduction in density and a 30% reduction in total mass compared to matched controls 
[37]. A progressive decline in β-cell function precedes diabetic onset, however it is 
unlikely the decrease in β-cell mass is entirely accountable [38].   
β-cell hypertrophy and proliferation are governed by availabilities of glucose, nutrients, 
growth factors and incretins [19] balancing rates of proliferation, neogenesis and 
apoptosis; the contribution of each varies throughout postnatal life. It remains unclear 
which mechanism(s) primarily drive diabetes-associated decreases in β-cell mass, 
although age-related increases in apoptosis partially explain increased diabetes 
susceptibility in the elderly [39]. β-cell apoptosis is increased in both lean and obese 
diabetic and obese non-diabetic patients, compensated for by appropriate increases in 
replication, neogenesis and cell size in the latter [36]. Increases in β-cell apoptosis are 
driven by combinations of ER stress [40], chronic hyperglycaemia [41-43], chronic 
hyperlipidaemia [44, 45], oxidative stress [46, 47], cytokines [48] and deposition of 
amyloid fibrils [49].  
Several important signalling pathways mediate β-cell survival and mass, including the 
insulin receptor substrate-2/ phosphatidylinositol-3 kinase/ AKT (IRS-2/PI3K/AKT) 
cascade, the RAS/ RAF/ mitogen-activated protein  kinase kinase/ extracellular-signal-
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regulated kinase (RAF/MEK/ERK) cascade, and the mammalian target of rapamycin/ S6 
kinase/ ribosomal protein S6 (mTOR/S6K/RPS6) cascade [50]. These cascades can all be 
impacted by zinc (illustrated in Figs 1.2-1.4 and discussed in section 1.5.2). The roles of 
these signalling cascades in β-cells are detailed below.  
1.2.2.1. IRS-2/PI3K/AKT signalling  
IRS-2/PI3K/AKT cascades mediate β-cell mass in response to growth factors, insulin, 
incretins and glucose [51]. IRS-2, an intracellular tyrosine kinase downstream of IRs and 
insulin-like growth factor receptors (IGFR), is especially potent at promoting β-cell 
survival; decreased IRS-2 signalling increases apoptosis and mutations are linked to Type 
2 Diabetes development [36]. IRS-2 phosphorylation activates PI3K, which converts the 
phosphatidylinositol (4,5) P2 phosphate (PIP2) into phosphatidylinositol (3,4,5) P3 
phosphate (PIP3).  PIP3 recruits AKT and phosphoinositide-dependent kinase-1 (PDK1) 
to the plasma membrane [52] where PDK1 phosphorylates and activates AKT [53]. 
Additional phosphorylation of AKT by mTOR complex 2 (mTORC2; 
mTOR/Rictor/GβL) is required for full activation [54]. In β-cells, AKT plays important 
roles in the adaptive response to increased insulin demand [51] through regulating insulin-
mediated glucose transport, protein and glycogen synthesis, proliferation, cell growth, 
differentiation and survival; an 80% reduction in AKT signalling causes defective insulin 
secretion without affecting β-cell mass [55]. Moreover, mice overexpressing 
constitutively active AKT (caAKTTg) exhibit increased β-cell mass, proliferation and 





Fig 1.2. IRS-2/PI3K/AKT signalling pathways. Activated IR or IGFR tyrosine kinase 
receptors phosphorylate and activate IRS-2, which binds the regulatory subunit (p85) of 
PI3K via SRC homology 2 domains. PI3K activation is inhibited by PTEN. Activated 
PI3K phosphorylates and activates PIP2 to form PIP3, which recruits AKT and PDK1 to 
the plasma membrane where PDK1 activates AKT. The mTORC2 complex additionally 
phosphorylates AKT for full activation. AKT is inactivated by TRB3. AKT inhibits 
downstream proteins regulating cellular survival. AKT signals via glycogen synthase 
kinase 3 (GSK-3)/Cyclin D1 and FOXO/p27 to mediate cell cycle progression; 
BAD/BCL-2 to mediate apoptosis and TSC1/2/RHEB/mTORC1 to mediate cellular 
growth. IR/IGFR are inactivated through dephosphorylation by protein tyrosine 
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phosphatases (PTPs). Zinc activates IR/IGFR signalling through inhibiting PTPs, PTEN 
and TRB3. Black arrows: A activates B. Red lines: A inhibits B. Adapted from [58, 59]. 
 
1.2.2.2. mTOR/S6K/RPS6 signalling  
mTOR cascades regulate mRNA translation to promote β-cell growth and proliferation 
in response to nutrients and growth factors [51]. An overview is depicted in Fig 1.3. 
mTOR is negatively regulated by TSC1/2 and the small G protein RHEB and is activated 
by AKT and ERK. AKT and ERK phosphorylate TSC2, disrupting the GTPase activating 
function (GAP activity) of TSC1-TSC2 to favour RHEB-GTP, which dissociates from 
and activates mTOR [60]. AKT further maintains AMP/ATP ratios in response to insulin 
and serum; elevated AMP activates the ATP sensor 5' AMP-activated protein kinase 
(AMPK) to inhibit induction of mTOR activity by growth factors and to phosphorylate 
and activate TSC2 [61] 
mTOR forms two distinct complexes: mTORC1 (mTOR/Raptor/GβL) and mTORC2. 
mTORC1 phosphorylates and activates the eukaryotic initiation factor 4 binding protein 
4E-BP1/2 and S6K1/2 [62]. S6K1/2 activation initiates multiple steps in protein synthesis 
including translation via RPS6, a component of the 40S ribosome. Both S6K1- and S6K2-
mediated phosphorylation is required for full RPS6 activity. Mice harbouring knock-in 
mutations at all RPS6 phosphorylatable serine residues present with impaired glucose 
tolerance, lowered pancreatic insulin levels and increased insulin sensitivity, but do not 
exhibit differences in β-cell mass [63].  
mTORC1 signalling is critical for regulating β-cell mass. Inhibition of mTOR by 
rapamycin reduces AKT-induced β-cell proliferation by destabilising cyclin D2, a critical 
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cell cycle regulator [64], and enhanced signalling increases β-cell mass to promote 
hyperinsulinemia [65]. Mice with conditional TSC2 knockout in β-cells present with 
hypoglycaemia, improved glucose metabolism and increased β-cell proliferation [66]. 
However, chronic S6K activation negatively regulates IRS, dampening PI3K/AKT 
cascades [67].   
 
 
Fig 1.3. mTOR signalling pathways. Activated AKT phosphorylates and inhibits 
TSC1/2. Low energy conditions increase AMP/ATP ratios, which activate AMPK to 
phosphorylate and activate TSC1/2. TSC1/2 inhibits the GTPase RHEB, which positively 
regulates mTORC1 activity. mTORC1 is further activated by signalling via ERK1/2/RSK 
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cascades. mTORC1 signals to regulate autophagy, cell growth, lipid metabolism, 
mitochondrial metabolism, insulin signalling, IGF2 mRNA and RNA expression. 
mTORC2 is predominantly regulated by unknown pathways in response to amino acids 
and growth factors. Activated mTORC2 is needed for full AKT activation. mTORC2 
regulates ion transport and the actin cytoskeleton. Black arrows: A activates B. Red lines: 
A inhibits B. Green dotted line: activation by zinc (intermediates may be present). 
Adapted from: [68]. 
 
1.2.2.3. RAS/RAF/MEK/ERK signalling  
Growth factors and mitogens signal via RAS/RAF/MEK/ERK mitogen-activated protein 
kinases (MAPK) cascades to mediate gene expression, proliferation and apoptosis [69]. 
An overview is depicted in Fig 1.4. The GTP-binding protein RAS is activated by 
SRC/GRB2/SOS coupling complexes downstream of cytokine, growth factor and 
mitogen receptors. RAS-GTP recruits the protein kinase RAF, of which three isoforms 
exist, to the plasma membrane. RAF is regulated by RAS and other kinases and 
scaffolding proteins [69], including the zinc transporter ZnT1 [70], to activate MEK, the 
downstream target of which is predominantly ERK [71]. ERK1/2 phosphorylates and 
activates p90RSK (RSK), leading to cAMP response element binding protein (CREB) 
activation [72], and targets additional substrate via downstream scaffolds and/or nuclear 
translocation. ERK induces expression of proteins involved in cell cycle progression, and 
prolonged activation leads to cellular growth and subsequent cell cycle arrest. ERK 
further mediates proteins involved in apoptosis including BAD, BIM, MCL-1, caspase 9 
and BCL-2 [73, 74] and promotes activation of nuclear factor immunoglobulin K chain 
enhancer in B cells (NF-KB) by activating inhibitor KB kinase [75].  
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RAS/RAF/MEK/ERK cascades are induced by reactive oxygen species (ROS) that 
influence the activities of growth factor receptors, such as epidermal growth factor 
receptor (EGFR) and platelet-derived growth factor receptor (PDGF-R), in a ligand-
independent manner [76]. ROS further inhibit Cys-dependent PTPs to prevent 
dephosphorylation of EGFRs and PDGF-Rs and promote signalling [77, 78], possibly via 
inducing increased cytosolic zinc, which inhibits the activities of PTPs [79]. ROS 
additionally target both RAS and c-SRC to induce ERK1/2 signalling independent of 
RAS [80].  
In human islets, mouse islets and MIN6 cells, RAS/RAF/MEK/ERK signalling primarily 
occurs via RAS-1 and activates ERK-dependent pathways involving Ca2+-dependent 
phosphorylation events [81]. ERK1/2 activation in β-cells is required for maximum 
glucose-induced insulin transcription [82] and stimulates p70RSK to trigger mitogenesis 
[50]. The β-cell transcription factor hepatocyte nuclear factor 4A (HNF4A) is required 
for RAS/RAF/MEK/ERK-mediated expansion of β-cell mass [83] and stimulates 
mitochondrial energy production to compensate for expenditure linked to GSIS [84]. In 
β-cells, sustained ERK1/2 activation in response to GLP-1 is dependent on continued L-
VGCC-induced Ca2+ signalling [85], which promotes cAMP-initiated activation of 







Fig 1.4. RAS/RAF/MEK/ERK signalling pathways. RAS/RAF/MEK/ERK pathways 
are activated by growth factor and integrin binding to receptor tyrosine kinases (RTK). 
SRC/SOS/GRB2 RTK coupling complexes recruit RAS, which is activated by GTP-
binding. RAS-GTP recruits and activates RAF, which subsequently activates MEK1/2 to 
phosphorylate and activate ERK1/2. Multiple pathways converge to mediate ERK1/2 
activity including signalling via the integrin receptor coupling complex SRC/FAK, which 
activates MEK1/2 via RAC1 and PAK, and via PI3K activation. Activated ERK1/2 
regulates numerous downstream pathways including RSK, to mediate cellular growth, 
survival and proliferation; Cyclin D to mediate cell cycle regulation; apoptotic regulatory 
proteins; and a vast array of transcription factors. ERK1/2 exhibits autoregulation through 
activation of SPRY and DUSP, which inhibit RAS-GTP. Zinc mediates ERK1/2 activity 
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through targeting upstream proteins. Black arrows: A activates B. Red lines: A inhibits 
B. Green dotted line: activation by zinc (intermediates may be present). Adapted from: 
[87, 88]. 
 
1.2.3. Regulation of β-cell phenotype  
Complex interplay between multiple transcription factors is required for β-cell 
differentiation and maintenance of phenotype. Differentiation occurs primarily during 
embryogenesis, controlled by temporal expression of transcription factors including 
pancreatic and duodenal homeobox 1 (PDX-1), NKX homeobox 1 (NKX6.1), 
neuorgenin-3 (NGN3) and neuronal differentiation 1 (NEUROD1) [89] (Fig 1.5). The 
mature β-cell phenotype is majorly regulated by PDX-1, MAF BZIP transcription factor 
A (MAFA) and NKX6.1 in combination with forkhead box A1 (FOXA1), forkhead box 
A2 (FOXA2), forkhead box O1 (FOXO1), hepatocyte nuclear factor 1A (HNF1A), 
hepatocyte nuclear factor 1B (HNF1B), HNF4A, MAF BZIP transcription factor B 
(MAFB; only primates), NEUROD1, NK2 homeobox 2 (NKX2.2), paired box 4 (PAX4) 








Fig 1.5. Transcription factors governing differentiation of β-cells from foregut 
endoderm progenitors. Adapted from [90]. 
 
1.2.3.1. PDX-1 
The homeodomain protein PDX-1 is the major transcription factor in β-cells and 
represents a key marker for the endocrine pancreas [91]. PDX-1 is essential for 
differentiation of all endocrine cells, however high expression is confined to β-cells in 
mature islets [92, 93]. PDX-1 knockout is embryonically lethal [94] and hypomorphic 
variants containing regulatory sequence deletions prevent development of the endocrine 
pancreas [95]. Heterozygous PDX-1+/- mice present with abnormal islet architecture, 
impaired insulin secretion, increased β-cell apoptosis and downregulation of GLUT2 [96, 
97]. PDX-1 interacts with specific co-factors to tightly regulate β-cell gene expression, 
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including NEUROD1 to mediate insulin [98, 99] and hepatocyte nuclear factor 6 to 
mediate NGN3 [100]. PDX-1 further regulates β-cell proliferation, in part through 
targeting FOXO1 downstream of IRs and IGFRs [101]. 
1.2.3.2. MAFA 
MAFA is highly expressed in mature β-cells [102] where it is critical for maintaining  
cellular phenotype; loss of MAFA promotes β-cell dedifferentiation [103]. Decreased 
MAFA expression and/or DNA-binding ability induces abnormal islet morphology [103] 
and is characteristic of most compromised β-cells in human type 2 diabetic islets [104]. 
MAFA-/- mice are glucose intolerant and develop age-dependent diabetes [105]. MAFA 
acts as a potent activator of insulin transcription through binding at the conserved 
C1/RIPE3b element in the promoter, interacting directly with PDX-1 and NEUROD1 
[106], and mediates expression of other important β-cell genes including GLUT2, the 
GLP-1 receptor (GLP-1R) and prohormone convertase 1/3 [107]. MAFA mRNA 
expression is regulated by FOXO1 in response to glucose and oxidative stress [108] and, 
specifically in β-cells, by PDX-1, FOXA2 and NKX2.2 at an upstream cis-regulatory 
region [109]. MAFA mRNA stability is further mediated post-transcriptionally in 
response to oxidative stress [107]. However, MAFA is not involved in specification of 
endocrine cells during development or initial differentiation [110, 111].  
1.2.3.3. NKX6.1 
NKX6.1 is a homeodomain transcription factor restricted to β-cells within the mature 
pancreas [112]. In both human and rodent, decreased NKX6.1 expression [113, 114] and 
variants identified through Genome-Wide Association Studies (GWAS) [115] result in 
loss of β-cell identify and diabetes development. NKX6.1 is necessary to confer β-cell 
identity to differentiating progenitors [116] and stimulates islet proliferation independent 
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to PDX-1 [92]. NKX6.1 expression is controlled at the transcriptional level by PDX-1 
and NKX2.2, and at either the post-transcriptional or post-translational level since 
NKX6.1 mRNA but not protein can be detected within mature α-cell lines [117].  
1.2.4. Loss of β-cell identity 
Loss of β-cell phenotype, function and mass are early indicators of β-cell failure. 
Differentiated endocrine cells are not terminally differentiated and can, under certain 
conditions, transdifferentiate into other hormone-expressing cell types. In human, 
pancreatic α- to β-cell ratios increase following Type 2 Diabetes onset [118], the major 
factor promoting loss of β-cell identity being glucotoxicity [119]. 
Loss of markers involved in maintaining β-cell specification alter cellular function and 
identity. NKX6.1-deficient β-cells transdifferentiate to acquire molecular characteristics 
of δ-cells [120] and FOXO1-deficient cells dedifferentiate to represent a distinctive pre-
β-cell differentiation stage [114]. MAFA null mice exhibit reduced β- to α-cell ratios, and 
β-cells contain ‘empty’ secretory granules due to reduced insulin synthesis [103]. 
Heterozygous mutations in PAX6 impair glucose tolerance and β-cell-specific 
inactivation in adult mice repress key β-cell genes including Ins2, Slc30a8 and MafA, 
upregulate genes usually ‘disallowed’ in mature β-cells such as Slc16a1, and promote 
progressive hyperglycaemia [121]. Liver kinase B1 and AMPK maintain β-cell identity 
through surpassing pathways linked to other cell types (including neuronal and hepatic) 
and loss of function induces expression of ‘disallowed’ genes [122]. Moreover, deletion 
of the von Hippel-Lindau genes, which encode an E3 ubiquitin ligase involved in oxygen 
sensing, disrupt effectors downstream of Notch, Wnt and Hedgehog signalling cascades 
and upregulate SOX9, which is normally repressed in adult β-cells [123]. Furthermore, 
knockdown of the repressor Groucho-related gene 3 (GRG3), which interacts with 
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NKX6.1 to supress glucagon activation and maintain monohormonal β-cell identity, in 
INS1-E cells promotes β- to α-cell transition [124]. Whereas in α-cells, expression of 
GRG3 represses glucagon and aristaless related homeobox (ARX) and, with addition to 
PDX-1, promotes GLUT2 expression and induces GSIS [125]. 
1.3. Zinc metabolism 
Zinc is an essential micronutrient that exists as a non-redox-active divalent cation (Zn2+) 
under physiological conditions. Intracellular zinc consists of zinc(II) bound to proteins 
and free Zn2+, which describes the labile cation freely available to bind proteins [126]. 
Zinc is fundamental for a multitude of biological processes as a structural, catalytic, and 
inter- and intracellular signalling component [127, 128]. The human genome encodes 
~3000 zinc(II)-binding metalloproteins [129] that affect diverse arrays of cellular 
processes ranging from DNA repair, replication and translation [130] to differentiation 
and protection against oxidative stress [131-133]. Zinc most commonly binds proteins at 
zinc-finger domains, which include classical C2H2-type domains in addition to RING-
type, PHD-type and LIM-type domains. A large number of transcription factors contain 
C2H2 ZNFs, to which zinc binding is essential for protein-DNA interactions [134]. An 
imbalance in intracellular zinc is linked to an array of disorders including Alzheimer’s 
disease [135], Acrodermatitis Enteropathica [136], cancer [137, 138] and diabetes [139-
141]. Zinc is implicated in almost all levels of glycaemic control from β-cell insulin 
release to insulin uptake and action at target tissues [142, 143].  
Alike all essential metal ions, intracellular zinc concentrations are tightly regulated, 
allowing for zinc-specific reactions whilst avoiding cross-metal interference. Cytosolic 
free Zn2+ is maintained within the pM range, with much higher concentrations in zinc-
storing intracellular compartments and vesicles [127]. Cells maintain zinc at specific 
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concentrations through buffering and muffling (time-dependent zinc redistribution 
through intracellular compartmentalisation) dynamics, which vary dependent on cellular 
state [144]. Buffering is mediated by metallothionein (MT1-4) zinc(II)-binding proteins 
and muffling by families of membrane transporters, namely the Zrt- and Irt-related protein 
(ZIP; SLC39A) and zinc transporter (ZnT; SLC30A) families, which flux zinc into and 
out of the cytosol, respectively [145]. Co-ordinated regulation allows environmental-
induced zinc fluctuations to mediate signalling pathways and physiological targets, 
thought to initiate from outside the cell and from intracellular organelles such as the 
endoplasmic reticulum (ER), Golgi apparatus and mitochondria, which contain high 
concentrations of zinc [146]. Responses are dependent on signal duration and amplitude, 
with both early and late zinc signalling described, associated with transcription-
independent and -dependent responses, respectively [147]. An overview of regulation of 
zinc homeostasis in mammalian cells is depicted in Fig 1.6. 
1.3.1. MTF1 
Zinc-dependent changes in gene expression are primarily regulated by the metal-response 
element–binding transcription factor 1 (MTF1) [148]. MTF1 comprises of six Cys2His2 
zinc fingers with the lowest Zn2+ affinities of any known zinc fingers (nM to sub-µM 
range) [149, 150]. MTF1 translocates to the nucleus in response to cytosolic free Zn2+, 
where it binds metal response elements (core sequence TGCRCNC) in the promoters of 
zinc-regulated genes; mtf1 knockdown in zebrafish ZF4 cells alters the transcriptional 
response to cytosolic zinc fluctuations for over 1000 genes [151]. MTF1 recruits the 
histone acetyltransferase p300/CBP and the transcription factor SP1 to form a 
multiprotein complex to potentiate its activity [152]. The zinc-finger transcription factors 
KLF4 [153] and ZNF658 [154] additionally mediate Zn2+-responsive gene expression. 
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Intracellular zinc homeostasis is further maintained through zinc-dependent marking of 
proteins for degradation by the ubiquitination pathway [155].  
 
 
Fig 1.6. Regulation of zinc homeostasis in mammalian cells. Mobilisation of zinc into 
and out of cells is mediated by the ZIP and ZnT families of transporters, respectively. MT 
proteins bind and buffer cytosolic free Zn2+. MTF1 binds zinc to regulate expression of 
zinc-regulated genes. Cytosolic free Zn2+ concentrations are maintained in the pM-low 




1.3.2. MT proteins  
MTs are low molecular weight (6-7kDa, 61-68 amino acid) cysteine-rich proteins, 
fundamental and ubiquitous in eukaryotes. MTs maintain cytosolic zinc concentrations 
by Zn2+ donation, sequestration and/or redox control [156]. The metal-free apo-protein 
binds zinc to activate zinc-inhibited enzymes, act as a buffer to provide zinc to target 
proteins in low zinc conditions, and act as a chaperone to remove zinc from zinc finger 
transcription factors such as TFIIIA and SP1, eliminating their DNA-binding abilities 
[157, 158]. MT C-terminal α-domains have high affinities for up to three Zn2+, and the 
N-terminal β-domains can coordinate four others, but at lower affinities. In total, MTs 
occupy 5-15% of the cellular zinc pool. MT buffering capacities depend on pZn, which 
describes the physiological Zn2+ potential, determined by the Kd of the buffering ligand(s) 
(pZn = -log[Zn2+]). Strongly buffered zinc is associated with low free Zn2+ and rapid 
returns to resting levels after stimulation, whereas weakly buffered zinc is associated with 
reaching a new steady-state following elevation [159].   
In human, eleven functional MT isoforms exist (MT1A, B, E, F, G, H, M and X, MT2A, 
MT3 and MT4), whereas one copy of each MT1-4 are harboured in mice [160]. MT1 and 
MT2 are expressed in almost all mammalian tissues and are responsible for zinc buffering 
within β-cells. MT3 and MT4 are generally tissue specific, primarily in the brain and 
certain epithelial tissues, respectively. MTs bind and release zinc dependent on changes 
to the oxidation environment: oxidation induces MT zinc release whereas reduction 
increases their zinc-binding capacities [161]. MTF1 is the main transactivator of MT1 
and MT2 expression [162, 163]. Although MT1 and MT2 abundances have been 
attributed to several conditions including oxidative stress and inflammation, it is fairly 
convincing that the MTF1 regulatory response is dominant and that other factors, such as 
hypoxia-inducible transcription factor 1 (HIF1), glucocorticoids and interleukin 6 (IL-6) 
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mediate this response [164-167]. Expression of MT1 and MT2 are further regulated by 
epigenetic mechanisms including cell-specific promoter methylation [168, 169].  
1.3.3. Zinc transporters 
The ZIP and ZnT transporters have multiplied through evolution through gene duplication 
events to exhibit tissue-, cellular- and subcellular-specific expression [170]. Mammalian 
paralogues show differing Zn2+-affinities, transporting efficiencies, regulatory 
mechanisms, metal-specificities (ZIP8 and ZIP14 transport non-transferrin bound iron 
and cadmium ions, amongst others, in addition to zinc [171-173]) and some functional 
redundancies [128, 174]. The transporters are regulated at epigenetic, transcriptional, 
post-transcriptional (microRNA [175, 176]), translational and protein (proteolysis, 
phosphorylation, ubiquitination and heterodimer formation) levels in response to stimuli 
and nutrients including zinc [177, 178]. Expression of many β-cell zinc transporters are 
dependent on sufficient concentrations of extracellular glucose [179].  
1.3.4. ZnT transporters   
ZnT transporters are members of the cation diffusion facilitators (CDFs) superfamily 
which, with the exception of ZnT5 [180], consist of six transmembrane domains (TMD) 
and cytoplasmic amino and carboxyl terminal domains (NTD and CTD, respectively) 
[62]. ZnT5 contains a nine TMD N-terminus fused to the conserved 6 TMD region at the 
C-terminus [180]. Zinc binding and transport is predicted to occur between TMDs IV and 
V [174]. ZnT paralogues can be grouped into four subgroups based on phylogenetic 
analysis and sequence similarities: (A) ZnT1 and ZnT10; (B) ZnT2, ZnT3, ZnT4 and 
ZnT8; (C) ZnT5 and ZnT7 and (D) ZnT6 [181]. All mammalian ZnT paralogues, with 
the exception of ZnT6, form homodimers [181, 182]; ZIP6 forms heterodimers with ZIP5 
in the early secretory pathway [183]. Many other ZnTs can additionally form 
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heterodimers, including ZnT1:ZnT2, ZnT1:ZnT3, ZnT1:ZnT4 and ZnT3:ZnT4, which 
often exhibit altered subcellular localisations from respective homodimers [184]. Details 
of predicted tissue distributions, subcellular localisations and disease associations of 
human ZnT paralogues are provided in Table 1.2.  
Most ZnT transporters are expressed in β-cells, with similar expression profiles predicted 
between human and mouse [185]. ZnT1 and ZnT2 are detected at the plasma membrane 
[185], suggesting key roles in β-cell zinc export, and supplementation of human islets 
with zinc increases expression of ZnT1 [186]. Although not described specifically for β-
cells, ZnT2 additionally localises to the secretory granules in specialised secretory tissues 
[187]. ZnT3, which is known to localise to neuronal synaptic vesicles [188], is implicated 
in insulin production in rat INS-1E cells, where it presumably localises to endosomes, 
and streptozotocin-treated ZnT3 null mice present with decreased insulin expression and 
secretion, and hyperglycaemia [189]. However, independent studies report ZnT3 at high 
levels in human but not mouse islets [185, 190]. ZnT4, ZnT5 and ZnT6 are abundantly 
expressed at the TGN and vesicular compartments in β-cells, and ZnT5 additionally 
localises to the secretory granules [185, 191-194]. An additional ZnT5 variant localises 
to the plasma membrane [193], however plasma membrane expression has not yet been 
described for β-cells. ZnT7 concentrates at the Golgi apparatus in β-cells [195] and ZnT7 
null mice show increased susceptibility to diet-induced glucose intolerance and insulin 
resistance, in part due to decreased insulin secretion [196]. ZnT9 and ZnT10 exhibit 
perinuclear and vesicular localisations and ZnT10 additionally localises to the plasma 
membrane in islets, but not cultured β-cells [185], possibly due to zinc-dependent 




Table 1.2. Overview of human ZnT (SLC30A) paralogues. Tissue distributions, 
subcellular localisations and associated diseases are listed. Adapted from [147, 187, 193]. 
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The most abundantly expressed ZnT paralogue in β-cells is ZnT8, which shows almost 
exclusive expression in pancreatic α- and β-cells. ZnT8 exists as a ~70kDa homodimer 
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that functions to flux zinc into β-cell insulin secretory granules [198, 199]. The role of 
ZnT8 in β-cells has been extensively explored and is discussed in section 1.4. ZnT8 
expression is regulated by multiple transcription factors including PDX-1 at two 
enhancers [200] and is mediated post-transcriptionally, since high mRNA levels recorded 
for both α- and β-cells are only reflected at the protein level in the latter [201, 202].  
1.3.5. ZIP transporters   
The ZIP transporter superfamily contains over 100 SLC39A sequences [178, 203], of 
which 14 mammalian paralogues exist. The 14 human and mouse SLC39A paralogues 
are grouped into 4 subcategories based on structural homology: Subfamily I (ZIP9), 
Subfamily II (ZIP1, ZIP2 and ZIP3), the LIV-1 subfamily (ZIP4-8, ZIP10 and ZIP12-14) 
and the GufA subfamily (ZIP11) [203]. Details of predicted tissue distributions, 
subcellular localisations and associated diseases are provided in Table 1.3. Some ZIP 
transporters show different subcellular localisations dependent on post-translational 
modifications and in response to stimuli. For example, ZIP6 is initially expressed at the 
ER but following cleavage of the NTD localises to the plasma membrane [204], and the 
N-terminal ectodomain of ZIP4 is cleaved in response to prolonged zinc deficiency to 
promote increased ZIP4 accumulation at the plasma membrane in the intestine and 
visceral endoderm [205]. There is some evidence for ZIP heterodimerisation, such as 
ZIP6:ZIP10, which heterodimerize to induce proliferation, protect against anoikis and 
promote cellular migration [206]. Many ZIP transporters exhibit roles in cells in addition 
to zinc transport and can be considered membrane-bound chaperones. Multiple kinases 
binding sites have been identified on ZIP cytoplasmic domains, such as binding sites for 
GSK-3 on histidine-rich cytoplasmic loops of ZIP6:ZIP10 heteromers [207].  
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Table 1.3. Overview of human ZIP (SLC39A) paralogues. Tissue distributions, 
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ZIPs comprise of a predicted 8 TMD topology with extracellular or intra-compartmental 
CTDs and NTDs. Highly conserved histidine, serine and glycine residues reside in 
TMDIV to facilitate zinc translocation and a histidine-rich sequence (HXHXH, where H 
is histidine and X is any amino acid) is present on the long intracellular loop between 
TMDIII and IV, critical for zinc binding [210]. LIV-1 subfamily members contain large 
extracellular domains that are important for optimal zinc transport activity. Crystal 
structures of the ZIP4 extracellular domain show that it exists as two structurally distinct 
subdomains with a conserved proline-alanine-leucine (PAL) motif at the dimerization 
interface, connected by a flexible bridging domain. The helix-rich NTD and bridging 
domain interact with core TMD components to facilitate zinc transport. ZIP4 forms 
homodimers via its extracellular domain, a mechanism predicted to be shared by 
additional LIV-1 members containing PAL motifs (ZIP5, ZIP6, ZIP8, ZIP10, ZIP12 and 
ZIP14) [211]. Crystal structures for prokaryotic ZIP homologs demonstrate that ZIPs 
encompass a 3+2+3 TMD architecture containing a binuclear metal centre. This fold is 
predicted to be different from other known substrate carriers, whereby an inward open 
confirmation occludes the extracellular side and symmetrically related substrate-binding 
TMDs (TMD4 and TMD5) are sandwiched by 3-TMD repeats [212]. However, ZIP 
transport mechanism(s) remain unresolved, partly due to conflicting transporter 
properties. ZIP1 and ZIP2 are homologous to Zrt1 and Zrt2 zinc transporters in the model 
fungus Saccharomyces cerevisiae; Zrt1 and Zrt2 [213, 214] but not human ZIP1 or ZIP2 
[215, 216] show ATP-dependent zinc transport. Moreover, ZIP8 and ZIP14 facilitate 
transport of Zn2+[HCO3
-]2 electroneutral complexes when overexpressed in Xenopus 
oocytes [217].  
Limited information is known about the ZIP transporters in β-cells [218]. Data from 
quantitative PCR (qPCR) studies [192, 218] suggest that ZIP6 and ZIP7 are highly 
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expressed and cooperate with ZnT paralogues to regulate zinc transport from the ER and 
plasma membrane (ZIP6), and the Golgi apparatus (ZIP7). However, the additional ZIPs 
chiefly responsible for β-cell zinc homeostasis remain less clear. ZIP4 overexpression in 
MIN6 cells increases cytosolic free Zn2+, resulting in increases in granule zinc and GSIS 
independent of the mitochondrial membrane potential, and ZIP4 deletion in mouse islets 
upregulates ZnT8 and marginally improves glucose homeostasis without inducing 
changes to insulin secretion [219], possibly an adaptive response to prevent granule zinc 
depletion [220]. However, ZIP4 shows low relative expression in mouse MIN6 cells 
[218]. Additional studies highlight high mRNA expression in β-cells for ZIP1 [221] and 
ZIP14 [218] in human, and for ZIP3 [218], ZIP8 [192, 218, 222] and ZIP13 [218] in 
mouse, indicative of a potential biological importance.  
1.3.6. Zinc transporting membrane channels  
Zinc additionally enters cells through certain membrane ion channels. β-cell L-VGCC 
show highly specific Zn2+, in addition to Ca2+, influx; surprisingly, a similar mechanism 
is not observed for α-cells, despite abundance of similar channels [223]. Multiple transient 
receptor potential (TRP) channels, of which six families exist, many exhibiting roles in 
insulin secretion, can specifically channel zinc into β-cells [224]. TRPV1 and TRPA1 are 
expressed in rat INS-1 and RINm5F cells, and the TRPM3 splice variant TRPM3a2 
mediates spontaneous β-cell zinc uptake with a high specificity [224]. β-cell TRPs are 
activated by GLP-1R stimulation, membrane depolarisation and extracellular zinc. 
Moreover, TRPA1 is activated by free Zn2+ concentrations within the low nM range in 
neurons [225] and TRPM7 can facilitate zinc uptake into neurons in total extracellular 




1.4. SLC30A8 – A diabetes susceptibility gene 
ZnT8 abundance and genotype have repeatedly been associated with β-cell function and 
Type 2 Diabetes development. ZnT8 downregulation is associated with stresses linked to 
β-cell dysfunction, including hypoxia [227], lipotoxicity [186], hypozincaemia [186] and 
cytokines [179], and is observed during the early stages of diabetes in both db/db and 
Akita mice [228]. Addition of the zinc chelator N,N,N’N’-tetrakis(-)(2-pyridylmethyl)-
ethylenediamine (TPEN) to human islets downregulates ZnT8, decreases GSIS through 
enhancing ATP production and increases apoptosis, whilst ZnT8 overexpression protects 
against decreases in GSIS induced by palmitate and TPEN [186]. ZnT8 overexpression 
in rat INS-1E cells increases cytosolic free Zn2+ and is protective against TPEN-induced 
apoptosis [191], indicating beneficial roles for ZnT8 against zinc depletion-induced β-
cell dysfunction. However, a recent study found that ZnT8 is upregulated in islets of 
diabetic and insulin-resistant patients, and that ZnT8 knockdown in MIN6 cells increases 
proliferation and protects against inflammation-induced cell death [229]. 
A shorter ZnT8 isoform has been recently described which lacks the N-terminal extension 
of the full-length protein (320 compared to 369 amino acids) but exhibits a comparable 
zinc-transporting capacity [230]. RNA-seq analysis suggests that the longer ZnT8 form 
accounts for 71.3% of SLC30A8 mRNA transcripts in human islets [231], however 
current understanding cannot confirm if both proteins are expressed in vivo. When 
overexpressed in HEK293 cells, a relatively small amount of full-length ZnT8 resides at 
the plasma membrane, whereas the shorter form is mainly intracellular, suggestive of 
additional roles for ZnT8 aside from granule zinc uptake [191, 230]. It currently remains 
unknown if plasma membrane ZnT8 exhibits roles in cellular zinc efflux; other human 
ZnT paralogues (ZnT2 and ZnT5) exist as different isoforms that localise to either the 
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plasma membrane or the membranes of intracellular organelles [230]. ZnT8 is 
additionally a major CD8+ T-cell recognised autoantigen in Type 1 Diabetes [232]. 
1.4.1. The rs13266684 polymorphism 
Over 100 genetic loci are linked to Type 2 Diabetes predisposition [233]. In 2007, ZnT8 
was first identified as a Type 2 Diabetes risk loci in a GWAS French cohort [234]. The 
identified non-synonymous C>T single nucleotide polymorphism (SNP) at rs13266684 
resides in exon 9 of the SLC30A8 coding region, in a 33-kb linkage disequilibrium block 
on chromosome 8 containing the 3’ end of the gene. The SNP results in an Arginine (R) 
to Tryptophan (W) substitution at amino acid position 325 in the unstructured CTD [235] 
(denoted ZnT8-R and ZnT8-W, respectively), substituting a hydrophobic polar amino 
acid in place of a basic amino acid [201]. Multiple GWAS have since replicated the 
finding and significant associations have been described in cohorts from European and 
Eastern Asian [21, 236-249], but not African [250, 251], Indian [252], Moroccan or 
Ashkenazi [253] populations. rs13266634 variants are additionally not associated with 
gestational diabetes in Euro-Brazilian populations [254], despite women exhibiting 
higher risks of Type 2 Diabetes following pregnancy [255]. The polymorphism therefore 
probably confers risk in the context of specific genetic backgrounds. HapMap data (build 
35) suggests that the ZnT8-R risk variant has an estimated prevalence of 55%, 75% and 
95% in Asian, European and African populations, respectively [243]. Independent meta-
analyses report an overall odds ratio for predisposition of 1.14-1.15, with a ~16.5% 
increase in relative risk per risk allele [243, 256-259].  
ZnT8-R carriers present with increased proinsulin:insulin ratios [260], lowered β-cell 
function (assessed through Homeostatic model assessment B) [261] and impaired insulin 
secretion during intravenous glucose tolerance tests [262, 263]. The mutation is thought 
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to alter the kinetics of zinc uptake into β-cell secretory granules, however the molecular 
details remain unclear. Alignment of ZnT8 sequences from several species shows that the 
amino acid at position 325 and its properties (such as hydrophobicity and ability to form 
H-bonds) are poorly conserved, leaving investigations challenging [230]. Zinc uptake 
assays using 65Zn and isolated β-cell vesicles or fluorescence probes and rodent cell lines 
[201, 264] suggest that ZnT8-R is less active than ZnT8-W and promotes decreased 
granule zinc uptake. However, when variants were overexpressed in Xenopus laevis 
oocytes, which do not normally exhibit net zinc flux, 65Zn transport assays did not reveal 
any differences in zinc flux between the two variants [230]. Whereas when variants were 
reconstituted in proteoliposomes, the ZnT8-R variant was found to be more active than 
ZnT8-W [265]. This study noted that the lipid environment affects loading of zinc into 
insulin granules during biogenesis. Consistent with the latter, higher islet zinc is 
associated with ZnT8-R risk variant carriers, potentially due to increased granule zinc 
influx [266]. Increased granule zinc may subsequently deplete cytosolic zinc and 
adversely affect β-cell function.  
There is currently no crystal structure for any eukaryotic CDF protein. All ZnT8 data-
structural relationships are based on the Escherichia coli homolog YiiP, which displays 
51.8% sequence homology to the mammalian protein [267]. YiiP dimers binds eight zinc 
ions: two in the primary TMD transport site; two between the domains, exhibiting an 
unknown function, and four at the CTD interface. The CTD is believed to be involved in 
metal sensing to induce conformational changes to the transporter and facilitate 
Zn2+/proton antiport [268]. In human, 3D homology models suggest that R/W325 is not 
directly involved in CTD Zn2+-binding and that both isoforms are predicted to adopt 
αββαβ structures, comparable to YiiP. However, mammalian zinc transporters must 
function differently than bacterial orthologues: bacterial zinc exporters only function in 
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high levels of cytosolic Zn2+ whereas loading of zinc into insulin secretory granules 
occurs under normal concentrations of cytosolic Zn2+. The human ZnT8-R/W genotype 
likely impacts zinc transport through altering transporter dimer formation and stability: 
the CTD of ZnT8-R (ZnT8-cR) exhibits a higher thermostability but a lower dimerization 
affinity than ZnT8-cW [269]. ZnT8-R/W polymorphisms may further alter protein-
protein interactions [270], however few biding partners have yet been identified.  
1.4.2. SLC30A8 truncating polymorphisms  
Twelve rare (<0.1% of the population) ZnT8 nonsense (truncating) or missense loss-of-
function variants are protective against Type 2 Diabetes, which collectively represent a 
65% decrease in disease risk [271]. These polymorphisms group into structurally distinct 
variants from ancestrally distinct cohorts, of which the two most common sequences fail 
to express stable proteins. Explanations for relative diabetic risk include a bimodal (bell-
shaped) impact of ZnT8 activity for β-cell zinc release and action on target tissues. A 
modest decrease in ZnT8 activity and zinc secretion may primarily enhance hepatic 
insulin clearance [272] (described in 1.5.5), whereas loss-of-function mutant proteins 
may increase pancreatic insulin release, outweighing the impact on insulin clearance.  
1.4.3. Animal studies  
Multiple groups have produced global and β-cell-specific ZnT8 knockout animals to help 
elucidate the role of ZnT8 in glucose homeostasis [201, 202, 227, 273]. Results from 
these studies are summarised in Table 1.4. Variations in the phenotypic traits observed 
are majorly attributed to differences in genetic background, environment and deletion 
strategy. For example, disrupted glucose tolerances were reported for mice from mixed 
[201, 202] but not C57BL6 [274] backgrounds, and several β-cell-specific Cre deleter 
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strains (notably PDX-1 and RIP2Cre) are complicated by off-target deletion in additional 
tissues such as in neuronal cells [275].  
In general, β-cells from ZnT8 null mice show large changes in granule morphologies. 
Granules lacking dense cores and granules containing ‘rod-like’ structures have been 
described that accompany ~12% larger fractions of the cells due to sparser packaging,  
possibly due to lack of insulin crystallisation in low zinc [202]. Concurrently, islets from 
ZnT8 null mice exhibit lowered total zinc contents [201, 273, 276], however no 
differences in insulin processing [201, 202], frequencies or amplitudes of Ca2+ 
oscillations, nor full or partial granule fusion events during exocytosis [201] have been 
described. Although GSIS from ZnT8 null islets remains unchanged or slightly elevated, 
consistent with insulin crystallisation having no effect on insulin diffusion into 
circulation, circulating insulin is generally lowered in ZnT8 null animals, similar to 
human ZnT8-R carriers [277]. Female mice transgenic for hZnT8-W (with native levels 
of mZnT8) are characterised by improved glucose tolerances without a change to insulin 
sensitivity, and islets secrete less insulin but more zinc in response to glucose compared 
to mZnT8 controls [278]. However, male mice transgenic for hZnT8-W (with native 
levels of mZnT8) exhibit lowered amounts of zinc and proinsulin in the pancreas, but 
higher rates of insulin secretion and increased glucose tolerances when fed on high fat 
diets compared to hZnT8-R transgenic mice [279]. Moreover, a recent study investigated 
the effects of one of the most abundant loss-of-function variants R138X, which encodes 
a premature stop codon, in mouse. Mice containing knock-in R138X mutations at Slc30a8 
exhibited loss of ZnT8 function, however islets secreted elevated amount of insulin in 
response to IR inhibition-induced hyperglycaemia [280]. 
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Table 1.4. Overview of ZnT8 knockout mouse studies using male mice. N.R. = not relevant. GSIS = glucose stimulated insulin secretion. 
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1.5. Zinc in β-cell function  
Pancreatic β-cells maintain one of the highest zinc contents of any known cell type. Total 
zinc concentrations reach 150-200µM, of which 70% is contained in insulin secretory 
granules [281]. β-cells exhibit an exceptionally high turnover of zinc [266]; high glucose 
stimulation doubles cytosolic free Zn2+ and up-regulates Zn2+-regulated genes [192]. 
Links between zinc and diabetes were established as early as 1938, when a 75% reduced 
pancreatic zinc content was described for diabetic compared to non-diabetic cadavers 
[282], and diabetes has since been associated with systemic hypozincaemia [140, 283, 
284]. A study of 82,000 women in the US reported that a low zinc intake increases the 
relative risk of diabetes by 17% compared to those taking sufficient amounts of zinc 
[285], and negative associations between plasma zinc and diabetes onset have been 
described in Chinese [286] and Japanese [287] populations. However, a further 
longitudinal study exploring zinc in toenails as a marker of long-term zinc exposure in 
American young adults [288] and a systematic review including 334,387 type 2 diabetic 
patients [289] did not find any associations between serum zinc and diabetes. Excessive 
oral zinc uptake can lead to cytotoxicity through inhibiting copper uptake [290] and 
altering lipid metabolism [291]. A tightly regulated zinc content is therefore fundamental 
for normal β-cell function and the endocrine pancreas encompasses specialist 
mechanisms to compensate for subclinical deficiency [292]. These functions are detailed 
below.  
1.5.1. Anti-oxidant properties  
Oxidative stress plays a major role in loss of β-cell mass and function through DNA, lipid 
and protein damage [293]. β-cells are particularly vulnerable to oxidative stress since 




by-products during glucose metabolism [295]. Moreover, chronic hyperglycaemia and 
hyperlipidaemia present in Type 2 Diabetes induce excess ROS production through 
increased mitochondrial oxidation [296] and β-cells produce low levels of ROS-
scavenging enzymes [297]. Unsurprisingly therefore diabetic animals exhibit significant 
redox imbalances compared to controls [298]. 
Oxidative stress can stimulate increases in cytosolic free Zn2+ to over 2nM within 
minutes, such as through oxidation or nitrosylation of zinc(II)-thiolate bonds [299]. 
Increases in cytosolic free Zn2+ mediate expression of antioxidant genes. For example, 
MTF-1 induces expression of selenoprotein 1, which encodes an antioxidant glutathione-
binding protein to scavenge free radicals [300]. Furthermore, zinc is an essential cofactor 
of superoxide dismutase, which detoxifies ROS [301], and interferes with mitochondrial 
antioxidant production by inhibiting α-ketoglutarate-dependent respiration to help 
prevent oxidative stress-induced dysfunction [302]. Zinc additionally binds sulfhydryl 
groups, protecting molecules from oxidation [293], and reduces and neutralises 
intracellular free radicals to prevent oxidation-induced damage [303]. Concurrently, zinc 
depletion is associated with increased sensitivity to oxidative stress-induced apoptosis 
[304].  
1.5.2. Intracellular signalling pathways  
Zn2+ is a potent signalling molecule in β-cells, implicated in glucose signal recognition, 
second messenger metabolism, protein kinase activity and transcription factor regulation 
[301]. Zinc inhibits PTP1B, a prominent β-cell phosphatase with an apparent Ki of 5.6 
nM for Zn2+ [79]. PTP1B inhibition ameliorates high-fat-diet and obesity-induced insulin 
resistance in mice [305], and genome-wide and tissue-specific PTP1B ablation increases 




allows zinc to mimic the actions of hormones and growth factors to activate important 
signalling cascades involved in β-cell function, survival and mass, including insulin 
secretion [308]. Loss of PTP1B activity increases net IRS-1/2 phosphorylation to promote 
IR and IGF-1R signalling and proliferation [309], activation of the MAPKs ERK1/2, c-
Jun N-terminal kinase (JNK) and p38 [310], and glycogen synthesis by inhibiting GSK-
2 [311]. Zinc additionally stimulates signalling via the G-protein coupled receptor 
(GPCR) GPR39 by activating Gαq, Gα12/13 and Gαs proteins, important for the normal 
insulin secretory response; GPR39 is considered an important transducer of autocrine and 
paracrine zinc signals in β-cells [312]. Zinc influences gene expression by mediating 
activation of mTORC1 [313] and ERK1/2 [314], and signals to regulate pathways 
influencing the activity of NF-κB. Moreover, zinc plays significant roles in lipoprotein 
and glucose metabolism through altering expression of proliferator-activated receptor α 
(PPAR-α), which additionally suppress NF-κB activity [315]. Zinc further influences 
signal transducer and activator of transcription (STAT) signalling cascades, which 
regulate proliferation, differentiation, survival and apoptosis. STAT3 induces 
transcription of ZIP6 and ZIP10 [207, 316] and zinc deficiency reduces STAT1 and 
STAT3 phosphorylation in foetal rat brains [317].  
Multiple zinc transporters are implicated in regulating intracellular signalling cascades. 
ZIP7 is a gated zinc transporter localised to the ER and Golgi apparatus and is activated 
by CK2 tyrosine kinase phosphorylation at multiple MAPK-binding motifs to initiate 
temporal zinc release and pathway activation [318]. ZIP6:ZIP10 heterodimers interact 
with GLP-1Rs to facilitate incretin signalling [218] and promote insulin gene expression 
and biosynthesis, GSIS, suppression of apoptosis, and restoration of glucose competence 




kinases GSK-3α and GSK-3β [206, 311] and downstream ERK1/2-SNAIL-SLUG 
pathways [320, 321] to mediate proliferation and epithelial-mesenchymal transition. 
Furthermore, ZnT1 interacts with RAF-1 via its CTD to activate ERK1/2 cascades [322], 
ZnT3 promotes ERK1/2 signalling from post-synaptic vesicles in the brain [323], and 
ZIP13 influences BMP/TGF-β cascades involved in cellular differentiation, growth and 
survival [324]. Moreover, ZIP14 is involved in GPCR cAMP signalling and knockout in 
mouse represses phosphodiesterase activity, leading to enhanced systemic growth [325].  
1.5.3. Transcription factor regulation  
Several transcription factors involved in islet development and endocrine function are 
Zn2+-responsive in zebrafish, including neurod1, hnf1ß, hnf4α, foxa1, nkx2.2, and pax6 
[151, 326-328]; of these, at least neurod1 and foxa1 are predicted to be directly regulated 
by mtf1 [151]. A recent study using human insulin-secreting β-cell like stem cells showed 
that zinc supplementation induces up-regulation of the β-cell markers PDX-1 and PAX4 
[329]. There might therefore be a link between β-cell zinc deregulation and loss of β-cell 
phenotype and function. The functions of these transcription factors and associations with 
Type 2 Diabetes are detailed below.  
1.5.3.1.  NEUROD1 
NEUROD1 is a basic helix-loop-helix transcription factor that mediates transcription 
through binding E-box containing promoter core sequences. NEUROD1 is critical for 
pancreatic development from progenitors and the function of mature β-cells by mediating 
a multitude of genes including insulin. NEUROD1 null mice develop severe diabetes at 
a young age and fail to develop properly differentiated islets [330], whilst β-cell-specific 




Heterozygous loss-of-function mutations result in MODY6 [332] and homozygous 
truncating mutations are associated with monogenic permanent neonatal diabetes [333]. 
1.5.3.2.  HNF1B 
HNF1B is a homeodomain-containing transcription factor which exists as either a 
homodimer or as a heterodimer with HNF1A. HNF1B exhibits critical roles in β-cell 
differentiation and regulates signalling cascades involved in glucose homeostasis [93]. 
HNF1B abundance is suppressed by palmitate, which further downregulates expression 
of HNF1A [334]. Heterozygous HNF1B mutations result in multi-system disorders 
including MODY5, and HNF1B SNPs have been shown to predispose to Type 2 Diabetes 
in Finnish, Swedish, Canadian and Chinese populations [335-338].  
1.5.3.3.  HNF4A 
HNF4A is an essential transcriptional regulator of β-cell phenotype, acting as a dimer to 
mediate expression of genes involved in glucose transport and glycolysis. HNF4A is 
required for maximal insulin production [339] and heterozygous mutations cause 
MODY1 [340, 341]. HNF4A null mice exhibit normal β-cell architecture but defective 
GSIS, and present with hyperinsulinemia and glucose intolerance [342]. However, an 
association study on a Japanese cohort did not find any variants in the HNF4A 
chromosomal loci associated with Type 2 Diabetes risk [343]. 
1.5.3.4.  FOXA1 
The FOXA1 transcription factor exhibits critical roles in differentiation and development 
of the endocrine pancreas. FOXA1 induces chromatin remodeling independent of ATP-
dependent remodeling complexes, acting as a pioneer factor to establish chromosomal 




346]. FOXA1 is further implicated in oxidative phosphorylation since FOXA1 knockout 
islets exhibit increased expression of mitochondrial protein uncoupling protein 2 and 
lowered intracellular ATP [347]. FOXA1 additionally mediates CREB, a master regulator 
of carbohydrate metabolism [348] and, along with the related protein FOXA2, interacts 
with PDX-1 enhancers during β-cell development [348]. FOXA1 knockout in the fetal 
pancreas induces hyperglycaemia as a consequence of defective insulin secretion and 
FOXA1 null mice present with hyperinsulinaemic hypoglycaemia and retarded growth 
[349].  
1.5.3.5.  NKX2.2 
The transcription factor NKX2.2 is involved in the final differentiation of β-cells and in 
maintaining mature β-cell phenotype and function [350, 351]. NKX2.2 interacts with 
ARX to regulate development of endocrine hormone expressing cells and NKX2.2 
mutations are linked to neonatal diabetes [351]. In NKX2.2 null mice, endocrine 
progenitors remain incompletely differentiated with a complete absence of insulin-
secreting β-cells, and mice present with severe hyperglycaemia [352]. Loss of NKX2.2 
function in the β-cells of NKX2.2-repressor transgenic mice further disrupts islet 
architecture [350].  
1.5.3.6.  PAX6 
The transcription factor PAX6 is essential for β-cell development, morphology and 
insulin expression through repressing alternative islet cell programs. In PAX6 null mice, 
production of both β- and α-cells are severely reduced [353]. PAX6 deletion in mature 
islets causes hyperglycaemia [354] and in adult mice causes lethal hyperglycaemia due 
to loss of β-cells coupled with increases in α-cells [353]. Both human and mouse 




through downregulating GLP-1 [356], and a common PAX6 variant reduces insulin 
secretion [357]. PAX6 is further downregulated in the β-cells of two diabetic mouse 
models: db/db mice and wildtype mice treated with an IR agonist [353]. 
1.5.4. The response to cytokines  
β-cells are extremely sensitive to cytokines. Interleukin 1β alone or in combination with 
interferon γ and tumour necrosis factor (TNF) α induces β-cell dysfunction and death 
[179, 200]. Cytokine sensitivity is dependent on the β-cell’s metabolic state, primarily 
mediated by inducing transcriptional changes such as insulin gene suppression. Multiple 
ZIP and ZnT paralogues show cytokine-responsive expression [179]. ZIP8 and ZIP14 are 
transcriptionally regulated by TNF and IL-6 in mouse, the response differing by time and 
between different tissues [358]. In independent studies, cytokine stimulation suppressed 
ZnT5 and ZnT8 in β-cells [179, 359] and ZnT8 knockdown in rat INS-1E cells increased 
sensitivity to IL-1β-induced apoptosis [179]. 
1.5.5. Insulin biosynthesis and crystallisation  
The role of zinc in insulin biosynthesis and crystallisation has been extensively described 
and is illustrated in Fig 1.7. Insulin gene transcription is initiated by the transcription 
factors MAFA, PDX-1 and NEUROD1 to express a 110 amino precursor, preproinsulin 
[360]. Preproinsulin enters the rough ER through peptide-conducting channels, where it 
is cleaved by signal peptidase to form proinsulin, a heterodimer containing a 21 amino 
acid A chain linked to a 30 amino acid B chain via two disulphide bonds and an 
intervening C-peptide, and is folded by chaperones [361]. Proinsulin is transported into 
the Golgi apparatus where it is packaged into immature secretory vesicles. Here, 
prohormone convertase 1/3 and prohormone convertase 2 cleave proinsulin and the CTD 




insulin and C-peptide [21]. C-peptide is able to bind cell membranes and activate specific 
GPCRs [362], and can be taken up into cellular endosomes to provide a platform for 
intracellular signalling [363], such as through inducing cytosolic Ca2+ signalling [364]. 
Intracellular C-peptide may additionally localise to nucleoli and promote transcription of 
























Fig 1.7. Insulin biosynthesis and crystallisation in β-cell insulin granules. The 
cytosolic insulin precursor preproinsulin is delivered to the ER via its N-terminal signal 
peptide, which is subsequently cleaved to form proinsulin. In the ER, proinsulin is 
oxidised to form three disulphide bridges, allowing the protein to fold and dimerise. 
Proinsulin travels through the Golgi apparatus into secretory granules, where it is 
processed by PC1/2, PC2 and CPE to create insulin and C-peptide. Insulin dimers form 





Zinc is transported into insulin granules via ZnT8, where local zinc concentrations reach 
20mM [281, 368]. Insulin monomers dimerise at increasing insulin concentrations, 
aggregating to form hexamers consisting of three dimers with near perfect 2-fold 
symmetry in the presence of high zinc, coordinating Zn2+ at His10 and Glu13 on the B-
peptide [369]. High granule zinc in addition to an acidic pH (pH <6) is required to 
maintain insulin hexamers and granule osmotic stability [370] and to protect against 
proteolytic degradation [371]. Insulin biosynthesis occurs within the region of 120 
minutes and mature insulin is stored for 4-8 days [26].  
1.5.6. Zinc secreted from pancreatic β-cells 
Two Zn2+ crystallise with each insulin hexamer, however core Zn2+/insulin hexamer 
ratios are predicted at 2:1-to-4:1, indicative of a further importance for granule zinc [272]. 
Zinc is co-released with insulin into the portal vein at a rate of 1.73 ± 0.74pmol/islet upon 
stimulation [202]. Secreted zinc suppresses insulin [132, 370] and IAPP [372] fibrillation 
at the site of release and in circulation under a physiological pH, avoiding formation of 
toxic amyloid deposits. Zinc shows autocrine effects on β-cells to reduce further insulin 
secretion through targeting KATP and L-VGCC channels [373] and suppresses cellular 
death [374]. A paracrine role of zinc on α-cells has been suggested whereby zinc binds α-
cell KATP channels to inhibit membrane depolarisation and glycogen secretion [375, 376], 
however this remains in dispute [377]. 
A role for β-cell zinc in peripheral insulin regulation has further been described [272]. 
Prior to systemic circulation, the portal vein transports insulin and zinc from the pancreas 
to the hepatic system, where around 50% of secreted insulin binds IRs and is internalised 
and proteolytically degraded by insulin-degrading enzymes to prevent hypoglycaemia 




[379], potentially regulated by dose-dependent zinc inhibition of clathrin-mediated IR 
endocytosis [272, 380].  
1.6. Targeting zinc homeostasis  
Multiple groups have investigated the consequences of zinc deficiency for rodent 
physiology [381-386]. Zinc deficient rats show impaired glucose tolerances compared to 
pair-fed controls following administration of glucose by both intravenous and 
intraperitoneal routes [381, 382]. Moreover, various zinc chelators induce diabetes in 
mammals (including hamsters, mice and rabbits) through β-cell destruction [387, 388] 
and zinc deficiency increases the risk of diabetes development in diabetic-prone animals. 
Diabetic mice are less able to maintain whole-body zinc levels following introduction of 
a low-zinc diet compared to non-diabetic controls, elevating this effect [389]. 
Zinc supplementation has been proposed as a potential therapy for Type 2 Diabetes [390]. 
Dietary zinc supplementation improves glycaemic control, promotes healthy lipid 
parameters [385], enhances antioxidant status [383, 384], and restores normal plasma zinc 
[386] in zinc deficient rodents. Zinc supplementation further attenuates hyperglycaemia 
and hyperinsulinemia in obese ob/ob [391], db/db mice [392] and high fat-fed mice [393], 
improves polydipsia and high density lipoprotein cholesterol levels in streptozotocin-
induced diabetic mice [394] and improves blood glucose and serum lipid profiles in type 
2 diabetic rats [298]. Moreover, zinc supplementation reduces the diabetic phenotype of 
human diabetic patients by improving glycaemic control and promoting healthy lipid 
parameters [142, 385, 395]; however, individual studies show considerable 
heterogenicity, with some concluding no benefit for zinc [142, 385]. Zinc administration 




[291], inhibit copper absorption [396] and can outcompete copper for substrate binding, 
such as to the Cu/Zn-superoxide dismutase [397]. Novel mechanisms to target disrupted 
zinc homeostasis specifically in β-cells may be needed before zinc supplementation 
therapies can meaningfully be implemented into clinical practice.  
1.7. Hypothesis and aims 
Maintaining adequate zinc is essential for normal β-cell function in glycaemic control. 
Systemic hypozincaemia is present in many type 2 diabetic patients [140, 283, 284] and 
polymorphisms in the predominantly β-cell-specific zinc transporter ZnT8 are associated 
with Type 2 Diabetes risk [234]. However, aside from its role in insulin granules, the 
importance of zinc for β-cell phenotype and survival remains largely unexplored. Since 
many zinc transporters carry out other very specific roles in addition to zinc transport and 
may be regarded as membrane-bound zinc chaperones, such as ZIP6:ZIP10 heteromers 
which stimulate proliferation through promoting phosphorylation and inhibition of GSK-
3 [207], altered zinc trafficking may induce β-cell dysfunction aside from disrupting the 
cellular zinc content; these mechanisms could be important to understand for 
development of novel therapeutics for type 2 diabetic patients. In this project we 
postulated that zinc uptake into insulin granules is coordinated with ZIP-facilitated 
cytosolic zinc influx and that different ZnT8 abundances and genotypes associated with 
Type 2 Diabetes interfere with ZIP-regulated zinc trafficking. We further hypothesized 
that alterations to the abundances/functions of these ZIP transporters impact β-cell 
phenotype and function. During this PhD project we therefore sought to address the 




I. To identify ZIP transporters that functionally coordinate with ZnT8 to 
maintain normal zinc trafficking in β-cells and explore whether these 
transporters are regulated differently based on ZnT8 activity. 
II. To explore the consequences of the hyperglycaemia and hypozincaemia 
associated with Type 2 Diabetes for β-cell ZIP transporter expression, zinc 
content and cellular phenotype. 















2. General methods  
2.1. Cell line and culture  
The adherent insulinoma β-cell–like clonal cell line MIN6 (Mus musculus) was 
maintained in Dulbecco’s Modified Eagle’s Medium containing 25mM glucose (DMEM, 
Thermo Fisher), supplemented with 15% fetal bovine serum (FBS, Thermo Fisher), 4mM 
L-glutamine, 50μM β-mercaptoethanol, 100μg/ml streptomycin and 100 units/ml 
penicillin (all Sigma Aldrich), at 37oC in a humidified atmosphere of 95% air and 5% 
CO2. Cells were used from passages 24-38. Cells were passaged through trypsinisation 
[0.25% trypsin-EDTA (Thermo Fisher) in PBS (5 mins, 37oC)] with passage intervals of 
3-4 days.  
2.1.1. Freezing cells 
Cells were suspended in 50% (v/v) cell culture medium, 40% (v/v) FBS and 10% (v/v) 
Dimethyl sulfoxide (Sigma Aldrich) in 1ml cryovials. Cells were immediately frozen at 
20oC (1 h) before transfer to -80oC. 
2.2. Stimulation of cells with zinc  
FBS was depleted of heavy metal ions through incubation with 5% (w/v) Chelex-100 
(Sigma Aldrich) for 1 h, and sterile filtered through a 0.22μm syringe. Chelex-100 treated 
FBS was diluted 1:100 in 0.5% nitric acid (Sigma Aldrich) and heavy metal analysis 
carried out through inductively-coupled plasma mass spectrometry (ICP-MS) [4] by the 
London Metallomics Facility funded by the Wellcome trust (grant reference 
202902/Z/16/Z). Chelex-100 treated FBS was supplemented with Ca2+ (CaCl2), K
+ (KCl) 




in chapter 5, section 5.3.5.3): growth media were replaced with 25mM glucose Roswell 
Park Memorial Institute (RPMI; Thermo Fisher) containing 10% Chelex-100 treated-
FBS, 4mM L-glutamine, 50μM β-mercaptoethanol, 100μg/ml streptomycin and 100 
units/ml penicillin, supplemented with ZnCl2 (Sigma Aldrich) to total concentrations of 
1µM or 8µM (control) Zn2+ for 48 h. MIN6 cells: growth media were replaced with 25mM 
glucose DMEM containing 15% Chelex-100 treated-FBS, 4mM L-glutamine, 50μM β-
mercaptoethanol, 100μg/ml streptomycin and 100 units/ml penicillin, supplemented with 
ZnCl2 to total concentrations of 1µM, 8µM (control) or 42µM Zn
2+ for 24 h, 48 h or 96 
h. The metal ion concentrations for all media used are provided in Appendix 5. 
2.3. Determination of cellular zinc content  
Cells were lysed in hot 0.2% sodium dodecyl sulphate (SDS; Sigma Aldrich). Samples 
were diluted 1:100 with trace element grade 0.5% nitric acid (Sigma Aldrich) and the zinc 
concentrations determined through ICP-MS [4], carried out by the London Metallomics 
Facility funded by the Wellcome trust (grant reference 202902/Z/16/Z). The total zinc 
content was normalised to protein content, determined through Bradford assays (Bio-Rad; 
2.7.2) [5].  
2.4. Cell transfection  
2.4.1. Transfection with siRNA 
Cells were transfected with siRNA using Lipofectamine RNAiMAX transfection reagent 
(Thermo Fisher) 24 h after seeding, following manufacturer’s instructions. Per well of 6-
well plate: 30pmol siRNA, 7.5ul Lipofectamine RNAiMAX reagent and 250μl Opti-




2.4.2. Transfection with plasmid DNA  
Cells were transfected with plasmid DNA using Lipofectamine 3000 transfection reagent 
(Thermo Fisher) 24 h after seeding, following manufacturer’s instructions. Per well of 6-
well plate: 7.5μL Lipofectamine 3000 reagent, 5μL P3000 transfection reagent, 2.5μg 
plasmid DNA and 250μL Opti-MEM medium was added. 
2.5. CRISPR/Cas9 gene knockout 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome 
editing technique based upon the Type II CRISPR-associated protein-9 nuclease (Cas9) 
system in Streptococcus pyrogenes. CRISPR/Cas9 technology utilises an RNA-guided 
nuclease system containing a guide RNA sequence in the form [5’20nt-NGG] to facilitate 
targeted double-stranded DNA cleavage. Cleavage promotes error-prone non-
homologous end joining repair and results in insertion, deletion and/or frameshift 
mutations, which disrupt the protein-coding capability [398]. Alternatively, 
CRISPR/Cas9 can replace target sequences with novel sequences of DNA. CRISPR/Cas9 
nickase technology decreases off-target mutation frequencies through requiring DNA 
binding and cleavage at the target loci by two mutated versions of Cas9 on opposite DNA 
strands [399]. CRISPR/Cas9 technology is an important tool for replacing point-
mutations in recessive disorders, studying complex diseases and vaccine development 
[400]. 
 
2.5.1. Cell transfection 
Cells were transfected with the SLC30A8 Double Nickase Plasmid (m) (sc-433687-NIC), 









Fig 2.1. The CRISPR/Cas9 double nickase plasmids. Plasmids encode single guide 
RNA targeting Slc39a6, Slc30a8 or scramble DNA, and either GFP or a puromycin 








2.5.2. Generation of clonal populations 
At 72 h following transfection, cells were selected using 1.25ng/μl puromycin 
dihydrochloride (Santa Cruz Biotechnologies) for 6 days and imaged for GFP 
fluorescence. Cells were transferred into a 96-well plate through serial dilution. Clonal 
cell populations were amplified through passaging cells into wells of increasing size.  
2.5.3. Verification of genome editing  
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen). DNA targeted by 
the CRISPR/Cas9 constructs were PCR amplified in reactions containing: 1X Taq 
reaction buffer, 200µM dNTP mix, 20µg DNA template, 1.25units/50µl PCR Taq 
Polymerase (all Thermo Fisher) and 0.2µM forward and reverse primers (Sigma Aldrich; 
sequences provided in relevant chapters), and subjected to the cycling conditions in Table 
2.1. Amplicons were separated on 2% agarose gels supplemented with 0.1% (v/v) gel red 
(Biotum) at 40V. Amplicons showing bands shifted from those from control cells were 
purified using the QIAquick Gel Extraction Kit (Qiagen). Amplicons were subjected to a 
second PCR amplification, treated with ExoSAP-IT PCR Product Clean-up Reagent 
[37oC, 15 mins, followed by 80oC, 15 mins (Affymetrix)] and Sanger sequenced 
(Eurofins Genomics). 
 
Table 2.1. Cycling conditions used for PCR assays.  
Stage Temperature (OC) Duration (seconds) Cycles 
Initial denaturation 95 30 1 
Denaturation 95 30 30 
Annealing 58 30 30 
Elongation 68 1 30 




2.5.4. In silico sequence analysis 
To explore predicted translation of mutated proteins, we uploaded edited mRNA 
sequences into ExPASy bioinformatics software [401] and aligned amino acid sequences 
to native sequences using the Clustal Omega multiple sequence alignment tool [402]. We 
depicted the protein domains for the edited proteins by using topology descriptions on 
UniProt [403]. 
2.6. Gene expression analysis  
2.6.1. RNA extraction and reverse transcription 
Total RNA was extracted using TRIzol Reagent (Invitrogen) and was assessed for purity 
and quantity using a Nanodrop 1000 spectrophotometer. RNA was reverse transcribed to 
cDNA using the high capacity RNA-to-cDNA kit (Thermo Fisher) and diluted ≥1:10 prior 
to experimentation. 
2.6.2. qPCR 
qPCR assays were designed using the online Universal Probe Library (UPL) assay design 
tool (Roche). Assay designs are provided in Tables 2.2.-2.3. Primer Blast [6] was used 
to predict the binding of primers to mouse and human SLC39A isoforms. The mouse 
primers bind all respective ZIP transporter isoforms. The human primers bind all isoforms 
for ZIP2, ZIP4, ZIP5, ZIP6, ZIP8, ZIP10, ZIP11, ZIP12 and ZIP13. Primers for ZIP1, 
ZIP3, ZIP7, ZIP9 and ZIP14 covered either all the isoforms expressed within human 
islets, or those predominantly expressed (Fig 3.1 and Appendices 6-7). PCR plates were 
loaded using the Biomek FX liquid handling robot (Beckman Coulter) and reactions [20-
40ng cDNA, 0.1µM UPL probe, 0.2µM forward primer, 0.2µM reverse primer and 1X 




Prism7900HT sequence detection system (Applied Biosystems) and analysed using 
sequence detection systems v2.4 software. All gene expression values were normalised 
to the housekeeping gene ubiquitin C (UBC). Validation of Ubc as an appropriate 
housekeeping gene is presented in Fig 2.2. Differential and relative expression were 
calculated using the ΔΔCT method as follows:  
Differential expression: 
log2 FC = log2(2
−ΔΔCT) 
Where: ΔΔCT =   ΔCt(Target sample)  −  ΔCt(Calibrator sample) 
And: ΔCT =   Ct(Target gene)  −  Ct(Housekeeping gene) 
 
Relative expression: 
% relative expression = 100 ∗(2−ΔΔCT) 
Where: ΔΔCT =   ΔCt(Target sample)  −  ΔCt(Calibrator sample) 
And: ΔCT =   Ct(Target gene)  −  Ct(Housekeeping gene) 
 
Assay efficiencies were validated through standard curves created from serial dilution of 
mRNA pooled from multiple samples (Fig 2.3). The efficiencies for primers targeting 
genes with appreciable expression ranged from 79.31 to 119.61% for mouse and 75.49 to 

























































Fig 2.2. Validation of Ubc as an appropriate housekeeping gene. Box plot showing 
qPCR Ct values for Ubc mRNA expression following culture of MIN6 cells in 6 
experimental conditions [1μM, 8μM, 42μM and 95μM zinc, 3mM glucose and 40mM 
potassium chloride (KCl)]. RNA (1.5μg) was reverse transcribed to cDNA and diluted 




Fig 2.3. Example standard curve plot for validation of primer efficiencies. Graph 
shows data for mouse primers targeting Ubc and is an average of three biological repeats. 




Table 2.2. qPCR assay designs for mouse genes undertaken in this study. * = Assay efficiency could not be determined due to low expression. 






Slc39a1 NM_013901.2 CGACAGCAATGGAGTGAGAC TCCGATGCGACTGCTTCT 119 #81 4689046001 89.24% 
Slc39a2 NM_001039676.2 CCTGCTTGCTCTTCTGGTTC ACCCTGTGGTGATGACCTG 99 #26 4687574001 100.12% 
Slc39a3 NM_134135.1 CGTATTCCTGGCTACATGCTT CGGGTAGTCGGTGCTGAT 97 #27 4687582001 92.17% 
Slc39a4 NM_028064.2 CAGCTACTGCAGAAGATTGAGG TCCAGCAGTTGGGGAAGAT 83 #07 4685059001 103.40% 
Slc39a5 NM_028051.3 GGCTGACCATCTGAATGAGG AGGGCTCAGTCCAAAATTGA 67 #33 4687663001 * 
Slc39a6 NM_139143.3 CCAGTCCCTTCGGACCTC CTGTGGCCATTGCACCTT 89 #70 4688937001 88.57% 
Slc39a6 (2) NM_139143.3 GTCGCTCTGGTTGACATGG CCGAGAAGTATCCCAGCATT 107 #4 4685016001 93.92% 
Slc39a7 NM_008202.2 GGATTTTGCCATCCTGGTC TTGCAGTCACGAGTTGCAG 71 #71 4688945001 101.18% 
Slc39a8 NM_026228.4 TCAGCGTTGTATCCCTCCA GTTTGGGCCCCTTCAGAC 69 #21 4686942001 102.43% 
Slc39a9 NM_026244.2 CGTGGCAATAATGCTACACAA CATGCATCAGGAAGGAAACC 62 #67 4688660001 110.68% 
Slc39a10 NM_172653.2 TTTCAGATCATAAGTTAAACAGCACA CCGAGTCATCCGTTCCAG 78 #89 4689143001 87.92% 
Slc39a11 NM_027216.5 GAGGATTGCTTTGCTCATCC AATCCTACGCCAACAGCAAG 72 #09 4685075001 99.96% 
Slc39a12 NM_001012305.2 TGGACACAAGGAGACTGCAA TTCCCCCAGCTGTGAGTAAC 64 #38 4687965001 * 
Slc39a13 NM_026721.2 AGATGTTCCTCAACAGCAAGG GCAGCAGTGGGGTCTTTG 61 #20 4686934001 96.92% 
Slc39a14 NM_001135151.1 GCTCTCTAACGCCCTTTTCC ATTGTCCTGAGGGTTGAAGC 61 #110 4692306001 97.39% 
Ubc NM_019639.4 GACCAGCAGCAGGCTGATCTT CCTCTGAGGCGAAGGACTAA 110 #11 4685105001 98.03% 
Gadph NM_008084.2 TGTCCGTCGTGGATCTGC CCTGCTTCACCACCTTCTTG 75 #80 4689038001 96.18% 
Slc30a1 NM_009579.3 AACACCAGCAATTCCAACG TCCACTGGGTCATCACTTCTC 74 #13 4685121001 101.31% 




Slc30a3 NM_011773.3 CTGCACACCTGGCTATTGAC GGGAATAGAGCCGGGATG 75 #41 4688007001 103.00% 
Slc30a4 NM_011774.2 TGCCATCATACTCACTCTGCTT ATCATGGCCGACAAAACCT 102 #05 4685024001 94.47% 
Slc30a5 NM_022885.2 CATTGTCGTAATCTCTCTGCTCA AAAGCAGCCCCTCTTGTCTT 78 #25 4686993001 87.34% 
Slc30a6 NM_144798.5 GCTTCCTGCTCATGTGGTG AAGATGGTGAGGTAAGTATAGGCAGT 70 #22 4686969001 98.23% 
Slc30a7 NM_023214.7 ATGGAGGTCACGGACATTCT GCACCATTAAAGAGGGAATGA 64 #21 4686942001 84.36% 
Slc30a8 NM_172816.3 GCTGCTTCAGCAATATGCTTC CAGACTCCCAGCAACGTGT 69 #53 4688503001 104.76% 
Slc30a9 NM_178651.3 GCTTTGAGTTCTGCGCCTAT GCTTTGAGTTCTGCGCCTAT 105 #100 4692187001 100.97% 
Slc30a10 NM_001033286.2 GGGCACAGCAGTGACTCTC TTCTCGGTGTTCAGGGAATC 102 #18 4686918001 * 
Mtf1 NM_008636.4 CCAAGAGACTAGTTGGCAGCA GGTGGGACCAAGATCACCT 65 #10 4685091001 102.61% 
Mt1 NM_013602.3 CAAGTGCACCTCCTGCAA TTCGTCACATCAGGCACAG 124 #18 4686918001 93.73% 
Mt2 NM_008630.2 CATGGACCCCAACTGCTC AGCAGGAGCAGCAGCTTT 110 #04 4685016001 95.64% 
Ins1 NM_008386.3 CGGGGACCTTCAGACCTT GTGCAGCACTGATCCACAAT 69 #10 4685091001 99.50% 
Ins2 NM_008387.5 GAAGTGGAGGACCCACAAGT CAGTGCCAAGGTCTGAAGGT 78 #32 4687655001 100.37% 
Foxa1 NM_008259.3 GAACAGCTACTACGCGGACA CGGAGTTCATGTTGCTGACA 65 #82 4689054001 96.03% 
Foxa2 NM_001291065.1 AAGTAGCCACCACACTTCAGG TGTGGCCCATCTATTTAGGG 71 #32 4687655001 94.39% 
Foxo1 NM_019739.3 GTGGGGCAACCTGTCGTA TTCTCGGCTGAGCTCTCG 60 #9 4685075001 93.99% 
Hnf1b NM_009330.2 AATCCCCAGCAATCTCAGAA GGCTTGGGAGGTGTTGAG 84 #109 4692284001 80.83% 
Hnf4a NM_008261.2 CAGCAATGGACAGATGTGTGA TGGTGATGGCTGTGGAGTC 76 #27 4687582001 119.61% 
MafA NM_194350.1 CTCCAGAGCCAGGTGGAG GTACAGGTCCCGCTCCTTG 66 #10 4685091001 98.11% 
Mnx1 NM_019944.2 GATGCCGGACTTCAGCTC AGCTGCTGGCTGGTGAAG 84 #60 4688589001 90.25% 
Neurod1 NM_010894.2 CGCAGAAGGCAAGGTGTC TTTGGTCATGTTTCCACTTCC 90 #01 4684974001 93.07% 
Nkx2.2 NM_010919.2 GCAGCGACAACCCCTACA ATTTGGAGCTCGAGTCTTGG 105 #20 4686934001 95.76% 




Pax4 NM_011038.2 AAGACCAGACCACCAGCAA AAGTTTCTCTTTGGGACTGGTTC 107 #01 4684974001 79.31% 
Pax6 NM_001244198.1 CACCAGACTCACCTGACACC ACCGCCCTTGGTTAAAGTC 62 #96 4692136001 96.37% 
Pdx-1 NM_008814.3 GAAATCCACCAAAGCTCACG CGGGTTCCGCTGTGTAAG 65 #51 4688481001 98.23% 
Arx NM_001305940.1 ACTTGTTACCGCTTGTCCTGA CCTCTGCTCCTCTCTCCTCA 64 #55 4688520001 117.14% 























Table 2.3. qPCR assay designs for human genes undertaken in this study. * = Assay efficiency could not be determined due to low expression. 






SLC39A1 NM_014437.3 GGAGAAAGCTCCGGGAAA GAGTGACGTCAGTTAGGAGCAA 91 #71 4688945001 106.38% 
SLC39A2 NM_014579.3 GAACAGATCAGCAAGTGAGAGAAA AGCTCTCCATAGGGATACTCCA 75 #09 4685075001 * 
SLC39A3 NM_144564.4 GTTTCTGGCCACGTGCTT AGGCTCAGGACCTTCTGGA 69 #74 4688970001 96.14% 
SLC39A4 NM_017767.2 GCTCCAGTGTGTGGGACA GCCTGTTCCGACAGTCCA 73 #46 4688066001 97.35% 
SLC39A5 NM_173596.2 CCTCTTCCTGCTCTTTGTGC TCGAGATTCCTTCGTTTTCG 96 #45 4688058001 93.22% 
SLC39A6 NM_012319.3 ACTGGCCGTTGGGACTTT ATGGTGGTGACTTGCATGAG 73 #09 4685075001 97.59% 
SLC39A7 NM_006979.2 CGAAGGTGGAACGGAACTT AGGCCTGGAAAGGATGGTAG 134 #55 4688520001 86.17% 
SLC39A8 NM_022154.5 TTTTGGTGGGCAACAATTTC CAGCATATCATTCATCTCTGGAA 107 #67 4688660001 92.53% 
SLC39A9 NM_018375.4 GGTCTGGTTGTCCATGCTG AACTGGACACTGGTCTGTGAAGT 77 #32 4687655001 75.49% 
SLC39A10 NM_001127257.1 TGTAGCCTTGGTGGATATGCT CCACAGGACAAAAGCCATGT 77 #09 4685075001 101.61% 
SLC39A11 NM_139177.3 GGGCTGATGGAAGTGCAG CCTTGGAGCATGCTGGATAC 63 #19 4686926001 * 
SLC39A12 NM_152725.3 TGAAATACTCTCCAGGATTTAAAAGG GGGGTAAACTTGTAACCAAAGGA 96 #50 4688112001 * 
SLC39A13 NM_001128225.2 GGCCAACACCATCGATAACT TTGTCAGGAGCCCGATCTT 83 #05 4685024001 95.72% 
SLC39A14 NM_015359.4 TCTCTGCCAACTGGATTTTTG CCTCATTCATCTCAGGGAACA 84 #78 4689011001 93.07% 
SLC30A8 NM_173851.2 AGTAATTCTCTCAGCTCATGTTGC GCAATTTCTCTCCGAACCAC 69 #66 4688651001 94.43% 
UBC M26880.1/M26880.EMI CAGAGGTTGATCTTTGCTGGA GCAGGGTGGACTCTTTCTGA 82 #11 4685105001 99.05% 
GADPH NM_002046.3 AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 66 #60 4688589001 106.38% 
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2.7. Protein expression analysis 
2.7.1. Protein extraction  
Cells were harvested by trypsinization (0.25% trypsin-EDTA (Thermo Fisher) in PBS) 
and lysed in ice-cold radioimmunoprecipitation buffer (50mM Tris (pH 8), 150mM NaCl, 
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1X 
Protease Inhibitor Cocktail and 1X Phosphatase Inhibitor Cocktail (both Sigma Aldrich). 
Lysates were incubated with agitation (40 mins, 4oC), the nucleic acids pelleted by 
centrifugation (12,000rpm, 20 mins, 4oC) and the protein lysate aspirated.  
2.7.2. Bradford assays 
Protein concentrations were calculated through Bradford assays. Samples were diluted 
1:100 with Bradford Reagent (Bio-Rad) in a microtiter plate in triplicate. Absorbance was 
measured at wavelength 595nm (reference: 450nm) using a microplate reader and 
standardised to dilutions of BSA (0.5, 1, 2, 5, 10, 20 and 30µg/ml; Sigma Aldrich) in 
PBS.  
2.7.3. Immunoblotting  
Protein lysates were prepared in 2x loading dye (Thermo Fisher) and boiled (10 mins, 
72oC). Lysates (20µg) were separated on 12% acrylamide SDS-PAGE gels (Thermo 
Fisher) using SDS-PAGE buffer (Thermo Fisher) supplemented with 0.1% SDS (200V, 
40 mins). Proteins were transferred onto nitrocellulose membranes [GE Healthcare Life 
Sciences (1 h, 100V)] using transfer buffer (25mM Tris, 192mM glycine, 10% methanol), 
and membranes blocked through incubation in 5% (w/v) BSA/Tris-buffered saline [TBS 
(50mM Tris-Cl pH 7.5, 150mM NaCl)] and 0.05% (v/v) TWEEN-20 [TBST (1 h, RT)]. 
Membranes were incubated with primary antibodies diluted in 1% BSA/TBST (16 h, 
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4oC), followed by HRP-linked secondary antibodies diluted in 1% BSA/TBST (1 h, RT). 
Details of the antibodies used are provided in the appropriate chapters. Cells were washed 
three times with TBST between each step. Membranes were treated with ECL Western 
Blotting Detection Reagent (GE Healthcare Life Sciences) and visualised on X-ray film 
(GE Healthcare Life Sciences) using a film imager. 
2.7.4. Membrane stripping  
Immunoblots were washed with TBST, incubated in stripping buffer [Thermo Fisher (15 
mins, RT)] and further washed with TBST (10 mins, RT). Membranes were blocked with 
5% (v/v) BSA/TBST (1 h, RT) before additional antibody incubation, as described in 
section 2.7.3. 
2.8. 65Zinc uptake assays  
Cells were washed in serum- and antibiotic-free DMEM (5 mins, RT) and incubated in 
Hepes control salt solution (HCSS; 145mM NaCl, 5.4mM KCl, 1.8mM CaCl2, 0.8mM 
MgCl2, 20mM HEPES, 5.5mM Glucose, pH to 7.4 with NaOH) containing 0-30µM 
65ZnCl [75MBq/mg, 25.8mM Zn2+ (15 mins, 37oC); Diagnostic Imaging]. To terminate 
the reaction, cells were immediately placed on ice, washed 3 times in ice-cold quench 
buffer (HCSS, 10mM CaCl2, 200µM ZnCl2, 5mM CaEDTA), and further incubated on 
ice (5 mins). Cells were lysed in hot 0.2% SDS solution and the radioactivity (cpm) of 
aspirated HCSS and the total cells counted using an automated gamma counter (1282 
compugamma; LKB Wallac). Zn2+ influx (Jin) was calculated as follows:  
 
𝐽𝑖𝑛 =  
𝑐𝑝𝑚 
𝑆𝐴 × 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 × 𝑡
 
Where cpm is the counts in the cells (cts min-1), SA is the average specific activity of Zn2+ 
transport throughout the assay (cts min-1 nmol-1), protein is the total amount of protein in 
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the assay, as calculated through Bradford assays of parallel (Bio-rad; section 2.7.2), non-
radioactive samples, and t is the time over which flux occurred (mins).  
2.9. Proliferation assays  
The rate of cellular proliferation was determined using the Cell Proliferation ELISA, 
BrdU (colorimetric) assay (Roche), following manufacturer’s instructions. A 2 h 
incubation period with BrdU labelling solution was used. The absorbance was measured 
using a microplate reader at wavelength 450nm (reference: 690nm).  
2.10. Apoptosis assays  
The rate of cellular apoptosis was determined through Caspase-Glo® 3/7 assays (Thermo 
Fisher), following manufacturer’s instructions, using 50μl reagent per 100μl sample. The 
luminescence was measured using a microplate reader.  
2.11. Assessment of oxidative stress  
Oxidative stress was assayed using dihydrofluorescin diacetate (Sigma Aldrich). Cells 
were washed once with warm Hanks Balanced Salt Solution (HBSS; Thermo Fisher) and 
incubated in HBSS containing 1μM dihydrofluorescin diacetate (30 mins, 37oC). Cells 
were placed on ice, washed with ice-cold HBSS and the fluorescence measured using a 
microplate reader (excitation/emission: 485/528).  
2.12. Insulin secretion assays  
Cells were starved in DMEM containing 3mM glucose (24 h, 37oC). Cells were washed 
with PBS, incubated in Krebs-ringer bicarbonate buffer [KRBH, 10mM Hepes, 2mM 
NaHCO3, 70mM NaCl, 3.6mM KCl, 0.5mM NaH2PO4, 0.5mM MgSO4, 1.5mM CaCl2. 
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10mM NaCl, 0.1% BSA, adjusted to pH 7.4 with NaOH (30 mins, 37oC)] supplemented 
with 3mM glucose (30 mins, 37oC), followed by KRBH supplemented with 3mM glucose 
or 3mM glucose and 40mM KCl (30 mins, 37oC). The supernatant containing secreted 
insulin was aspirated and diluted 1:20. The amounts of secreted insulin were determined 
using the colorimetric Rat/Mouse Insulin ELISA assay kit (EZRMI-13K, Merck 
Millipore), following manufacturer’s instructions, and normalised to total protein, 
determined through Bradford assays (Bio-Rad; section 2.7.2).  
2.13. Statistical analysis  
Unless otherwise stated, all statistical analysis was carried out through unpaired t-tests or 
2-way ANOVA followed by either Tukey’s or Sidak’s multiple comparison tests, as 
appropriate. Data were considered statistically significant when p <0.05 and presented as 















3. Expression of the ZIP/SLC39A transporters in β-cells: a 
systematic review and integration of multiple datasets 
3.1. Candidate contributions to chapter 3 
The work in this chapter has been published in BMC Genomics (published online 
September 2017; DOI: 10.1186/s12864-017-4119-2 [404]). I carried out all data 
collection and analysis and constructed all the tables and figures. I additionally produced 
the original draft and all further revisions of the manuscript, under the supervision of my 
supervisors. 
3.2. Context of chapter 3 in this thesis 
The work in this chapter goes towards addressing the first aim of this project: To identify 
ZIP transporters that functionally coordinate with ZnT8 to maintain normal zinc 
trafficking in β-cells and explore whether these transporters are regulated differently 
based on ZnT8 activity. I encompass a systematic approach to reveal ZIP transporters 
potentially important for β-cell function and complement these findings with 
experimental data to support a biological relevance of these results. The data presented in 










































3.3. Additional files in publication  
 










Table 3.1. Additional table 1: Designs for human qPCR assays undertaken. 
 
 
Gene RefSeq ID Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Amplicon 
UPL 
Probe 
SLC39A1 NM_014437.3 GGAGAAAGCTCCGGGAAA GAGTGACGTCAGTTAGGAGCAA 91 #71 
SLC39A2 NM_014579.3 GAACAGATCAGCAAGTGAGAGAAA AGCTCTCCATAGGGATACTCCA 75 #09 
SLC39A3 NM_144564.4 GTTTCTGGCCACGTGCTT AGGCTCAGGACCTTCTGGA 69 #74 
SLC39A4 NM_017767.2 GCTCCAGTGTGTGGGACA GCCTGTTCCGACAGTCCA 73 #46 
SLC39A5 NM_173596.2 CCTCTTCCTGCTCTTTGTGC TCGAGATTCCTTCGTTTTCG 96 #45 
SLC39A6 NM_012319.3 ACTGGCCGTTGGGACTTT ATGGTGGTGACTTGCATGAG 73 #09 
SLC39A7 NM_006979.2 CGAAGGTGGAACGGAACTT AGGCCTGGAAAGGATGGTAG 134 #55 
SLC39A8 NM_022154.5 TTTTGGTGGGCAACAATTTC CAGCATATCATTCATCTCTGGAA 107 #67 
SLC39A9 NM_018375.4 GGTCTGGTTGTCCATGCTG AACTGGACACTGGTCTGTGAAGT 77 #32 
SLC39A10 NM_001127257.1 TGTAGCCTTGGTGGATATGCT CCACAGGACAAAAGCCATGT 77 #09 
SLC39A11 NM_139177.3 GGGCTGATGGAAGTGCAG CCTTGGAGCATGCTGGATAC 63 #19 
SLC39A12 NM_152725.3 TGAAATACTCTCCAGGATTTAAAAGG GGGGTAAACTTGTAACCAAAGGA 96 #50 
SLC39A13 NM_001128225.2 GGCCAACACCATCGATAACT TTGTCAGGAGCCCGATCTT 83 #05 
SLC39A14 NM_015359.4 TCTCTGCCAACTGGATTTTTG CCTCATTCATCTCAGGGAACA 84 #78 
UBC M26880.1/M26880.EMI CAGAGGTTGATCTTTGCTGGA GCAGGGTGGACTCTTTCTGA 82 #11 
GAPDH NM_002046.3 AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 66 #60 
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Table 3.2. Additional table 2: Designs for mouse qPCR assays undertaken.  
Gene RefSeq ID Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Amplicon 
UPL 
Probe 
Slc39a1 NM_013901.2 CGACAGCAATGGAGTGAGAC TCCGATGCGACTGCTTCT 119 #81 
Slc39a2 NM_001039676.2 CCTGCTTGCTCTTCTGGTTC ACCCTGTGGTGATGACCTG 99 #26 
Slc39a3 NM_134135.1 CGTATTCCTGGCTACATGCTT CGGGTAGTCGGTGCTGAT 97 #27 
Slc39a4 NM_028064.2 CAGCTACTGCAGAAGATTGAGG TCCAGCAGTTGGGGAAGAT 83 #07 
Slc39a5 NM_028051.3 GGCTGACCATCTGAATGAGG AGGGCTCAGTCCAAAATTGA 67 #33 
Slc39a6 NM_139143.3 CCAGTCCCTTCGGACCTC CTGTGGCCATTGCACCTT 89 #70 
Slc39a7 NM_008202.2 GGATTTTGCCATCCTGGTC TTGCAGTCACGAGTTGCAG 71 #71 
Slc39a8 NM_026228.4 TCAGCGTTGTATCCCTCCA GTTTGGGCCCCTTCAGAC 69 #21 
Slc39a9 NM_026244.2 CGTGGCAATAATGCTACACAA CATGCATCAGGAAGGAAACC 62 #67 
Slc39a10 NM_172653.2 TTTCAGATCATAAGTTAAACAGCACA CCGAGTCATCCGTTCCAG 78 #89 
Slc39a11 NM_027216.5 GAGGATTGCTTTGCTCATCC AATCCTACGCCAACAGCAAG 72 #09 
Slc39a12 NM_001012305.2 TGGACACAAGGAGACTGCAA TTCCCCCAGCTGTGAGTAAC 64 #38 
Slc39a13 NM_026721.2 AGATGTTCCTCAACAGCAAGG GCAGCAGTGGGGTCTTTG 61 #20 
Slc39a14 NM_001135151.1 GCTCTCTAACGCCCTTTTCC ATTGTCCTGAGGGTTGAAGC 61 #110 
Ubc NM_019639.4 GACCAGCAGCAGGCTGATCTT CCTCTGAGGCGAAGGACTAA 110 #11 





Fig 3.1. Additional file 4: ZIP isoforms in human islets. Data produced through 


















4. Prolonged stimulation of insulin-release from MIN6 cells 
causes zinc depletion and loss of β-cell markers 
 
4.1. Candidate contributions to chapter 4 
The work in this chapter has been published in The Journal of Trace Elements in Medicine 
and Biology (published online April 2018; DOI: 10.1016/j.jtemb.2018.04.020 [405]). I 
carried out all the data collection and analysis and constructed all the tables and figures. 
I additionally produced the original draft and all subsequent revisions of the manuscript, 
under the supervision of my supervisors.  
4.2. Context of chapter 4 in this thesis 
The work in this chapter goes towards addressing the second aim of this project: To 
explore the consequences of the hyperglycaemia and hypozincaemia associated with Type 
2 Diabetes for β-cell ZIP transporter expression, zinc content and cellular phenotype. I 
examined the consequences of chronic stimulation, representative of the hyperglycaemia 
present in Type 2 Diabetes, for the β-cell zinc content, and explored the biological 
relevance of these data by assessing expression of Zn2+-responsive β-cell markers. The 
data presented in this publication reveal a plausible link between hyperglycaemia and 
zinc-induced loss of β-cell phenotype. These results strengthen the basis for chapters 5-7 
of this thesis by showing that decreases in cellular zinc may be detrimental for β-cell 





















4.3. Additional files in publication  
Table 4.1. Additional table 1: Designs for qPCR assays undertaken. 
Transcript RefSeq ID Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Amplicon 
UPL 
Probe 
Slc39a1 NM_013901.2 CGACAGCAATGGAGTGAGAC TCCGATGCGACTGCTTCT 119 #81 
Slc39a6 NM_139143.3 CCAGTCCCTTCGGACCTC CTGTGGCCATTGCACCTT 89 #70 
Slc39a7 NM_008202.2 GGATTTTGCCATCCTGGTC TTGCAGTCACGAGTTGCAG 71 #71 
Slc39a9 NM_026244.2 CGTGGCAATAATGCTACACAA CATGCATCAGGAAGGAAACC 62 #67 
Slc39a14 NM_001135151.1 GCTCTCTAACGCCCTTTTCC ATTGTCCTGAGGGTTGAAGC 61 #110 
Mtf1 NM_008636.4 CCAAGAGACTAGTTGGCAGCA GGTGGGACCAAGATCACCT 65 #10 
Mt1 NM_013602.3 CAAGTGCACCTCCTGCAA TTCGTCACATCAGGCACAG 124 #18 
Mt2 NM_008630.2 CATGGACCCCAACTGCTC AGCAGGAGCAGCAGCTTT 110 #04 
Foxa1 NM_008259.3 GAACAGCTACTACGCGGACA CGGAGTTCATGTTGCTGACA 65 #82 
Foxo1 NM_019739.3 GTGGGGCAACCTGTCGTA TTCTCGGCTGAGCTCTCG 60 #9 
Hnf1b NM_009330.2 AATCCCCAGCAATCTCAGAA GGCTTGGGAGGTGTTGAG 84 #109 
Hnf4a NM_008261.2 CAGCAATGGACAGATGTGTGA TGGTGATGGCTGTGGAGTC 76 #27 
MafA NM_194350.1 CTCCAGAGCCAGGTGGAG GTACAGGTCCCGCTCCTTG 66 #10 
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Mnx1 NM_019944.2 GATGCCGGACTTCAGCTC AGCTGCTGGCTGGTGAAG 84 #60 
Neurod1 NM_010894.2 CGCAGAAGGCAAGGTGTC TTTGGTCATGTTTCCACTTCC 90 #01 
Nkx2.2 NM_010919.2 GCAGCGACAACCCCTACA ATTTGGAGCTCGAGTCTTGG 105 #20 
Nkx6.1 NM_144955.2 CCCGGAGTGATGCAGAGT GAACGTGGGTCTGGTGTGTT 114 #103 
Pax4 NM_011038.2 AAGACCAGACCACCAGCAA AAGTTTCTCTTTGGGACTGGTTC 107 #01 
Pax6 NM_001244198.1 CACCAGACTCACCTGACACC ACCGCCCTTGGTTAAAGTC 62 #96 
Pdx-1 NM_008814.3 GAAATCCACCAAAGCTCACG CGGGTTCCGCTGTGTAAG 65 #51 





Additional file 2. Interactions report (excel file available online; DOI: 10.1016/j.jtemb.2018.04.020).
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5. Extracellular zinc depletion lowers β-cell zinc content, 
disrupts the transcriptome and reduces cellular survival  
5.1. Abstract 
Large amounts of zinc are lost from pancreatic β-cells during GSIS. Adequate zinc 
replenishment is therefore required to maintain normal intracellular concentrations, 
mediated by ZIP transporters at the plasma membrane and membranes of intracellular 
organelles. However, hypozincaemia present in many type 2 diabetic patients and animal 
models of diabetes reduces the amount of zinc available for β-cell zinc uptake. We 
hypothesised that changes to extracellular zinc alter the β-cell zinc content and phenotype. 
We cultured MIN6 cells with depleted (1µM), adequate (8µM) and excess (42µM) zinc 
to show that zinc depletion lowers total cellular zinc and downregulates mRNA for Mt1 
and Mt2, indicative of decreased cytosolic free Zn2+, but upregulates expression of 
Slc39a8 and Slc39a14, presumably to increase cellular zinc uptake. Concurrently, excess 
zinc upregulates Mt1 and Mt2. Culture of MIN6 cells with each of depleted or excess zinc 
lowers cellular proliferation and increases apoptosis compared to cells cultured with 
adequate zinc, each associated with reduced signalling via mTOR and MAPK cascades. 
To further investigate the impact of zinc depletion for β-cells, we carried out RNA-seq 
on MIN6 cells and mouse islets to show differentially expressed genes were enriched for 
phosphatases and that HIF1A regulation may be a key pathway disrupted by zinc 
depletion. These data indicate hypozincaemia present in some type 2 diabetic patients 
may lower the zinc content of β-cells to mediate intracellular signalling and reduce 





Zinc is fundamental for a multitude of biological processes as a structural, catalytic, and 
signalling component [127, 128]. β-cells contain one of the highest zinc contents of any 
known cell type, with total concentrations reaching 150-200µM [281]. The 
predominantly β-cell-specific zinc transporter ZnT8 facilitates zinc uptake into insulin 
secretory granules, where zinc in involved in proper insulin processing and is secreted 
with insulin during GSIS. Large amounts of zinc are therefore lost from β-cells during 
Zn2+/insulin co-exocytosis and β-cells must maintain exceptionally high turnovers to 
replenish normal concentrations [266], mediated by members of the ZIP family of zinc 
importer proteins. Upon high glucose stimulation and enhanced ZnT8-facilitated granule 
zinc uptake, β-cells exhibit significant increases in cytosolic free Zn2+ and expression of 
Zn2+-regulated genes (chapter 4 [405] and [192]), suggestive of additional roles for the 
elevated zinc aside from in insulin granules.  
In human, normal serum zinc concentrations range from 0.66 to 1.10 mg/mL [406]. 
Metabolically obese individuals, type 2 diabetic patients and animal models of diabetes 
often exhibit systemic hypozincaemia [140, 283, 284, 407] and lowered zinc intakes have 
been shown to increase the relative risk of Type 2 Diabetes development by 17% [285]. 
In healthy individuals, approximately 80% of absorbed zinc is transported through the 
bloodstream associated with the serum protein Human Serum Albumin (HSA) [408]. 
Persistent hyperglycaemia present in diabetes induces non-enzymatic glycation of HSA, 
which alters its tertiary structure and lowers its zinc binding ability, reducing transport 
and distribution of zinc around the body and promoting hypozincaemia [409]. Diabetic 
hypozincaemia is further induced by increased urinary zinc loss [410]. Since zinc cannot 
be stored in mammals for more than a few days [411], hypozincaemia reduces the 
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amounts of zinc available for β-cell zinc replenishment following GSIS and this may 
promote dysfunction. Concurrently, zinc supplementation enhances β-cell function in 
high fat-fed mice [393], and increases insulin sensitivity [139] and improves glycaemic 
control in multiple animal models of diabetes [391-393] and in hypozincaemic type 2 
diabetic patients [412, 413].  
RNA-seq is a high-throughput sequencing technique used to quantify genome-wide 
changes to transcript expression. A population of RNA is fragmented and converted into 
a cDNA library containing adaptors at one or both ends. cDNA is amplified and 
sequenced to obtain 30-400 bp sequences, which generate high resolution expression 
profiles for multiple types of coding and noncoding RNA species, including mRNA, 
microRNA, long noncoding RNA, small nuclear RNA, small nucleolar RNA and Piwi-
interacting RNA [414, 415]. Reads are mapped to the respective reference genome to 
produce a genome-wide transcriptomics map containing the structure and/or level of 
expression for each part of the genome. For accurate bioinformatic analysis, read counts 
are normalised to correct for systematic variability including sequence composition bias, 
differences in read depth and reads mapping to multiple transcripts, such as to gene 
isoforms [414]. RNA-seq can be used to detail genome annotations at base resolution, 
allowing genomic variations such as SNPs to be identified with low or non-existent 
background signals. RNA-seq offers further benefits over alternative expression analysis 
techniques (hybridization-based microarrays and Sanger sequencing) including increased 
sensitivity for genes expressed at low and very high levels, the requirement for less 
sample, novel gene discovery and enabling analysis of alternative splicing and allele-
specific expression [414, 415].  
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A constant supply of zinc is essential to maintain β-cell zinc contents and both disrupted 
β-cell zinc [416] and hypozincaemia [140, 283, 284, 407] are linked to loss of glycaemic 
control. We therefore hypothesised that changes to extracellular zinc alter β-cell zinc 
uptake and accumulation and that subsequent changes to cellular zinc alter the β-cell 
phenotype. We aimed to characterise MIN6 cells in response to depleted and excess zinc 
and to identify pathways deregulated by zinc depletion that may help explain the 
phenotypes observed in hypozincaemic type 2 diabetic patients.  
In this study, we stressed MIN6 cells with low, adequate (control) and high concentrations 
of zinc for 24, 48 and 96 h. We showed that zinc depletion reduces the zinc content of 
MIN6 cells but upregulates mRNA expression for Slc39a8 and Slc39a14 and increases 
the cellular zinc uptake capacity. Moreover, incubation of MIN6 cells with both depleted 
and excess zinc lowers cellular proliferation and increases apoptosis at 96 h, associated 
with reduced activation of MAPK and mTOR cascades. However, we did not record any 
differences in insulin gene expression or secretion. Finally, we used RNA-seq to explore 
transcriptomic changes induced by zinc depletion in MIN6 cells and mouse islets. We 
demonstrated that differentially expressed genes were enriched for phosphatases and that 
HIF1A regulation may be a key pathway mediated by zinc depletion. Critically, these 
data demonstrate the hypozincaemia present in some type 2 diabetic patients may lower 






5.3. Methods  
5.3.1. Cell line and culture  
MIN6 cells were cultured as described in 2.1. For experimentation, standard growth 
medium was replaced with growth media containing 25mM glucose and 1μM, 8μM or 
42μM zinc for 24, 48 or 96 h (section 2.2). 
5.3.2. Cellular zinc parameters  
The total cellular zinc content was determined through ICP-MS (section 2.3). The kinetics 
of zinc uptake into MIN6 cells were assessed through 65Zinc uptake assays (section 2.8).  
5.3.3. Gene expression analysis 
RNA was extracted from MIN6 cells, reverse transcribed to cDNA and relative 
expression assayed through qPCR. The full methodology and details of primers used are 
provided in section 2.6. All results are presented as fold changes (Log2) in expression.  
5.3.4. Cellular proliferation, apoptosis and oxidative stress 
MIN6 cell proliferation, apoptosis and oxidative stress were determined as described in 
sections 2.9-2.11. To explore signalling via MAPK and mTOR cascades, protein was 
extracted from cells and phosphorylation of ERK1/2 (MAPK) and RPS6 (mTOR) were 
determined by immunoblot (section 2.7), expressed as a ratio to total ERK1/2 or RPS6. 
Primary antibodies used, with dilutions in 1% BSA/TBST, were ERK1/2 [#9102, Cell 
Signalling Technologies (1:1,000)], p42/44 ERK1/2 [#4370, Cell Signalling 
Technologies (1:2,000)], RPS6 [#2217, Cell Signalling Technologies (1:1,000)], 
Ser235/236 RPS6 [#4858, Cell Signalling Technologies (1:2,000)]. The HRP-linked 




5.3.5. Mouse islets 
5.3.5.1. Pancreas isolation 
Male CD-1 mice were used as pancreatic donors. Mice were sacrificed by cervical 
dislocation at 12 weeks and pancreases isolated through collagenase digestion [1mg/ml 
(w/v) clostridium histolyticum, type X1 (Sigma Aldrich) in Modified Eagle’s Medium 
(MEM; Sigma Aldrich)]. Isolated pancreases were heated at 37oC for 10 mins and 
immediately placed on ice.  
5.3.5.2. Islet isolation and purification  
Isolated pancreases were washed three times with 25ml MEM containing 10% newborn 
calf serum, 100μg/ml streptomycin and 100 units/ml penicillin (all Sigma Aldrich; 
supplemented MEM) through vigorous shaking and centrifugation (1400rpm, 1 min 15, 
RT). Pancreases were resuspended in supplemented MEM and the islets isolated by 
passing through a 425mm sieve. The islets were pelleted (1500rpm, 1 min 30, RT), 
airdried, and resuspended in 15ml histopaque-1077 (Sigma Aldrich). Supplemented 
MEM (10ml) was added slowly to create two distinct layers, the suspension centrifuged 
(3510rpm, 24 mins, 10oC), and the islets removed from just below the interface. Islets 
were washed three times with 50ml supplemented MEM (replacing only the top 25ml 
MEM each time) through vortex and centrifugation (1500rpm, 1.5 min, RT). Purified 
islets were placed into non-stick Sterlin® petri-dishes (Thermo Fisher) and removed 
using a 19G needle. 
5.3.5.3. Islet culture  
Isolated islets were resuspended in RPMI medium containing 11mM glucose (Thermo 
Fisher) supplemented with 10% FBS, 4mM L-glutamine, 50μM β-mercaptoethanol, 
100μg/ml streptomycin and 100 units/ml penicillin. Media contained total zinc 
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concentrations of 1µM or 8µM (section 2.3). Islets were cultured in 60ml Sterlin® petri-
dishes at 37oC in a humidified atmosphere of 95% air and 5% CO2.   
5.3.6. Transcriptomic analysis  
5.3.6.1. RNA extraction  
Total RNA was extracted from MIN6 cells and mouse islets using the RNeasy Mini Kit 
(Qiagen) with on-column DNase I treatment, according to manufacturer’s instructions. 
Purified RNA was assessed for purity and quantity using a Nanodrop 1000 
spectrophotometer and for quality using the RNA 6000 Nano Kit on a Bioanalyzer 2100 
(both Agilent Technologies). Agilent Bioanalyzer analysis assigns RIN numbers 
(estimations of RNA integrity) to indicate RNA quality. The RIN numbers for all samples 
ranged between 9 and 10, indicating high quality RNA. Electropherograms and 
corresponding RIN numbers are provided in Appendix 8. To proceed onwards with 
RNA-seq, three biological repeats for MIN6 cells and five biological repeats for islets 
were chosen. These samples were annotated as follows during Agilent Bioanalyzer 
analysis: MIN6 cells (1μM zinc, samples 1, 2 and 3; 8μM zinc, samples 1, 3 and 4) and 
islets (both 1μM and 8μM zinc for samples 1, 2, 4, 7 and 10).  
5.3.6.2. RNA-seq 
Intact high-quality total RNA (RIN >9; 100ng) was used as input RNA to generate 
libraries for RNA-seq using the NEBNext Ultra II Directional kit (NEB, Cat.no: E7760S), 
as per manufacturer’s recommendations. This protocol involved an initial step of 
ribosomal RNA depletion before the remaining RNA is fragmented. The first cDNA 
strand is then synthesised followed by the second strand, which is barcoded with indices 
for Illumina sequencing for final library amplification (13-cycles). The resulting libraries 
(330-380 bp full size) were assessed on a Bioanlyzer 2100 for purity. The NEBNext® 
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Library Quant Kit for Illumina (E7630L) was used to calculate the quantity of each 
library. The quantification data were used to pool the libraries in equal molarity prior to 
performing a QC run on the MiSeq [MiSeq Reagent Kit v3 (150-cycle); Cat no: MS-102-
3001]. Further deep sequencing was performed on the pooled library using a HiSeq4000 
to generate approximately 65 million reads per sample. 
5.3.6.3. Data pre-processing  
RNA-seq output data were provided as fastq files as two reads per lane for each sample. 
Reads were merged to make a composite for each sample. The quality of the sequencing 
data was assessed using FastQC to assess parameters such as per base sequencing quality 
and duplication. The adapters were trimmed using the FastQ toolkit on BaseSpace (5’ 
adaptor: CAA GCA GAA GAC GGC ATA CGA T; 3’ adapter: GTG ACT GGA GTT CAG 
ACG TGT GCT CTT CCG ATC T) and aligned using STAR to mm10 (GRCm38.90) to 
detect novel splice variants and fusion callings. Following alignment, Seqmonk 
(Babraham) was used to view the mapped data (Appendices 9-11). The RNA-seq QC 
plot showed ~100% reads mapped to genes, ~75% mapped to exons, with some spliced 
transcripts present, and 0% mapped to ribosomal RNA. The cumulative distribution plot 
showed there was no contamination of samples with ribosomal RNA or guide DNA, and 
the data store tree showed predicted grouping of the biological replicates with no obvious 
technical bias.  
5.3.6.4. Differential expression analysis 
Aligned data files were uploaded into Qlucore Omics Explorer (version 3.2; Qlucore AB, 
Lund, Sweden) bioinformatics software. Data were normalised by trimmed mean of M 
values (TMM) normalisation, which uses a weighted trimmed mean of the log expression 
ratios to estimate the ratio of RNA production and account for dataset composition bias 
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[417]. We visualised similarities in gene expression between different samples through 
generating principal component analysis (PCA) plots. Fold differences (FD) in gene 
expression were derived for the relevant conditions: MIN6 cells (1µM vs 8µM zinc), 
islets (1µM vs 8µM zinc) and MIN6 cells and islets (1µM vs 8µM zinc, eliminating the 
effect of sample origin during statistical analysis). We optimised the gene lists by filtering 
the variance (σ/σmax) to 0.33. Differential expression was calculated through unpaired t-
tests (≠), adjusted for multiple comparison testing, and q-values <0.1 were used to 
indicate statistically significant differences. The literature was searched for previous 
associations between differentially expressed genes and zinc, and genes lists were 
inserted into DisGeNET software (http://www.disgenet.org) [418] to explore previous 
associations with diabetes.  
Since only a limited number of genes were identified as differentially expressed (q <0.01), 
we used variance-optimised (σ/σmax: 0.57) gene lists that were not corrected for multiple 
comparison testing (p-values <0.05) for further analysis. This is still a reasonable robust 
approach as subsequent enrichment analysis entails another layer of statistics. If tested 
gene lists are random, it is unlikely there will be any statistically significant enrichment 
or depletion of networks or gene categories. The intersection between comparisons 
(MIN6 cells: 1µM vs 8µM zinc; islets: 1µM vs 8µM zinc, and MIN6 cells and islets: 1µM 
vs 8µM zinc; p <0.05) were visualised in Venn diagrams created using GeneVenn 
software (http://genevenn.sourceforge.net/) [419]. 
5.3.6.5. Gene enrichment and network analysis 
We used GeneGo MetaCoreTM bioinformatics software version 6.35 (Thomson Reuters; 
https://portal.genego.com/) to analyse the gene list for our combined data [MIN6 cells 
and islets (1µM vs 8µM zinc), p <0.05]. We explored enriched protein functions, enriched 
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gene ontology (GO) cellular processes and enriched pathways for differentially expressed 
genes and identified transcription factors overly connected to differentially expressed 
genes in the dataset. For analysis of enriched protein functions and overly connected 
transcription factors, we recorded the ratio of hits in the dataset compared to the number 
expected by chance and the p-values for the significances. For enriched GO cellular 
processes and pathways, we recorded the number of hits in the dataset compared to the 
total number of genes associated with the process/pathway, the p-values for the 
significances and the false discovery rates (FDRs). For the pathway ‘negative regulation 
of HIF1A function’, we explored where zinc impacts the pathway through generating a 
pathway map, which highlights the differentially expressed genes alongside their relative 
levels of expression.   
5.3.6.6. Comparison of RNA-seq and qPCR data 
We compared differential expression of genes in MIN6 cells assessed through both RNA-
seq and qPCR (data presented in chapters 4 [405] and 5) following 48 h culture with 1µM 
or 8µM zinc. We collated and compared FD in expression and the significances for 
differential expression. For RNA-seq data, the p-values presented were not corrected for 
multiple comparison testing since we were interrogating a specific set of genes in this 
instance and not looking genome-wide. 
5.4. Results 
5.4.1. Zinc depletion decreases the zinc content of MIN6 cells 
β-cells exhibit exceptionally high turnovers of zinc [266] to maintain normal zinc contents 
following Zn2+/insulin co-exocytosis. Zinc is delivered to islets through the bloodstream 
[408], however the amounts of serum zinc available for β-cell uptake is decreased in many 
type 2 diabetic patients [140, 283, 284]. To explore if changes to extracellular zinc 
122 
 
influence β-cell zinc content, we incubated MIN6 cells with depleted (1µM), adequate 
(8µM; control) or excess (42µM) zinc for 24, 48 or 96 h. 
MIN6 cells cultured with depleted zinc medium exhibited lowered total zinc contents 
compared to cells cultured with adequate (48 h: 1.26-fold; 96 h: 1.90-fold) or excess zinc 
(48 h: 1.37-fold; 96 h: 2.01-fold). However, we did not record any differences in total 
cellular zinc between MIN6 cells cultured with excess zinc or controls (Fig 5.1A). To 
explore changes to cytosolic zinc, we assayed mRNA expression for Mt1, Mt2 and Mtf1. 
Zinc depletion downregulated Mt1 and Mt2 compared to controls at 24 h (Mt1: 3.46-fold; 
Mt2: 4.02-fold), 48 h (Mt1: 5.40-fold; Mt2: 6.98-fold) and 96 h (Mt1: 1.73-fold; Mt2: 
2.48-fold), whereas excess zinc upregulated both transcripts at 48 h (Mt1: 2.76-fold; Mt2: 
3.46-fold) and 96 h (Mt1: 2.94-fold; Mt2: 4.78-fold) (Fig 5.1B-C). These results are 
consistent with a positive correlation between extracellular and cytosolic zinc. However, 
we did not record any differences in mRNA expression for Mtf1 following culture of cells 





Fig 5.1. Zinc content of MIN6 cells in response to changes in extracellular zinc. (A) 
Total MIN6 cell zinc content following culture with 1µM, 8µM or 42µM zinc for 24, 48 
or 96 h. Total zinc was determined through ICP-MS and normalised to protein. N=4. (B-
D) mRNA expression for (B) Mt1, (C) Mt2 and (D) Mtf1 following culture with 1µM, 
8µM or 42µM zinc for 24, 48 or 96 h. Changes in mRNA expression were calculated 
through qPCR and FD (Log2) in expression presented relative to MIN6 cells cultured with 
8µM zinc (control) at each time-point. N=3. All data were analysed by 2-way ANOVA 
followed by Tukey’s multiple comparison test. Error bars show ± SEM. *p <0.05, **p 
<0.005, ****p <0.0001. 
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5.4.2. Zinc depletion increases the MIN6 cell zinc uptake capacity  
Cytosolic zinc uptake is facilitated by ZIP transporters at the plasma membrane and 
membranes of intracellular organelles [420, 421]. We and others suggest ZIP1, ZIP6, 
ZIP7, ZIP8, ZIP9 and ZIP14 [192, 218, 404] are important for zinc trafficking into β-
cells. Moreover, the abundance of ZnT8, which functions to transport zinc into insulin 
secretory granules, is associated with increased cytosolic zinc [201, 278] and is 
downregulated by stresses that negatively impact β-cell function [179, 186, 227]. To 
examine the role of the ZIP transporters for maintaining β-cell zinc homeostasis, we 
characterised zinc influx into MIN6 cells in response to changes in extracellular zinc. 
MIN6 cells cultured with zinc depletion exhibited upregulation of mRNA for Slc39a8 
(2.13-fold) and Slc39a14 (1.60-fold) at 48 h, however only Slc39a8 remained upregulated 
(2.71-fold) at 96 h compared to controls. Whereas cells cultured with excess zinc 
downregulated mRNA for Slc39a8 at both 24 h (1.67-fold) and 96 h (1.78-fold), and 
upregulated mRNA for Slc39a6 1.56-fold at 96 h (Fig 5.2). To attribute these changes in 
mRNA abundance to cytosolic zinc influx, we examined the zinc uptake kinetics for 
MIN6 cells. We cultured cells in 1µM, 8µM or 42µM zinc for 24, 48 or 96 h and then 
assayed 65Zn uptake over a range of concentrations. Following pre-treatment with zinc 
depletion, we observed higher zinc influx into MIN6 cells at the highest two 65Zn 
concentrations tested (23.85µM and 14.30µM) at 48 h compared to cells pre-treated with 
adequate zinc. Although not statistically significant, a similar trend was observed at both 
24 and 96 h (Fig 5.3). However, these observations did not translate into significant 






Fig 5.2. Abundances of Slc39a and Slc30a8 mRNA in MIN6 cells in response to 
changes in extracellular zinc. Expression of (A) Slc39a1, (B) Slc39a6, (C) Slc39a7, (D) 
Slc39a8, (E) Slc39a9, (F) Slc39a14, and (G) Slc30a8. Experiments were carried out 
following culture with 1µM, 8µM or 42µM zinc for 24, 48 or 96 h. Expression was 
determined through qPCR and expressed as FD (Log2) in expression relative to control 
cells (8µM zinc) at each time-point. Data were analysed by 2-way ANOVA followed by 




Fig 5.3. Kinetics of zinc uptake into MIN6 cells in response to changes in 
extracellular zinc. Uptake kinetics of 65Zn into MIN6 cells following pre-treatment with 
1µM, 8µM or 42µM zinc for (A) 24, (B) 48 or (C) 96 h. The rates of zinc uptake were 
assessed through 65Zn uptake assays. N=3. Red: 1µM zinc, black: 8µM zinc, blue: 42µM 
zinc. Data were analysed by 2-way ANOVA followed by Tukey’s multiple comparison 
test. Error bars show ± SEM. For 1µM vs 8µM zinc: *p <0.05, **p <0.005, ***p <0.001. 
For 42µM vs 8µM zinc: #p <0.05, ##p <0.005. 
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5.4.3. Zinc depletion and excess decrease MIN6 cell survival  
Adequate zinc is essential for cellular survival and growth. Zinc promotes survival 
through mediating numerous signalling pathways as a protein-binding and signalling 
component, with roles described in AKT [59], JAK/STAT [317], MAPK (including 
ERK1/2 [314], c-JNK and p38 [310]) and mTORC1 [313] signalling cascades. However, 
excess zinc decreases viability of human islets and mouse MIN6N8 cells [374]. We 
therefore examined whether changes to MIN6 cell zinc impact cellular viability.  
MIN6 cells cultured in medium containing either depleted (1µM) or excess (42µM) zinc 
for 96 h exhibited decreased proliferation (1µM: 1.25-fold; 42µM: 1.35-fold) compared 
to controls. We further observed increased apoptosis (1.37-fold) for cells cultured with 
depleted zinc and increased amounts of oxidative stress (1.78-fold), as measured by the 
abundance of oxidizing metabolites that are increased by oxidant stress [422, 423], for 
cells cultured with excess zinc (Fig 5.4A-C). To explore if zinc may signal via MAPK or 
mTOR cascades to drive these changes to MIN6 cell viability, we examined 
phosphorylation of the downstream effectors ERK1/2 (MAPK cascades) and RPS6 
(mTOR cascades), which are both activated by phosphorylation. Diagrams illustrating 
how ERK1/2 and RPS6 phosphorylation relate to cellular survival are provided in Fig 
5.5. We examined phosphorylation at both 48 and 96 h since these changes may occur at 
an earlier time-point to drive the changes in proliferation and apoptosis. At 96 h, we 
observed decreased phosphorylation for both RPS6 and ERK1/2 in MIN6 cells cultured 
with either depleted (RPS6: 1.43-fold; ERK1/2: 1.79-fold) or excess (RPS6: 1.55-fold; 
ERK1/2: 1.35-fold) zinc compared to controls (Fig 5.4D-E). We did not record any 
differences in proliferation, apoptosis, oxidative stress or signalling via MAPK or mTOR 
cascades between MIN6 cells cultured with deficient, adequate or excess zinc for 48 h 




Fig 5.4. Survival of MIN6 cells in response to changes in extracellular zinc. (A) MIN6 
cell proliferation, calculated by BrdU incorporation. (B) MIN6 cell apoptosis, measured 
by Caspase 3/7 assays. (C) MIN6 cell oxidative stress, measured by dihydrofluorescin 
diacetate fluorescence. (D-F) Phosphorylation of RPS6 and ERK1/2. (D) Immunoblots 
for Ser235/236 RPS6, RPS6, p42/p44 ERK1/2 and ERK1/2. (E-F) Quantification of 
immunoblots for (E) Ser235/236 RPS6 vs RPS6 and (F) p42/p44 ERK1/2 vs ERK1/2. 
Immunoblot quantification was carried out using ImageJ software.  All experiments were 
carried out following culture of MIN6 cells with 1µM, 8µM or 42µM zinc for 96 h. 
Results are relative to MIN6 cells in 8µM zinc (control). Data were analysed by 2-way 
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ANOVA followed by Tukey’s multiple comparison test. Error bars show ± SEM. N=3-




Fig 5.5. RPS6, ERK1/2 and cellular survival. (A) mTOR (mTORC1) activates p70S6K, 
which phosphorylates and activates RPS6. Phosphorylated RPS6 activates protein 
translation to drive proliferation and inhibit apoptosis. (B) Phosphorylated ERK1/2 
promotes cellular growth and proliferation through phosphorylating and activating RSK, 
c-FOS, ELK, STAT and c-JUN. Phosphorylated ERK1/2 inhibits apoptosis through 
activating Bcl-2 and suppressing Caspase 3, which induces DNA fragmentation. (P) = the 
protein is phosphorylated. 
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5.4.4. Zinc does not affect MIN6 cell insulin expression or secretion  
β-cells function to mount adequate insulin secretory responses to glucose to maintain 
glycaemic control. Disruption of insulin gene regulation and insulin secretion is 
characteristic of β-cell dysfunction and represents a hallmark of β-cell failure during 
diabetes. Zinc is reported to promote both stimulatory [219, 329] and inhibitory [424] 
effects on β-cell insulin secretion. We therefore explored expression of insulin, of which 
two paralogues exist in rodent, in MIN6 cells and insulin secretion from MIN6 cells in 
response to changes in extracellular zinc. We did not observe any differences in mRNA 
abundances for Ins1 or Ins2 in cells cultured with depleted or excess zinc compared to 
controls. Moreover, we did not record any differences in basal or KCl-stimulated insulin 
release from MIN6 cells grown in either 1, 8 or 42µM zinc for 24, 48 or 96 h. Data for 






Fig 5.6. MIN6 cell insulin gene expression and insulin secretion in response to 
changes in extracellular zinc. (A-B) Abundance of (A) Ins1 or (B) Ins2 mRNA 
expression following culture with 1µM, 8µM or 42µM zinc for 96 h. Expression was 
assayed through qPCR and calculated as FD (Log2) relative to MIN6 cells cultured with 
8µM zinc (control). (C) Insulin secretion from MIN6 cells in response to 3mM glucose 
(basal) or 40mM KCl (stimulated) following culture with 1µM, 8µM or 42µM zinc for 
96 h. The amounts of secreted insulin were calculated through insulin secretion assays 
and normalised to total protein. Data were analysed by 2-way ANOVA followed by 





5.4.5. Zinc and the β-cell transcriptome  
In chapter 4 [405], we showed that multiple important β-cell markers are Zn2+-responsive. 
Zinc binds ~3000 proteins in mammals [129] that are involved in diverse arrays of cellular 
processes [130, 301]. However, this does not mean that Zn2+-responsive genes encode 
zinc(II)-binding proteins since regulation may be secondary to the cellular phenotype 
induced by zinc depletion. To avoid restricting investigation to pre-defined gene lists, we 
sought to explore the full set of processes to which zinc deficiency causes alterations in 
β-cells through transcriptomic analysis. We carried out RNA-seq on MIN6 cells and 
mouse islets following culture with depleted (1µM) or adequate (8µM) zinc for 48 h. 
Mouse islets were included in this study to increase the confidence of applying results 
from monolayer MIN6 cells to a physiological system, whilst being mindful that rodent 
islets do not only comprise of β-cells but also contain 20-40% other islet cell types [425]. 
The data produced during this analysis should generate a comprehensive view of zinc-
induced β-cell dysfunction and may lead to discovery of novel Zn2+-responsive genes and 
pathways.  
5.4.5.1. Examination of RNA-seq data   
PCA is used to reduce complex data so that variations and patterns can be readily 
visualised [426]. High-dimensional multivariate data are transformed into a small set of 
orthogonal variables that capture most of the dataset variation whilst maintaining as much 
information as possible [427, 428]. We generated PCA plots to visualise the similarities 
between each of MIN6 cells and islets following culture with 1µM or 8µM zinc (Fig 5.7). 
We observed high similarities between all MIN6 cell replicates cultured with 8µM zinc. 
However, only two of the three replicates cultured with 1µM zinc grouped together, and 
large variation, primarily in the second principal component, was observed between these 
and the third. Since we only obtained three replicates, we were unable to exclude the 
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outlier from analysis, despite this sample probably occluding identification of differential 
expression. For islets, the replicates did not group by treatment (1µM or 8µM zinc), 




Fig 5.7. PCA plots for MIN6 cells and islets cultured with 1µM or 8µM zinc. Variation 
of expression for all genes in (A) MIN6 cells or (B) Islets following culture with 1µM 
(blue) or 8µM (yellow) zinc for 48 h. The PCA plots were created using Qlucore Omics 
Explorer (v3.4).  
 
 
5.4.5.2. Differential gene expression 
To identify genes differentially expressed in MIN6 cells and islets following culture with 
1µM or 8µM zinc, we performed the following comparisons using Qlucore Omics 
Explorer (v3.4):  
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(1) MIN6 cells: 1µM vs 8µM zinc. 
(2) Islets: 1µM vs 8µM zinc. 
(3) MIN6 cells and islets: 1µM vs 8µM zinc (eliminating the effect of sample origin). 
We filtered gene lists by variance (σ/σmax: 0.33) and the significances of differential 
expression were corrected for multiple comparison testing (q-values). However, when 
using q <0.1 to indicate differential expression, we only identified 21 differentially 
expressed genes (all downregulated by zinc depletion) for MIN6 cells (1µM vs 8µM zinc; 
comparison 1) and 7 differentially expressed genes (3 upregulated and 4 downregulated 
by zinc depletion) for islets (1µM vs 8µM zinc; comparison 2). These genes are listed in 
Tables 5.1 and 5.2, alongside any known associations with zinc. 
Genes downregulated in MIN6 cells by zinc depletion included genes involved in signal 
transduction (Tenm2), pH regulation and cellular signalling (Otop3), mitochondrial 
regulation (Nlrx1), RTK signalling (Plch2), protein degradation (Prss27 and Psmb11), 
steroid synthesis (Hsd17b11), tethering (Ubxn10), cellular adhesion (Lrrn4), 
development (Edaradd) and gene expression regulation (Ercc5, Zfg334, Zbtb44). Six of 
the identified genes encode proteins that either bind zinc or are involved in zinc-mediated 
pathways and, therefore, adequate amounts of zinc are essential for their normal function. 
ZFP334 and ZBTB44 are zinc-finger transcription factors that require zinc for DNA 
binding [429], ERCC5 mediates DNA repair with the zinc(II)-binding metalloprotein 
XPA [430, 431] and SEC23B requires zinc binding to couple with SEC23A and form a 
GTPase activating protein (GAP) in the membranes of coat complex II-coated vesicles 
[432]. Moreover, PXN binds zinc to function as a docking site at focal adhesions for 
cytoskeletal proteins, kinases, GAPs and other adaptor proteins [433] and is suppressed 
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by ZIP6:ZIP10 heteromers [206], and OTOP3 forms a proton-selective ion channel 
required for zinc-sensitive proton conductance [434]. 
For islets, differentially expressed genes included genes involved in cell cycle regulation 
(Cep126 was upregulated and Spc24 was downregulated following zinc depletion). We 
additionally noted downregulation of genes involved in metabolic breakdown (Uox) and 
RNA transcription (Mov1011) and upregulation of two components of metal ion channels 
(Kcnn3 and Lrriq4), suggesting zinc may control cellular metal ion distributions via 
transporter regulation. We did not identify any previously documented associations 
between any of these differentially expressed genes and zinc.  
We additionally explored associations between the Zn2+-responsive genes identified in 
MIN6 cells and islets with diabetes. We noted that Uox (downregulated in islets in 
response to zinc depletion) is associated with both obesity in diabetic patients [435] and 
metabolic disturbances [436], which are characteristic of diabetes. However, we did not 




Table 5.1. Genes differentially expressed in MIN6 cells in response to zinc depletion. Gene lists were identified through RNA-seq analysis 
following culture of MIN6 cells with 1µM or 8µM zinc for 48 h. Gene lists were filtered by variance (σ/σmax: 0.33) and genes were considered 
differentially expressed when q <0.01. #  = no known associations with zinc. 
Gene symbol Gene name q-value 
Fold 
change 
Previous associations with zinc 
Zfp334 Zinc finger protein 334 1.52E-03 -4.302 Zinc binding protein [429] 
Ercc5 
Excision Repair 5, 
Endonuclease 
1.52E-03 -4.302 Involved in zinc finger-regulated DNA repair pathways [437] 




1.52E-03 -4.302 # 
Nlrx1 NLR Family Member X1 1.52E-03 -4.302 # 




1.52E-03 -4.302 # 
Prss27 Serine protease 27 1.52E-03 -4.303 # 
Psmb11 Proteasome Subunit Beta 11 1.52E-03 -4.303 # 
Gm7847 Non-protein coding 1.52E-03 -4.303 # 
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AC154592.1 Non-protein coding 1.52E-03 -4.302 # 
Sec23b 
Sec23 Homolog B, Coat 
Complex II Component 
1.63E-02 -4.813 Zinc binding protein [438] 
Pxn Paxillin 1.63E-02 -4.813 
Zinc binding protein [134] 
Suppressed by ZIP6:ZIP10 heteromers at focal adhesions [206] 
Lrrn4 
Leucine Rich Repeat 
Neuronal 4 
1.63E-02 -4.813 # 
Gm12808 Non-protein coding 1.63E-02 -4.813 # 
Zbtb44 
Zinc Finger and BTB Domain 
Containing 44 
2.73E-02 -6.205 Zinc binding protein [429] 
Edaradd 
EDAR Associated Death 
Domain 
4.67E-02 -5.101 # 
Gm43121 Non-protein coding 4.67E-02 -5.101 # 
Gm19219 Non-protein coding 4.67E-02 -5.101 # 
4930597O21Rik RIKEN cDNA 4930597O21 6.48E-02 -6.634 # 









Table 5.2. Genes differentially expressed in islets in response to zinc depletion. Gene lists were identified through RNA-seq analysis following 
culture of mouse islets with 1µM or 8µM zinc for 48 h. Gene lists were filtered by variance (σ/σmax: 0.33) and genes were considered differentially 
expressed when q <0.01. #  = no known associations with zinc.  
 
Gene Symbol Gene name q-value 
Fold 
change 
Previous associations with zinc 
Kcnn3 
Potassium Calcium-Activated 
Channel Subfamily N Member 3 
8.67E-02 3.601 # 
Mov10l1 
Mov10 RISC Complex RNA 
Helicase Like 1 
8.67E-02 -3.976 # 
Lrriq4 
Leucine Rich Repeats and IQ 
Motif Containing 4 
8.67E-02 3.406 # 
Uox Urate Oxidase 8.67E-02 -3.976 # 
Cep126 Centrosomal Protein 126 8.67E-02 3.988 # 
Spc24 Kinetochore Protein Spc24 8.67E-02 -3.976 # 
Gm17112 Non-protein coding 8.67E-02 -3.590 # 
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We next sought to compare zinc depletion-induced differential gene expression (q <0.1) 
between MIN6 cells and islets. However, we did not highlight any commonly regulated 
genes. Above (section 5.4.5.1), we show that large variation existed between MIN6 cell 
replicates (1µM zinc) but that there was not much variation between the islet replicates 
(1µM and 8µM zinc); using q <0.1 to indicate differential expression may be too stringent 
to identify potentially important results. We therefore used p <0.05 (not corrected for 
multiple comparison testing) to indicate differential expression in gene lists for use in 
subsequent data analysis. Accordingly, the following results should be taken with caution 
due to the relatively high possibility they may have occurred by chance. 
We identified 1439 differentially expressed genes (1059 upregulated and 380 
downregulated; p <0.05) between MIN6 cells cultured with 1µM or 8µM zinc 
(comparison 1). Whereas between islets cultured with 1µM or 8µM zinc (comparison 2), 
we revealed differential expression for 826 genes (396 upregulated and 430 
downregulated; p <0.05). When the effect of sample type was eliminated (MIN6 cells and 
islets cultured with 1µM or 8µM zinc; comparison 3), we uncovered differential 
expression for 715 genes (439 upregulated and 276 downregulated; p <0.05) (Fig 5.8). 
We noted that a total of 60 genes were commonly regulated between MIN6 cells and 





Fig 5.8. Gene differentially expressed in response to zinc depletion (p <0.05). Venn 
diagram showing differential gene expression in MIN6 cells (comparison 1), islets 
(comparison 2) and MIN6 cells and islets (eliminating the effects of sample origin; 
comparison 3) following culture of cells with 1µM or 8µM zinc. Gene lists were filtered 
by variance (σ/σmax: 0.57). The numbers of genes showing differential expression (p 
<0.05) are indicated. Created using GeneVenn software [419].  
 
5.4.6. Enrichment and pathway analysis  
GeneGo MetaCoreTM bioinformatics software allows for analysis of a given list of genes 
based on relative changes in gene expression. Enrichment analysis consists of matching 
genes to functional ontologies to identify protein functions, processes and pathways 
(amongst others) over- or underrepresented in the dataset. Since we did not record 
adequate numbers of differentially expressed genes (q <0.1) for investigation, we focused 
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analysis on gene lists created using p <0.05. This approach is reasonable when the data is 
subjected to an additional level of robust statistical analysis. To increase the power of this 
analysis by including a greater number of replicates, we decided to analyse data derived 
from both MIN6 cells and islets (eliminating the effect of sample origin) cultured with 
1µM or 8µM zinc (comparison 3). We generated PCA plots to confirm that, based on 
differential expression (p <0.05), samples grouped by treatment (1µM or 8µM zinc) and, 
therefore, similar processes and/or pathways may be altered in each MIN6 cells and islets 
by zinc depletion (Fig 5.9). 
 
 
Fig 5.9. PCA plot for differential gene expression in MIN6 cells and islets (p <0.05). 
Variation of gene expression in MIN6 cells and islets (eliminating the effect of sample 
origin) following culture with 1µM (blue) or 8µM (yellow) zinc (comparison 3). Gene 
lists were filtered by variance (σ/σmax: 0.57). The PCA plots were created using Qlucore 
Omics Explorer (v3.4). 
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5.4.6.1. Identification of enriched protein functions 
We first sought to investigate protein functions either enriched or depleted for 
differentially expressed genes (Table 5.3). These functions correspond to a higher or 
lower fraction of genes in the gene list than is expected in the global genome. We noted 
enrichment for enzymes (ratio: 1.353) and phosphatases (ratio: 1.943) and depletion for 
proteins classed as ‘other’ (ratio: 0.9398).  
 
 
Table 5.3. Protein functions enriched or depleted for genes differentially expressed 
(p <0.05) in response to zinc depletion. Enrichment and depletion for MIN6 cells and 
islets cultured with 1µM or 8µM zinc. For each protein function, the number of actual 
and expected mapped genes are listed, alongside the p-value for the significance.  
Protein function  Actual/Expected p-value 
Enzymes  107/79.1 6.90E-04 
Other 464/493.7 7.89E-03 
Phosphatases 13/6.7 1.75E-02 
Transcription factors 26/32.6 1.33E-01 
Kinases 23/19.2 2.12E-01 
Receptors 43/45.2 4.01E-01 
Ligands 14/14.4 5.27E-01 
Proteases 17/17.2 5.47E-01 
 
 
5.4.6.2. Identification of enriched GO cellular processes  
We next identified GO cellular processes enriched for differentially expressed genes 
(Table 5.4). Hits indicate that a higher fraction of genes in the gene lists are involved in 
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the respective process than is expected in the global genome. Top hits included 
enrichment of genes involved in the response to oxygen-containing compounds (hits: 
140/2780), negative regulation of phosphorus metabolic processes (hits: 61/901), 
organophosphate metabolic processes (hits: 79/1311), regulation of protein kinase (hits: 
70/1110) and transferase (hits: 86/1490) activities, and the cellular response to stress (hits: 
120/2342).  
 
Table 5.4. GO cellular processes enriched for genes differentially expressed in 
response to zinc depletion (p <0.05). Enrichment for MIN6 cells and islets cultured with 
1µM or 8µM zinc. For each GO cellular process, the number of hits in the dataset 
compared to the total number encoded in the genome, the p-value for the significance and 
FDR are presented.  
GO Process Hits p-value FDR 
Response to oxygen-containing compound 140/2780 1.132E-09 8.676E-06 
Negative regulation of phosphorus metabolic 
process 
61/901 5.562E-09 1.103E-05 
Organophosphate metabolic process 79/1311 5.751E-09 1.103E-05 
Regulation of protein kinase activity 70/1110 7.474E-09 1.103E-05 
Regulation of transferase activity 86/1490 8.607E-09 1.103E-05 
Cellular response to stress 120/2342 8.638E-09 1.103E-05 
Regulation of purine nucleotide metabolic 
process 
35/385 1.034E-08 1.132E-05 
Negative regulation of phosphate metabolic 
process 
60/900 1.310E-08 1.183E-05 
Nervous system development 160/3438 1.536E-08 1.183E-05 





5.4.6.3. Identification of overly connected transcription factors   
We further identified transcription factors overly connected to differentially expressed 
genes (Table 5.5). These transcription factors regulate a greater or lower fraction of genes 
in the gene list than is expected in the global genome and may therefore represent 
potential hubs for driving changes to β-cell function. We noted 13 overly connected 
transcription factors, which are involved in cell cycle regulation, proliferation, survival 
and growth [p53 (ratio: 1.58), c-Myc (ratio: 1.36), CUX1 (ratio: 1.69) and RelA (ratio: 
1.47)], cellular responses to hormone stimulation [CREB1 (ratio: 1.34)] and hypoxia 
[HIF1A (ratio: 1.63)], and fatty acid storage and glucose metabolism [PPAR-γ (ratio: 
1.97)]. Of the listed transcription factors, only HIF1A showed differential expression in 
MIN6 cells and islets (eliminating the effect of sample origin, comparison 3; p <0.05) 











Table 5.5. Transcription factors overly connected to genes differentially expressed 
in response to zinc depletion (p <0.05). Data for MIN6 cells and islets cultured with 
1µM or 8µM zinc. For each transcription factor, the ratio of actual and expected 
connection hits are listed, alongside the p-value for the significance.  
Transcription factor Actual/Expected p-value 
CREB1 213/158.9 1.04E-06 
p53 102/64.7 2.51E-06 
CUX1 (p110) 66/39.1 2.38E-05 
PPAR-γ 40/20.3 4.19E-05 
DPF2 9/1.9 1.22E-04 
TIF1-β 80/52.9 1.38E-04 
c-Myc 126/92.5 1.63E-04 
RelA (p65 NF-kB subunit) 86/58.5 1.94E-04 
YY1 116/84.7 2.54E-04 
RXRA 24/11 3.24E-04 
HIF1A 52/31.9 3.98E-04 
ZNF131 5/0.7 5.25E-04 
p63 37/21 6.97E-04 
 
 
5.4.6.4. Identification of enriched pathways  
Finally, we identified intracellular pathways enriched for differentially expressed genes 
(Table 5.6). These pathways include a higher fraction of genes in the gene list than is 
expected in the global genome. Top hits included possible regulation of the HSF-
1/chaperone pathway (hits: 7/21), negative regulation of HIF1A function (hits: 9/69) and 
anti-apoptotic TNFs/NF-kB/Bcl-2 pathways (hits: 6/42).  
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Table 5.6. Pathways enriched for genes differentially expressed in response to zinc 
depletion (p <0.05). Enrichment for MIN6 cells and islets cultured with 1µM or 8µM 
zinc. For each pathway, the number of gene hits in the dataset compared to total number 




5.4.6.5. Regulation of HIF1A 
HIF1A mediates a vast array of cellular processes including apoptosis [440], angiogenesis 
[441] and the adaptive response to hypoxia [442]. HIF1A is stabilised by inflammation 
[443], growth factors [444] and increased levels of ROS [445], and is regulated by insulin 
via PI3K/AKT cascades [446]. HIF1A is mediated by the Zn2+-responsive transcription 
factor MTF1 during hypoxic stress [447] and facilitates hypoxia-induced MT activation 
[165]. Targeted knockout of HIF1A in the β-cells of C57BL/6 mice induces glucose 
Pathway Hits p-value FDR 
Possible regulation of HSF-1/chaperone 
pathway in Huntington's disease 
7/21 2.961E-07 3.251E-04 
Rheumatoid arthritis (general schema) 8/50 1.754E-05 9.630E-03 
Transcription: negative regulation of HIF1A 
function 
9/69 2.874E-05 1.052E-02 
Regulation of Tissue factor signalling in 
cancer 
7/43 5.300E-05 1.209E-02 
Colorectal cancer (general schema) 6/30 5.504E-05 1.209E-02 
Stellate cells activation and liver fibrosis 8/70 2.067E-04 3.782E-02 
Apoptosis and survival: Anti-apoptotic 
TNFs/NF-kB/Bcl-2 pathway 
6/42 3.851E-04 6.040E-02 
Macrophage and dendritic cell phenotype 
shift in cancer 
9/100 5.162E-04 6.585E-02 
Inhibition of Ephrin receptors in colorectal 
cancer 
5/30 5.756E-04 6.585E-02 
FGF signalling in pancreatic cancer 6/46 6.363E-04 6.585E-02 
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intolerance, impairs GSIS and contributes to onset of Type 2 Diabetes [448]. Moreover, 
we identified above that HIF1A is overly connected to genes differentially expressed in 
response to zinc depletion (section 5.4.6.3). To explore how zinc may impact pathways 
mediating HIF1A expression and/or activity, we generated a pathway map for HIF1A 
regulation to reveal the locations of Zn2+-responsive genes in HIF1A regulatory pathways 
and their relative changes in expression (Fig 5.10). We demonstrate these Zn2+-responsive 
genes encode proteins involved in oxygen-dependent HIF1A regulation (EGLIN2, OS-9, 
SIRTUIN2 and ARD1), HIF1A transcription (RUVBL2), activation of HIF1A via protein 






Fig 5.10. Negative regulation of HIF1A function. Pathway map created using GeneGo 
MetaCoreTM from Thomson Reuters. For genes showing differential expression in MIN6 
cells and islets cultured with 1µM or 8µM zinc for 48 h (p <0.05), relative changes in 











5.4.7. Comparison with qPCR data 
In chapter 4 [405], we showed that multiple markers of β-cell identity and function are 
Zn2+-responsive, indicating important roles for zinc in mediating β-cell phenotype. 
Moreover, earlier in the present chapter we showed that zinc depletion downregulates 
Mt1 and Mt2 and upregulates Slc39a8 and Slc39a14 in MIN6 cells. To validate our RNA-
seq results, we next compared expression of these genes in the RNA-seq dataset to 
previous qPCR data [β-cell transcription factors: chapter 4 [405]; Slc39a paralogues, 
Slc30a8, Mt1, Mt2 and Mtf1: chapter 5 (sections 5.4.1 and 5.4.2)]. However, we only 
revealed significant downregulation of mRNA for Mt1 and Hnf4a in the RNA-seq dataset. 
In line with our qPCR data, in response to zinc depletion we further noted a trend for 
Slc39a14 upregulation and downregulation of mRNA for all other Zn2+-responsive 
transcription factors investigated aside from Pax4, including >1.2-fold downregulation of 














Table 5.7. Expression of qPCR-verified genes in the RNA-seq dataset. FD in 
expression are presented for MIN6 cells cultured with 1µM or 8µM zinc for 48 h, as 
measured by RNA-seq and qPCR. p-values for the significances of differential expression 
are indicated.   
Transcript 
RNA-seq qPCR 
Fold change p-value Fold change p-value 
Mt1 -2.041 0.028 -5.400 <0.0001 
Mt2 -1.007 0.981 -6.976 <0.0001 
Mtf1 -1.091 0.443 -1.087 0.968 
Slc39a1 -1.170 0.608 1.550 0.148 
Slc39a6 -1.078 0.867 -1.129 0.615 
Slc39a7 -1.824 0.163 -1.438 0.055 
Slc39a8 -1.321 0.609 2.128 0.014 
Slc39a9 -1.344 0.424 1.360 0.209 
Slc39a14 1.127 0.774 1.601 0.050 
Slc30a8 -1.249 0.325 -1.301 0.022 
Hnf1b -1.022 0.979 -3.346 0.040 
Hnf4a -2.135 0.009 -2.918 0.010 
MafA -1.126 0.342 -1.797 0.004 
Mnx-1 -1.068 0.720 -3.564 0.007 
Nkx2.2 -1.221 0.178 -1.238 0.007 
Nkx6.1 -1.219 0.219 -2.539 0.029 
Pax4 1.293 0.240 -1.461 0.048 
Pax6 -1.031 0.713 -3.234 0.009 






5.5. Discussion  
Systemic hypozincaemia is present in many metabolically obese individuals, type 2 
diabetic patients and animal models of diabetes [140, 283, 284, 407]. Since zinc is 
important for β-cell function in glycaemic control, a constant zinc supply is essential to 
restore intracellular concentrations following Zn2+/insulin co-exocytosis [266, 411]. 
Hypozincaemia reduces the amounts of zinc available for β-cell uptake and may therefore 
alter β-cell zinc homeostasis and induce dysfunction.  
5.5.1. Cellular zinc content and survival 
The total zinc contents of human β-cells are sustained at 150-200µM [127, 146]. Zinc 
concentrations reach 20mM in insulin secretory granules [281] whereas cytosolic free 
Zn2+ is maintained within the pM range [127]. Extracellular zinc depletion (48 and 96 h) 
lowered the total zinc contents of MIN6 cells and downregulated mRNA expression for 
Mt1 and Mt2, indicative of decreased cytosolic free Zn2+ and downregulation of Zn2+-
regulated genes [449]. Since 70% of β-cell zinc is contained in insulin secretory granules 
[281], cellular zinc depletion may reflect a reduced amount of zinc in the secretory 
pathway, and/or result from depletion of intracellular zinc stores to compensate for 
reduced uptake from outside the cell. Concurrently, excess zinc only upregulated Mt1 and 
Mt2, indicative of an increased cytosolic free Zn2+ buffering capacity [449] without 
changes to the zinc contents of the secretory granule or zinc-containing organelles.  
Zinc transporters are tightly regulated to maintain adequate intracellular zinc [147, 420]. 
Previous investigations highlight ZIP1, ZIP6, ZIP7, ZIP8, ZIP9 and ZIP14 as potentially 
biologically important for β-cell function (chapters 3-4 [404, 405] and [192, 218]); we 
therefore focused analysis on these paralogues. Zinc depletion upregulated mRNA 
expression for Slc39a8 and Slc39a14 and, in response to excess zinc, we observed 
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downregulation of Slc39a8. ZIP8 and ZIP14 may therefore be key paralogues regulating 
β-cell zinc in response changes in extracellular zinc. ZIP8 and ZIP14 upregulation in cells 
cultured with depleted zinc was coupled with increased cellular zinc uptake capacities, 
presumably to compensate for lowered amounts of available zinc. ZIP8 and ZIP14 are 
phylogenetically closely related [450] and both localise to the plasma membrane and 
membranes of intracellular zinc-storing organelles and vesicles [171, 209]. ZIP8 and 
ZIP14 have both been reported to regulate zinc accumulation into mitochondria, 
implicating zinc and these transporters in β-cell energy synthesis [451]. ZIP14 expression 
is induced during zinc deficiency via activation by ATF6 and JNK [452] and ZIP14 
facilitates GPCR-mediated cAMP-CREB signalling through suppressing 
phosphodiesterase activity [325]. ZIP8 and ZIP14 both transport other metal ions in 
addition to zinc including non-transferrin bound iron [171, 172], cadmium [173] and 
manganese [453, 454], and altered transporter expression may therefore induce off-target 
effects consequential to redistribution of these metal ions. We further observed a trend 
for zinc depletion-induced upregulation of mRNA for Slc39a1 at 48 h and show that 
Slc39a6 is upregulated in response to high zinc at 96 h. Time-dependent changes to ZIP1 
and ZIP6 abundances may fine-tune the β-cell response to extracellular zinc. ZIP1 and 
ZIP6 are ubiquitously expressed zinc transporters that facilitate cellular zinc influx at the 
plasma membrane [216, 319]. ZIP1 is highly expressed in mouse β-cells (chapter 3 [404]) 
and is important for mediating the initial zinc response to chronic MIN6 cell stimulation 
(chapter 4 [405]). ZIP6 expression is induced by STAT3 and the absence of ZIP10 [209] 
and ZIP6 forms a heteromer with ZIP10 (ZIP6:ZIP10) to interact with GLP-1R and 
potentiate GSIS [319]. ZIP6:ZIP10 heteromers facilitate inhibitory phosphorylation of 
GSK-3 [206, 311] and activation of downstream ERK1/2 cascades [320, 321] to promote 
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proliferation; ZIP6 may therefore be upregulated to compensate for lowered MIN6 cell 
proliferation.  
Cells require intracellular zinc to be maintained within a narrow concentration range to 
avoid dysfunction [455]. Since culture of MIN6 cells with depleted and excess zinc alters 
cellular zinc homeostasis and since disrupted β-cell zinc is associated with loss of cellular 
phenotype (chapter 4 [405]), changes to extracellular zinc may impact β-cell survival. 
MIN6 cells cultured with either depleted or excess zinc exhibited increased apoptosis and 
decreased proliferation. We showed that the lowered cellular survival may be promoted 
by reduced mTOR and MAPK signalling. mTOR cascades are activated by growth factors 
and nutrients [51] to promote protein synthesis and maintain β-cell mass [62], and MAPK 
cascades respond to growth factors and mitogens to mediate cell cycle progression [69]. 
For MIN6 cells cultured with depleted zinc, the lowered cytosolic free Zn2+ may suppress 
mTOR and MAPK signalling cascades. Zinc inhibits PTP1B [79] leading to increases in 
IR and IGF-1R signalling [309] and activation of downstream MAPK and mTOR 
cascades. PTP1B inhibition ameliorates high-fat-diet and obesity-induced insulin 
resistance in mice [305], and genome-wide and tissue-specific PTP1B ablation increases 
insulin sensitivity and protects against obesity and diabetes [306, 307]. Zinc activates 
RAS upstream of ERK1/2 [314] and inactivates the dual specificity phosphatase DUSP, 
which dephosphorylates and inactivates ERK1/2 [456]. Moreover, the zinc transporter 
ZnT1 interacts with RAF-1 via its CTD to promote ERK1/2 activation [322] and 
activation of ZIP7-mediated zinc release from intracellular stores drives MAPK, mTOR 
and PI3K-AKT cascades [457]. MIN6 cells cultured with excess zinc exhibited elevated 
cytosolic free Zn2+, which may explain the observed increase in apoptosis since cells 
require free Zn2+ to be maintained within a narrow range to avoid toxicity [455]. 
Concurrently, we noted increased amounts of oxidizing reagents in MIN6 cells cultured 
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with excess zinc, which are indicative of elevated oxidative stress [422, 423]. Although 
zinc exhibits potent anti-oxidant properties and protects against oxidative stress-induced 
β-cell dysfunction [270, 458], supraphysiological concentrations of zinc were used in this 
study which may have induced chronic oxidative stress [459]. Critically, we did not 
observe differences in cellular proliferation, apoptosis or oxidative stress at 24 or 48 h, 
suggesting MIN6 cells temporarily cope with changes in zinc concentrations.  
Zinc co-secreted with insulin from β-cells exhibits autocrine effects for suppressing 
further insulin secretion by targeting KATP and L-VGCC channels [373]. It is therefore 
plausible that changes to serum zinc induce similar effects. However, we did not observe 
any differences for insulin expression in MIN6 cells or KCl-stimulated insulin secretion 
from MIN6 cells cultured with depleted or excess zinc. This observation may stem from 
differing roles of secreted and serum zinc for β-cells such as due to differing zinc 
coordination environments. Moreover, since the MIN6 cells used in this study were not 
glucose-responsive, we used KCl to stimulate insulin secretion and the high potency of 
KCl stimulation may mask zinc-induced suppression of insulin secretion. Alternatively, 
zinc may require the presence of additional stimuli to induce inhibitory effects that were 
not present in our experimental conditions. A further study indicates that zinc may affect 
the half-time but not the amplitude of the secretory response [460]; detailed analysis of 
the first and second phases of insulin secretion could therefore be required to identify 
temporal changes indicative of defective secretory function [461].  
5.5.2. The β-cell transcriptome 
Zinc binds over 10% of proteins in mammals [129] and influences expression of hundreds 
of genes [462, 463]. Zinc therefore has potential to affect virtually all aspects of β-cell 
physiology and function [130-133]. We carried out RNA-seq analysis on MIN6 cells and 
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islets cultured with deficient and adequate zinc to identify novel Zn2+-responsive genes 
and pathways that could be deregulated in β-cells by hypozincaemia.  
The genes we identified as differentially expressed (q <0.1) in response to zinc depletion 
reflect the diverse roles of zinc in cells. For MIN6 cells, differentially expressed genes 
are involved in signal transduction, pH regulation and cellular signalling, mitochondrial 
regulation, receptor tyrosine kinase signalling, protein degradation, steroid synthesis, 
tethering, cellular adhesion, development and gene expression regulation. Whereas for 
islets, differentially expressed genes are involved in cell cycle regulation, metabolic 
breakdown, RNA transcription and metal ion transport. However, we only uncovered 
previous associations between six of these genes with zinc or zinc-mediated pathways (all 
of these were noted in MIN6 cells) and only Uox has been previously associated with the 
diabetic phenotype [435, 436]. Moreover, a total of six differentially expressed genes 
were identified as non-protein coding. Non-protein coding DNA makes up almost 98.5% 
of the genome, most of which is transcribed into RNA, including microRNAs, long 
noncoding RNAs, Piwi-interacting RNAs and small nuclear RNAs [464]. These 
transcripts have potential to regulate transcription and stability of mRNA to determine 
how much is translated into protein [465] and may contribute to the observed changes in 
expression of protein-coding genes. However, we could not find anything documented 
about the regulatory roles of the transcripts that we uncovered during this study. We did 
not identify enough differentially expressed genes to carry out enrichment and pathway 
analysis and, therefore, used gene lists for genes differentially expressed when p <0.05 




Zinc is required for the catalytic activities of >300 metalloenzymes [466-468] and 
differential expression may be consequential to reduced formation of zinc(II)-enzyme 
complexes. In response to depleted zinc, we noted differentially expressed genes (p 
<0.05) were enriched for enzymes, in particular phosphatases. Protein phosphorylation is 
the most prevalent post-translational modification in cells and regulates over 30% of 
cellular proteins [469]. Kinases facilitate protein phosphorylation through catalysing 
transfer of γ-phosphate from ATP or GTP to a protein substrate and phosphatases 
facilitate protein dephosphorylation through catalysing transfer of phosphate from a 
phosphoprotein to a water molecule [470]. Consistently, GO cellular processes enriched 
for differentially expressed genes (p <0.05) included negative regulation of phosphorus 
metabolic processes, organophosphate metabolic processes, negative regulation of 
phosphate metabolic process and regulation of protein kinase activity. Zinc is a known 
negative regulator of phosphatase activity and zinc depletion may lead to increased 
activation of PTP1B [79], resulting in lowered phosphorylation of IRs and suppression of 
mTOR and ERK1/2 cascades [471]. This is consistent with our immunoblot data, albeit 
we did not observe differences in these signalling pathways until 96 h following treatment 
with depleted or sufficient zinc. 
We demonstrated that the Zn2+-responsive genes in MIN6 cells and islets are enriched for 
genes involved in the cellular response to oxygen-containing compounds. The 
transcription factor HIF1A is a key regulator of cellular hypoxia [442], and is directly 
regulated by ROS, including nitric oxide and superoxide [472]. Although we did not 
observe increases in oxidative stress for MIN6 cells cultured with depleted zinc, zinc is 
known to exhibit potent antioxidant properties: zinc mediates expression of many 
antioxidant genes including superoxide dismutase, for which zinc additionally acts as an 
important cofactor [301]. During pathway analysis, we highlighted regulation of HIF1A 
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by zinc depletion and we noted that HIF1A is an overly connected transcription factor to 
genes showing differential expression (p <0.05) in response to depleted zinc. HIF1A may 
therefore represent a hub for mediating the β-cell response to zinc depletion. Zinc induces 
accumulation of transcriptionally active HIF1A in mammary epithelial cells in normoxic 
conditions [473] to upregulate genes involved in glucose transport, angiogenesis, pH 
control and cell cycle progression [474-476]. However, our data suggest that zinc 
depletion upregulates HIF1A abundance through disrupting expression of genes involved 
in oxygen-dependent HIF1A regulation, HIF1A transcription and HIF1A activation via 
protein folding and cell cycle progression. Confusingly, in response to zinc depletion we 
noted upregulation of the HIF1A inhibitor Sintuin2, which requires zinc binding for 
normal function [477], and downregulation of the upstream effector PTEN, which is 
inhibited and degraded in response to zinc [478]. HIF1A mRNA expression is 
additionally induced by STAT3 [479] and mTORC1 cascades [480], which we 
demonstrate are downregulated following incubation with zinc depletion for 96 h. 
Moreover, HIF1A is a direct substrate of GSK-3 [481], indicating HIF1A may be 
activated by ZIP6:ZIP10/GSK-3 interactions [207]. Of potential importance, the 
abundance of HIF1A is decreased in type 2 diabetic individuals and loss of HIF1A in the 
β-cells of C57BL/6 mice impairs ATP generation and GSIS to induce glucose intolerance 
[482]. These data suggest β-cells adapt to hypozincaemia through upregulating HIF1A, 
thus decreasing cellular sensitivity to oxidative-stress induced dysfunction. 
Amongst the transcription factors overly connected to Zn2+-responsive genes (p <0.05) in 
MIN6 cells and islets, we additionally identified PPAR-γ and CREB. PPAR-γ controls 
expression of genes required for fatty acid synthesis and esterification [483] and exhibits 
important roles in β-cell proliferation and hyperplasia [484]. Activation of PPAR-γ in β-
cells increases intracellular calcium signalling, insulin secretion and β-cell gene 
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expression [485]. The DNA binding domains of PPAR-γ and its binding partner RXR 
both consist of two zinc fingers [486, 487] and PPAR-γ signalling is inhibited during zinc 
deficiency [488]. Whereas CREB controls expression of pro-survival and pro-adaptive 
genes in response to a range of external stimuli. In β-cells, CREB induces IRS-2 
expression to promote cell survival signalling downstream of the IR [489] and IRS-2-
dependent increases in insulin signalling promote cellular growth through mTORC1 
activation and induction of HIF1A [490]. Sustained CREB activation increases β-cell 
proliferation [491] and depletion of intracellular zinc downregulates CREB in 
hippocampal neurons [492]. PPAR-γ and CREB are both activated by mTOR signalling 
[493, 494], which we demonstrate is suppressed following zinc depletion for 96 h, and by 
post-translational phosphorylation [495, 496], which may explain why we did not observe 
differential expression for these transcription factors in our RNA-seq dataset. 
In chapter 4 [405], we revealed that multiple markers for β-cell identity are Zn2+-
responsive. Earlier in this chapter, we additionally showed that extracellular zinc 
depletion downregulates the Zn2+-responsive cytosolic zinc buffering proteins MT1 and 
MT2 and upregulates ZIP8 and ZIP14 in MIN6 cells. However, when we examined 
expression of these genes in our RNA-seq dataset, we only observed statistically 
significant differential expression for Mt1 and the β-cell transcription factor Hnf4a. MT1 
and MT2 are highly sensitive to zinc and zinc supplementation should promote MTF1-
induced Mt1 and Mt2 upregulation to mediate cellular zinc availability and distribution 
by zinc chelation and donation [156], which is consistent with our qPCR data. However, 
in our RNA-seq dataset we did not observe Mt2 downregulation following zinc depletion. 
This is likely due to low similarities between the MIN6 cell replicates cultured with 
depleted zinc, which we show included one outlier, and may explain why only a limited 
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number of genes exhibited differential expression (q <0.1). Our RNA-seq data should 
therefore be taken with caution prior to experimental confirmation.   
5.6. Conclusion  
In this study, we explored the impact of changes to extracellular zinc on MIN6 cell zinc 
content, phenotype and survival. We showed that depleted zinc reduces the total and 
cytosolic zinc contents of MIN6 cells but increases cellular zinc uptake capacities through 
upregulation of ZIP8 and ZIP14, probably as an adaptive response to counteract zinc 
depletion-induced dysfunction. Whereas excess zinc increases the cytosolic zinc content 
of MIN6 cells but downregulates ZIP8 and ZIP14, and both depleted and excess zinc 
decrease cellular survival through suppressing MAPK and mTOR cascades. For MIN6 
cells and islets, depleted zinc alters expression of genes involved in protein 
phosphorylation and we identified regulation of HIF1A as a key pathway mediated by 
zinc depletion. However, inconsistencies between qPCR and RNA-seq data suggest 
further experimentation is needed to confirm these results. Moreover, since our 
experiments explored the effects of short-term severe zinc depletion rather than long-term 
relatively mild hypozincaemia (potentially over years) of type 2 diabetic patients, whether 
these results can be translated to physiological conditions in vivo remains to be 
determined. Overall, we suggest hypozincaemia present in Type 2 Diabetes lowers the 
zinc content β-cells, and that this may alter expression of genes involved in protein 





6. ZnT8 haploinsufficiency impacts MIN6 cell zinc content 
and phenotype via ZnT8-ZIP coregulation   
 
6.1. Abstract  
The predominantly β-cell-specific zinc transporter ZnT8 localises to insulin secretory 
granules where it facilitates zinc uptake and accumulation. Prior to ZnT8-mediated 
granule zinc influx, zinc is imported into the cytosol by members of the ZIP family of 
zinc transporters. ZnT8 abundance is linked to β-cell survival and phenotype, however 
the consequences of ZnT8 haploinsufficiency for β-cell zinc trafficking and function 
remain unknown. We hypothesised ZnT8-ZIP coregulation maintains β-cell zinc in 
response to hypozincaemia present in some type 2 diabetic patients and that ZnT8 
haploinsufficiency induces dysfunction. We used CRISPR/Cas9 technology to generate 
ZnT8 haploinsufficient MIN6 cells and showed that lowered ZnT8 abundance is 
associated with downregulation of mRNA for Slc39a8 and Slc39a14, lowered cellular 
zinc and a reduced cellular zinc uptake capacity in zinc deficient culture. Moreover, ZnT8 
haploinsufficiency disrupts expression of a distinct array of important β-cell markers, 
decreases cellular proliferation via MAPK cascades and downregulates insulin gene 
expression. We additionally demonstrate that the major β-cell transcriptional regulator 
PDX-1 may mediate zinc trafficking via transcriptional co-regulation of ZIP6 and ZIP9 
alongside ZnT8. Critically, we suggest that ZnT8-ZIP cooperation maintains β-cell zinc 




6.2. Introduction  
In mammals, the 14 ZIP paralogues influx zinc into the cytosol and the 10 ZnT paralogues 
function in cytosolic zinc efflux and compartmentalisation of zinc into intracellular 
organelles and vesicles [420, 421]. Approximately 50% of cellular zinc is distributed to 
the cytosol [145], where it is buffered at 0.4nM in β-cells [497] by MTs, which occupy 
5-15% of the total zinc pool [156]. Cytosolic zinc is further involved in cellular signalling 
and tightly binds to metalloproteins as a structural component and/or cofactor [498]. The 
predominantly islet-specific zinc transporter ZnT8 is the most highly expressed zinc 
transporter in β-cells. ZnT8 localises to the membranes of insulin secretory granules 
where it regulates granule zinc uptake and accumulation, important for normal insulin 
maturation [198]. Disruption of ZnT8 activity is associated with β-cell dysfunction and 
polymorphisms are strongly linked to Type 2 Diabetes risk [234, 236, 262].  
The role of ZnT8 for β-cell function has been extensively explored [198], although the 
precise mechanism of action remains inconclusive. Decreased ZnT8 abundance is 
associated with stresses that negatively impact β-cell function and mass including 
hypoxia [227], lipotoxicity [186] and cytokine stimulation [179]. ZnT8 overexpression 
protects against palmitate- and TPEN-induced decreases in GSIS in human islets [186] 
and increases cellular zinc content and protects against zinc depletion-induced apoptosis 
in INS-1E cells [191].  However, an additional study indicates ZnT8 is upregulated in 
islets of diabetic and insulin-resistant patients whilst knockdown in MIN6 cells increases 
proliferation and protects against inflammation-induced cell death [229]. Consistent with 
a positive correlation between ZnT8 and Type 2 Diabetes risk, twelve rare loss-of-
function nonsense and missense polymorphisms are protective against the disease [271]. 
Islets from mice containing knock-in mutations of the most common loss-of-function 
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variant R138X exhibit reduced ZnT8 activity coupled with increased insulin secretory 
function [280]. ZnT8 knockout in mouse induces large changes to secretory granule 
morphologies and lowers β-cell zinc contents, however few differences in glycaemic 
parameters have been recorded [201, 202, 273, 276]. In human, only ZnT8 
haploinsufficient genotypes are described and the effects of absolute loss of function 
remain unknown.  
The polymorphic variant rs13266634 in the ZnT8 gene SLC30A8 is strongly associated 
with Type 2 Diabetes risk [234, 236, 262], however it remains unclear whether the 
mutation induces a loss- or gain-of-function. The CTD of ZnT8-R exhibits a higher 
thermostability but lower dimerization affinity than that of ZnT8-W, suggesting the 
mutation impacts transporter stability [269]. The ZnT8-R risk variant is more active than 
ZnT8-W when reconstituted with artificial phospholipids [265] but is less able to promote 
granule zinc accumulation when overexpressed in MIN6 cells [201]. Mouse islets 
transgenic for hZnT8-W exhibit reduced zinc contents compared to hZnT8-R controls 
[279] and human ZnT8-R variant carriers present with increased proinsulin:insulin ratios 
[260], lowered β-cell function [261] and impaired insulin secretion during intravenous 
glucose tolerance tests [262, 263].  
The transcription factor PDX-1 governs development and differentiation of the endocrine 
pancreas [91, 101, 499]. In mature islets, high PDX-1 expression is restricted to β-cells 
where it exhibits critical roles in maintaining cellular phenotype and function, including 
transcriptional regulation of the insulin gene [500] and repression of genes characteristic 
of other islet cell types, such as glucagon [91]. PDX-1 knockout is embryonically lethal 
[94] and heterozygous frameshift and missense mutations in human result in MODY4 
development [4]. Animal models suggest PDX-1 downregulation in mature β-cells 
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induces loss of cellular identity and promotes β- to α-cell reprogramming [114], and that 
this underlies secretory failure and Type 2 Diabetes development [501, 502]. PDX-1 
regulates β-cell zinc by targeting two promoters for the ZnT8 gene SLC30A8 [200] and 
mediates expression of the Zn2+-responsive transcription factor PAX4 [503]. Our 
previous data suggest that PDX-1 may additionally regulate expression of multiple ZIP 
paralogues, in particular ZIP1, ZIP5, ZIP6, ZIP8 and ZIP14 (chapter 3 [404]). PDX-1 
therefore represents a plausible β-cell-specific regulator of zinc trafficking to ensure β-
cells maintain their unique requirement for zinc in insulin secretory granules.  
In chapters 4 [405] and 5, we demonstrated that prolonged stimulation and extracellular 
zinc depletion decrease the total zinc contents of MIN6 cells and disrupt expression of 
genes involved in zinc regulation. Since ZnT8 abundance is linked to β-cell survival and 
function [179, 186, 191, 227, 229, 271] and that increased ZnT8 activity during cellular 
stimulation elevates cytosolic free Zn2+ [192], ZnT8 is likely central to β-cell zinc 
trafficking and homeostasis. In this chapter, we postulated that ZnT8 functions 
cooperatively with ZIP transporters to mediate β-cells zinc homeostasis, phenotype and 
survival in response to hypozincaemia. We additionally hypothesised that PDX-1 co-
regulates ZnT8-ZIP transcription to ensure normal β-cell zinc trafficking. We aimed to 
generate and characterise ZnT8 haploinsufficient MIN6 cells, representing lowered ZnT8 







6.3. Methods  
6.3.1. Cell line and culture 
MIN6 cells were cultured as described in section 2.1. For zinc depletion experiments, 
standard growth medium was replaced with growth media containing 25mM glucose and 
1μM or 8μM zinc for 48 h (section 2.2). 
6.3.2. CRISPR/Cas9 gene editing 
ZnT8/Slc30a8 gene editing was carried out using CRISPR/Cas9 gene technology, as 
detailed in section 2.5. Primers to assess the occurrence of genome editing were designed 
through computationally aligning ZnT8 Cas9 nickase guide sequences to the mouse 
genome assembly mm10 (forward: TCATCTCCGTGCTCAAACCC, reverse: 
TCTGTCATCGTGGCACTCAA (Sigma Aldrich); Fig 6.1A). Six potential clonal 
Slc30a8 knockout populations were generated by serial dilution. PCR amplifications of 
the Cas9-targeted genomic loci were separated by agarose gel electrophoresis to reveal 
multiple variants in three of the six colonies (clones 3, 4 and 5; Fig 6.1B), consistent with 
editing of one Slc30a8 copy variant to result in heterogeneous knockdown populations, 




Fig 6.1. Amplification of the ZnT8 CRISPR/Cas9-targeted genomic DNA. (A) 
Binding of CRISPR/Cas9 constructs to Slc30a8 genomic DNA. ZnT8 was mapped to 
chromosome 15 (52,295,553-52,335,798) on mouse genome GRCm38.p6 using the 
NCBI Ensembl genome browser 92. The Cas9 nuclease binds at the sequences 
highlighted in grey. Primers to assess knockdown bind at the sequences highlighted in 
turquoise. Red: exon 4. (B) Agarose gel electrophoresis showing PCR-amplified regions 
of Slc30a8 from clonal MIN6 cell populations, transfected with ZnT8 CRISPR/Cas9 or 







6.3.3. Cell transfection 
For gene knockdown experiments, MIN6 cells were transfected with siRNA targeting 
Slc30a8 mRNA [s108999; 5’-3’ sequence: CUUUAAGCCUGACUACAAAtt (Thermo 
Fisher)] or with Silencer® Select negative control siRNA (4390844; Thermo Fisher). For 
overexpression experiments, MIN6 cells were transfected with plasmid DNA encoding 
the open reading frame for mouse PDX-1 [Myc-DDK-tagged (MR227421; Origene)] or 
water as a control (mock transfected). Details for MIN6 cell transfection with siRNA and 
plasmid DNA are provided in section 2.4.   
6.3.4. Gene expression analysis 
RNA was extracted from MIN6 cells, reverse transcribed to cDNA and relative 
expression assayed through qPCR. The full methodology and details of primers used are 
provided in section 2.6. All results are presented as expression ratios compared to control 
cells except for insulin gene expression, where values for FD (Log2) in expression are 
presented.  
6.3.5. Cellular zinc parameters  
Total cellular zinc contents were determined through ICP-MS (section 2.3). The kinetics 
of zinc uptake into MIN6 cells were assessed through 65Zinc uptake assays (section 2.8).  
6.3.6. Cellular proliferation and apoptosis  
The rates of MIN6 cell proliferation and apoptosis were determined as described in 
sections 2.9-2.10.  
6.3.7. Immunoblotting  
Immunoblotting was carried out as previously described (section 2.7) using antibodies 
listed in section 5.3.4. The additional primary antibodies used in this chapter, with 
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dilutions in 1% BSA/TBST, were α-MYC [9E10, Thermo Fisher (1:1,000)] and α-
Tubulin [T9026, Sigma (1:15,000)]. The additional HRP-linked secondary antibody used, 
diluted in 1% BSA/TBST, was α-mouse [NA931V, Amersham (1:20,000)].  
6.3.8. Insulin secretion assays  
The amounts of secreted insulin were determined through insulin secretion assays and 
quantified using insulin ELISA assays, as described in section 2.12.  
6.3.9. Prediction of PDX-1 binding sites   
6.3.9.1. ChIP-Seq data analysis  
The Pubmed database was searched for chromatin immunoprecipitation sequencing 
(ChIP-Seq) datasets of PDX-1 binding to human and rodent β-cell or islet DNA. Datasets 
were filtered for binding loci in SLC39A/Slc39a genes. The binding loci from differing 
genome assemblies were lifted and the coordinates converted to Human Genome, Dec. 
2013 (GRCh38/hg38) using the Batch Coordinate Conversion (LiftOver) software from 
the UCSC Genome Browser [504]. The identified loci were visualised schematically 
using GraphPad Prism 7.  
6.3.9.2. Binding to intronic, 3’UTR, 5’UTR and promoter regions  
The intronic, 3’UTR and 5’UTR regions of human SLC39A genomic sequences were 
aligned to genomes from 26 species using the ConTra v2 web server [505]. The major 
SLC39A transcripts in β-cells (as shown in Fig 3.1) were used as the reference sequences 
for alignment. Conserved PDX-1 binding loci were identified using the TRANSFAC 




6.3.9.3. Alignment of candidate PDX-1 binding sites 
Predicted transcription factor biding sites from ChIP-Seq datasets and bioinformatic 
alignments were collectively aligned. Loci overlapping between experiments were 
considered to include potentially important PDX-1 binding sites within β-cells and were 
identified as candidates for further investigation. 
 
6.4. Results  
6.4.1. ZnT8 is associated with expression of ZIP8 and ZIP14 
ZnT8 transports zinc out of the cytosol and into insulin granules [198]. However, ZnT8 
activity is positively correlated with cytosolic free Zn2+: overexpression of human 
orthologues in MIN6 cells elevates free Zn2+ [201] whereas knockdown in mouse islets 
reduces free Zn2+ [201, 278]. ZnT8 activity is therefore likely to be co-regulated with the 
expression and/or activities of ZIP zinc importers.  
ZnT8 is downregulated by cellular stresses that negatively impact β-cell function [179, 
186, 227]. To explore the temporal ZIP response as cells adjust to ZnT8 deficiency, we 
knocked down Slc30a8 mRNA in MIN6 cells using siRNA and assayed expression of the 
Slc39a paralogues that we and others previously identified as important for β-cell function 
(chapter 3 [404] and [192, 218]) at 48, 72 and 96 h (Fig 6.2). Slc30a8 showed >2-fold 
depletion at all three time-points. At 48 h, we observed upregulation of mRNA for 
Slc39a14 (8.56-fold), and downregulation for Slc39a1 (5.39-fold), Slc39a8 (2.20-fold) 
and Slc39a9 (2.22-fold). At both 72 and 96 h, only Slc39a8 remained differentially 





Fig 6.2. Slc39a mRNA expression following temporal Slc30a8 knockdown in MIN6 
cells. mRNA expression for Slc30a8, Slc39a1, Slc39a6, Slc39a7, Slc39a8, Slc39a9 and 
 170 
 
Slc39a14 following knockdown of Slc30a8 by siRNA. Expression was assayed at 48, 72 
and 96 h post-transfection. Changes in mRNA abundances were calculated through qPCR 
and presented as expression ratios relative to MIN6 cells transfected with Silencer® 
Select negative control siRNA (control) at each time-point. Data were analysed by 2-way 
ANOVA followed by Sidak’s multiple comparison test. Error bars show ± SEM. N=3. *p 
<0.05, **p <0.005, ***p <0.001.  
 
 
We next examined the final state of reducing ZnT8 abundance through examining the 
expression profiles for ZnT and ZIP paralogues in ZnT8 haploinsufficient MIN6 cells. In 
silico sequence analysis revealed that ZnT8 CRISPR close 3 MIN6 cells are predicted to 
encode a 187 amino truncated version of ZnT8 in addition to the 367 amino wildtype (Fig 
6.3). However, we observed a 2.1-fold decrease in mRNA abundance for Slc30a8, 
suggesting that genome editing either prevented transcription of the truncated Slc30a8 
copy variant or resulted in transcription of unstable, rapidly degraded mRNA, therefore 
confirming the ZnT8 haploinsufficient genotype. We did not record differences in mRNA 
abundances for any other ZnT paralogues (Fig 6.4A), indicating lack of transporter 
redundancy and/or a compensatory response. When we examined expression of the ZIP 
paralogues in ZnT8 haploinsufficient MIN6 cells, we recorded downregulation of mRNA 









Fig 6.3. Slc30a8 genome editing. Editing at Slc30a8 exon 4 for ZnT8 CRISPR clone 3 
MIN6 cells. The reference sequence was downloaded from the NCBI Ensembl genome 
browser 92 and binding of the ZnT8 Cas9 nickase constructs illustrated. The region 
shown spans Chr15:52321762-52321832 (mouse genome GRCm38.p6). The sequence of 




    
Fig 6.4. Zinc transporter expression in ZnT8 haploinsufficient MIN6 cells. mRNA 
expression for (A) Slc30a and (B) Slc39a paralogues in ZnT8 haploinsufficient MIN6 
cells generated by CRISPR/Cas9 technology. We were unable to detect quantifiable 
expression for Slc30a10, Slc39a4, Slc39a5 or Slc39a12. Changes in mRNA expression 
were calculated through qPCR and are presented relative to sham-CRISPR MIN6 cells 
(control). Data were analysed through t-tests and corrected for multiple comparisons. 
Error bars show ± SEM. N=3. *p <0.05, **p <0.005.   
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6.4.2. ZnT8 haploinsufficiency decreases zinc uptake into MIN6 cells  
ZnT8 knockout in mouse decreases the zinc content of islets [201, 202, 272-274, 276], 
indicating ZnT8 is important for normal zinc uptake and accumulation. Above, we show 
that ZnT8 haploinsufficient MIN6 cells have lowered expression of mRNA encoding for 
ZIP8 and ZIP14, suggesting ZnT8 coordinates cellular zinc uptake through cooperating 
with these paralogues. We next aimed to characterise the impact of ZnT8 
haploinsufficiency on zinc uptake and accumulation into MIN6 cells and explore whether 
these responses are influenced by extracellular zinc depletion.  
We incubated ZnT8 haploinsufficient MIN6 cells in both zinc deficient (1µM) and 
adequate (8µM) culture for 48 h to show that ZnT8 haploinsufficiency lowers total 
cellular zinc contents compared to sham-CRISPR MIN6 cells (1µM: 1.34-fold and 8µM: 
1.43-fold) (Fig 6.5A). Cellular zinc depletion was not associated with any differences in 
mRNA abundances for Mt1 or Mt2, suggesting haploinsufficiency does not alter the 
cytosolic zinc content. However, we observed 1.5-fold depletion of mRNA for Mtf1 in 
ZnT8 haploinsufficient MIN6 cells cultured with 1µM but not 8µM zinc (Fig 6.5B). To 
attribute these changes in mRNA abundance to cytosolic zinc influx, we examined the 
zinc uptake kinetics. We cultured MIN6 cells with 1µM or 8µM zinc for 48 h and then 
assayed 65Zn uptake over a range of concentrations. We revealed that pre-treatment with 
zinc depletion decreased zinc influx into ZnT8 haploinsufficient cells at the highest two 
65Zn concentrations tested (27.25µM and 13.63µM) compared to sham-CRISPR controls 






Fig 6.5. Zinc content and uptake kinetics of ZnT8 haploinsufficient MIN6 cells in 
response to extracellular zinc depletion. (A) Total cellular zinc content. Zinc content 
was determined through ICP-MS and normalised to protein. (B) mRNA expression for 
Mt1, Mt2 and Mtf1. Changes in mRNA expression were calculated by qPCR and 
expressed as an expression ratio relative to sham-CRISPR MIN6 cells cultured with 8µM 
zinc (control). (C-D) Uptake kinetics of zinc into cells cultured with (C) 1µM or (D) 8µM 
zinc. Red: ZnT8 haploinsufficient MIN6 cells; black: sham-CRISPR MIN6 cells 
(control). ZnT8 haploinsufficient MIN6 cells: ZnT8+/-. All experiments were carried out 
following culture with 1µM or 8µM zinc for 48 h. Data were analysed by 2-way ANOVA 
followed by (A-B) Tukey’s multiple comparison test or (C-D) Sidak’s multiple 
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comparison test. Error bars show ± SEM. For (A) N=4 and (B-D) N=3. *p <0.05, **p 
<0.005, ***p <0.001.   
6.4.3. ZnT8 haploinsufficiency alters expression of important β-cell markers  
We have previously shown that multiple markers for β-cell identity and function are zinc 
responsive [Hnf1b, Hnf4a, MafA, Mnx-1, Nkx2.2, Nkx6.1, Pax4, Pax6 and Pdx-1] 
(chapter 4 [405]). Since lowered ZnT8 activity alters β-cell zinc trafficking and induces 
a depleted zinc phenotype, it is likely ZnT8 haploinsufficiency impacts expression of 
these transcription factors. We therefore examined mRNA abundances for the Zn2+-
responsive transcription factors Hnf1b, Hnf4a, MafA, Mnx-1, Nkx2.2, Nkx6.1, Pax4, Pax6 
and Pdx-1 in ZnT8 haploinsufficient MIN6 cells following culture with 1µM or 8µM 
zinc. We additionally included Foxa1, Foxa2, Foxo1 and Neurod1 in our analysis to 
account for Zn2+-independent roles of β-cell ZnT8.  
We observed altered expression for a small but distinct array of β-cell markers in ZnT8 
haploinsufficient MIN6 cells (Fig 6.6). In response to both 1µM and 8µM zinc, we 
recorded upregulation of mRNA for Pax4 (1µM: 2.37-fold; 8µM: 2.03-fold) and 
downregulation for Foxa1 (1µM: 4.06-fold; 8µM: 2.48-fold). We further noted 1.61-fold 
upregulation of Hnf4a mRNA following culture with 8µM zinc and decreases in mRNA 




Fig 6.6. mRNA expression for transcription factors in ZnT8 haploinsufficient MIN6 
cells. Expression in MIN6 cells in response to culture with (A) 1µM or (B) 8µM zinc. 
Expression was assayed through qPCR and calculated as a ratio compared to sham-
CRISPR MIN6 cells cultured with (A) 1µM or (B) 8µM zinc (control). Experiments were 
carried out at 48 h. Data were analysed through t-tests and corrected for multiple 




6.4.5. ZnT8 haploinsufficiency reduces MIN6 cell proliferation and Ins1 expression  
We demonstrate above that ZnT8 haploinsufficiency disrupts expression of a distinct 
array of markers for β-cell identity, with differences observed based on extracellular zinc. 
To investigate whether these transcriptional changes alter the β-cell functional phenotype, 
we examined the survival parameters and insulin secretory response of ZnT8 
haploinsufficient MIN6 cells following culture with zinc depletion. 
ZnT8 haploinsufficient MIN6 cells cultured with either 1µM or 8µM zinc for 48 h 
exhibited lowered rates of proliferation compared to sham-CRISPR controls (1µM zinc: 
1.24-fold; 8µM zinc: 1.30-fold). We additionally observed a 1.59-fold increase in 
apoptosis for cells in response to 8µM zinc (Fig 6.7A-B). MAPK cascades mediate 
proliferation through cell cycle regulation [69] and mTOR cascades promote proliferation 
through mediating mRNA translation [51] (depicted in chapter 5, Fig 5.5); both MAPK 
and mTOR pathways can be regulated by zinc [313, 314]. To explore if the decreased 
proliferation of ZnT8 haploinsufficient MIN6 cells may be driven by MAPK or mTOR 
cascades, we examined phosphorylation of the downstream effectors ERK1/2 (MAPK) 
and RPS6 (mTOR), which are both activated by phosphorylation. We observed decreased 
phosphorylation of ERK1/2 at p42/p44 compared to sham-CRISPR MIN6 cells (1µM 
zinc: 1.61-fold; 8µM zinc: 1.79-fold) and a small but significant increase in 
phosphorylation of RPS6 at Ser235/236 (1.22-fold) following culture with zinc depletion 
(Fig 6.7C-E). We further examined the abundance of STAT3, which mediates key roles 
in growth, survival and development [507] (Fig 6.8) and is activated by zinc-dependent 
phosphorylation [317]. We noted a 2.15-fold (p=0.03, n=3) decrease in Stat3 mRNA 





Fig 6.7. Survival of ZnT8 haploinsufficient MIN6 cells in response to zinc depletion. 
(A) MIN6 cell proliferation, determined by BrdU incorporation. (B) MIN6 cell apoptosis, 
determined by Caspase 3/7 assays. (C-E) Phosphorylation of ERK1/2 and RPS6. (C) 
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Immunoblots of p42/p44 ERK1/2, ERK1/2, Ser235/236 RPS6 and RPS6. (D-E) 
Quantification of immunoblots for (D) p42/p44 ERK1/2 vs ERK1/2 and (E) Ser235/236 
RPS6 vs RPS6. Immunoblot quantification was carried out using ImageJ software. All 
experiments were carried out following culture of cells with 1µM or 8µM zinc for 48 h.  
(A-B, D-E) Results are relative to sham-CRISPR MIN6 cells cultured with 8µM zinc 
(control). Data were analysed by 2-way ANOVA followed by Sidak’s multiple 
comparison test. ZnT8 haploinsufficient MIN6 cells: ZnT8+/-. Error bars show ± SEM. 






Fig 6.8. STAT3 and cellular survival. STAT3 is activated by phosphorylation. 
Phosphorylated STAT3 translocates to the nucleus where it mediates expression of genes 
driving proliferation and survival, including Cyclin D1, Mcl1, Survivin and c-Myc. 




Finally, we explored the impact of ZnT8 haploinsufficiency on insulin expression and 
secretion, downregulation of which is a hallmark of β-cell dysfunction and failure. Unlike 
in human, rodents encode two insulin genes, Ins1 and Ins2, however the contribution of 
each for glucose regulation remain inconclusive [508]. We observed downregulation of 
Ins1 mRNA in ZnT8 haploinsufficient MIN6 cells following culture with both 1µM 
(2.01-fold) and 8µM (1.65-fold) zinc. However, we did not observe any differences in 







Fig 6.9. Insulin parameters for ZnT8 haploinsufficient MIN6 cells in response to zinc 
depletion. (A) Ins1 and Ins2 mRNA expression. Expression was assayed through qPCR 
and calculated as FD (Log2) compared sham-CRISPR MIN6 cells cultured with 8µM 
zinc (control). (B) Insulin secretion from MIN6 cells following addition of 3mM glucose 
(basal) or 40mM KCl (stimulated). The amounts of secreted insulin were calculated 
through insulin secretion assays and normalised to protein. All experiments were carried 
out following culture with 1µM or 8µM zinc for 48 h. Data were analysed by 2-way 
ANOVA followed by Tukey’s multiple comparison test. ZnT8 haploinsufficient MIN6 
cells: ZnT8+/-. Error bars show ± SEM. N=3. *p <0.05. 
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6.4.6. Prediction of PDX-1 binding to SLC39A DNA 
PDX-1 regulates zinc homeostasis in β-cells through targeting enhancers for ZnT8 [200]. 
Results presented in our systematic review (chapter 3 [404]) indicate PDX-1 abundance 
is additionally associated with mRNA expression for Slc39a1, Slc39a5, Slc39a6, Slc39a8 
and Slc39a14. In the present chapter, we show that ZnT8 functions corporately with ZIP8 
and ZIP14 to facilitate zinc trafficking and accumulation in β-cells, indicating potential 
ZnT8-ZIP coregulation. To examine whether PDX-1 may be involved in mediating 
coordinated ZnT8-ZIP expression, we examined transcriptional regulation of SLC39A 
mRNA in β-cells by PDX-1.  
We collated three independent PDX-1 ChIP-seq datasets for analysis of significant PDX-
1 binding to SLC39A exons and/or regulatory regions. Datasets included binding in 
nondiabetic human islets, mouse islets [509] and human embryonic stem cells 
differentiated into proliferative PDX-1+ pancreatic progenitor cells, representative of β-
cell progenitors [510]. To account for differences in genome annotations between 
assemblies, we lifted coordinates to the Human Genome, Dec. 2013 (GRCh38/hg38). We 
aligned PDX-1 binding coordinates to show overlap of significant binding sites between 
three independent studies for SLC39A3 and SLC39A6, and two independent studies for 
SLC39A9 and SLC39A13 (human and mouse islets) (Fig 6.10). We additionally identified 
significant PDX-1 binding to SLC39A9, SLC39A11, SLC39A12 and SLC39A14 in human 
islets, SLC39A8, SLC39A10, SLC39A812 and SLC39A14 in human PDX-1+ pancreatic 





Fig 6.10. Genomic regions harbouring significant PDX-1 binding sites. Loci were 
identified through analysis of published ChIP-seq datasets. Only identified genomic 








Table 6.1. Significant PDX-1 binding coordinates identified through ChIP-seq 
dataset analysis. Data were derived from human islets, mouse islets [509] and embryonic 
stem cell derived proliferative PDX-1+ pancreatic progenitor cells [510]. Coordinates 
overlapping between ChIP-seq studies are highlighted. Repeated coordinates that mapped 







To predict the PDX-1 binding sites at the identified SLC39A3, SLC39A6, SLC39A9 and 
SLC39A13 coordinates, we resorted to comparative genomics. We used ConTra V2 to 
map potential binding sites to the promoter (and up to 5000 bases upstream), 5’UTR, 
3’UTR and intronic regions, using the ‘minimize false positive’ position weight matrix 
and the TRANSFAC database. We then aligned the coordinates identified through ChIP-
Seq and ConTra V2 analysis (Table 6.2) to uncover a potential PDX-1 binding site within 
the 5’UTR of SLC39A6 (Hg38 loci chr18:36129333-36129348), conserved between 20 
of the 27 species assessed (Table 6.3). This loci maps to coordinates identified through 
analysis of ChIP-seq data from human and mouse islets and resides <200 bases from 
coordinates identified in PDX-1+ pancreatic progenitor cells.  
We further noted a potential PDX-1 binding site within intron 1 of SLC39A9 (Hg38 loci 
chr14:69403222-69403231), which maps to coordinates identified through analysis of 
ChIP-seq data from human and mouse islets and is conserved in 11 out of the 26 species 
assessed (Table 6.4). However, TRANSFAC did not predict binding in rodents. There 
was no predicted PDX-1 binding by TRANSFAC within the coordinates identified for 











Table 6.2. Predicted PDX-1 binding loci within SLC39A genomic DNA. All 
coordinates are expressed in Hg38 nomenclature. * = No PDX-1 binding predicted in 

















Table 6.3. Predicted PDX-1 binding loci in the 5’UTR of SLC39A6 (Hg38: 
chr18:36129333-36129348). The core PDX-1 binding sequence (TAAT) is conserved in 








































Table 6.4. Predicted PDX-1 binding loci in exon 1 of SLC39A9 (Hg38: 
chr14:69403222-69403231). The core PDX-1 binding sequence (TAAT) is conserved in 






































6.4.7. PDX-1 and abundances of Slc39a mRNA  
To explore regulation of the ZIP paralogues by PDX-1, we overexpressed PDX-1 
transgenes in MIN6 cells. We first confirmed overexpression by detecting high transgene 




Fig 6.11. PDX-1 transgene overexpression in MIN6 cells. Overexpression was detected 
by immunoblot using antibodies targeting the PDX-1 Myc synthetic tag.  
 
Overexpression of PDX-1 in MIN6 cells for 72 h increased the abundance of Pdx-1 
mRNA 43.29-fold. Overexpression was accompanied with upregulation of mRNA for 
eight Slc39a paralogues under investigation (Slc39a1: 2.09-fold, Slc39a3: 2.24-fold, 
Slc39a6: 1.61-fold, Slc39a8: 2.13-fold, Slc39a9: 1.75-fold, Slc39a10: 1.32-fold, 
Slc39a11: 2.49-fold and Slc39a13: 2.13-fold). We additionally assayed mRNA 
abundances for Oct-4, Ins1, Ins2, Slc30a8 and Slc39a7 as controls. PDX-1 downregulates 
Oct-4, a marker of endocrine pluripotency [510], upregulates Ins1, Ins2 and Slc30a8 [200, 
511] and is not predicted to transcriptionally regulate Slc39a7 (above). Consistent with 
elevated PDX-1 activity, we observed Oct-4 downregulation 3.56-fold and Slc30a8 
upregulation 1.41-fold; however, we could not detect any differences in mRNA 
abundances for Ins1 nor Ins2. We further noted Slc39a7 upregulation 1.78-fold despite 
not harbouring a significant PDX-1 binding site identified during ChIP-seq dataset 
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analysis (Table 6.1). These discrepancies may be explained by time-dependent responses, 






















































































































Fig 6.12. Slc39a mRNA abundances in MIN6 cells in response to PDX-1 
overexpression. Expression of Slc39a1, Slc39a3, Slc39a6, Slc39a8. Slc39a9, Slc39a10, 
Slc39a11, Slc39a13 and Slc39a14 mRNA. Positive controls: Pdx-1, Ins1, Ins2 and 
Slc30a8; neutral control: Slc39a7; negative control: Oct-4. Expression was assayed 
through qPCR and calculated as a ratio compared to mock transfected cells (controls) at 
72 h. N=3. *p <0.05, **p <0.005, ****p <0.0001. 
 
Finally, to infer whether PDX-1-mediated ZIP upregulation is likely to increase cellular 
zinc, we assayed mRNA expression for Mtf1 and the metallothioneins Mt1 and Mt2. 
MTF1 responds to zinc to mediate expression of Zn2+-responsive genes [148] and the 
MTs bind and buffer cytosolic zinc to maintain optimal free Zn2+ concentrations [145]. 
Following overexpression of PDX-1 for 72 h, we did not observe any differences in the 
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abundances of Mt1 or Mt2, however Mtf1 was upregulated 1.88-fold (p=0.02) (data not 
shown).  
6.5. Discussion  
Lowered ZnT8 activity is associated with both protective and destructive effects for β-
cell phenotype and function. Twelve rare ZnT8 nonsense or missense loss-of-function 
variants collectively represent a 65% decrease in Type 2 Diabetes risk [271] whereas 
ZnT8 overexpression protects against zinc depletion-induced reductions in human islet 
and rat INS-1E cell function [186, 191]. Furthermore, it is unclear whether the diabetes-
susceptibility ZnT8 polymorphic variant at amino acid position 325 encodes a gain- or 
loss-of-function mutation [201, 265]. Since complete loss of abundance has not been 
reported for ZnT8 in human, ZnT8 haploinsufficient cells represent a model to examine 
the dampened ZnT8 expression that is induced by polymorphisms [271] and/or stresses 
that negatively impact β-cell function and mass [179, 186, 227].  
6.5.1. Zinc characteristics of ZnT8 haploinsufficient MIN6 cells  
Prior to uptake of zinc into insulin granules by ZnT8, β-cells exhibit increases in cytosolic 
free Zn2+ [192], suggesting ZnT8 activity is coordinated with ZIP-facilitated cytosolic 
zinc influx at the plasma membrane and/or membranes of intracellular zinc stores [146]. 
Concurrently, temporal loss of ZnT8 expression induced during β-cell dysfunction is 
coupled with decreased cytosolic free Zn2+ and a reduced insulin secretory capacity [179, 
186, 227]. The lowered cytosolic Zn2+ is probably mediated by rapid changes to ZIP 
expression and/or activities coordinated with ZnT8 abundance. Following ZnT8 depletion 
with siRNA, we observed initial transcriptional upregulation of Slc39a14 and 
downregulation of Slc39a1, Slc39a8 and Slc39a9. Expression of ZIP1, ZIP8 and ZIP9 
may be supressed to prevent excess cytosolic free Zn2+ accumulation in response to 
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decreased granule uptake. Of potential importance, ZIP9 functions as an androgen 
receptor in addition to as a zinc transporter, and downregulation may further impact β-
cell function via associated G-protein signal transduction pathways [512]. The spike in 
ZIP14 abundance could reflect an adaptive response to increase cytosolic free Zn2+, which 
we have previously shown is promoted by zinc depletion (chapter 5). 
ZnT8 haploinsufficient cells may represent the final state of stress-induced 
downregulation of ZnT8 abundance. In MIN6 cells, ZnT8 haploinsufficiency was not 
associated with disrupted mRNA expression for any other ZnT paralogues, indicating 
MIN6 cells do not induce Slc30a transcription to compensate for partial loss of ZnT8, 
consistent with observations recorded for ZnT8 null mouse islets [202]. ZnT8 
haploinsufficiency was associated with lowered mRNA expression for Slc39a8 and 
Slc39a14, suggesting ZIP8 and ZIP14 are important for coordinating cytosolic zinc influx 
in the steady state with ZnT8 activity. MIN6 cells may downregulate ZIP8 and ZIP14 to 
prevent destructive effects of cytosolic free Zn2+ overload (chapter 5 and [459]) when 
efflux into secretory granules is reduced. The implications of changes to ZIP8 and ZIP14 
abundances in MIN6 cells are discussed in chapter 5 (section 5.5.1). Our previous studies 
demonstrate that stresses associated with β-cell dysfunction deregulate expression of 
multiple ZIP paralogues (chapters 3-5 [404, 405]); our present data demonstrate these 
transcriptional changes could be consequential to lowered ZnT8 activity or result from 
disruption of a factor co-regulating ZnT8 and coordinated ZIP paralogues. 
Lowered ZnT8 activity decreases β-cell/islet zinc contents [201, 202, 273, 276]. 
Consistently, we demonstrate that ZnT8 haploinsufficient MIN6 cells exhibit reduced 
total zinc contents compared to controls. Since we did not observe differences in MT 
expression, the decrease in zinc likely represents lowered granule rather than cytosolic 
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free Zn2+, which has previously been observed for ZnT8 null mouse models [201, 202, 
273]. We noted that reduced cellular zinc was coupled with a trend for a lowered zinc 
influx capacity for cells cultured with depleted zinc, probably representing reduced 
trafficking of zinc to secretory granules due to downregulated ZIP expression and 
decreased amounts of available zinc. These differences to the zinc uptake capacity suggest 
that ZIP abundances are mediated simultaneously by both ZnT8 activity and zinc 
availability to regulate β-cell zinc homeostasis.  
6.5.2. Phenotypes of ZnT8 haploinsufficient MIN6 cells  
An array of endocrine-specific markers function to tightly maintain β-cell phenotype 
[114]. We have previously demonstrated that multiple transcription factors important for 
β-cell identity and endocrine function show Zn2+-responsive expression (HNF1B, 
HNF4A, MAFA, MNX-1, NKX2.2, NKX6.1, PAX4, PAX6 and PDX-1; Chapter 4 
[405]). Since ZnT8 haploinsufficient MIN6 cells exhibit lowered zinc contents compared 
to controls, it is likely that a lowered ZnT8 abundance additionally impacts β-cell 
transcription factor expression and identity. In MIN6 cells, ZnT8 haploinsufficiency 
induced upregulation of Pax4 and downregulation of Foxa1. We additionally recorded 
small but significant upregulation of mRNA for Hnf4a in response to adequate zinc 
culture and downregulation for Foxo1 and MafA following zinc depletion. Although 
PAX4 and HNF4A are Zn2+-responsive [329, 405], their expression is tightly maintained 
by multiple factors; upregulation in ZnT8 haploinsufficient cells suggests they are 
additionally regulated by other roles of ZnT8, which likely dominate under these 
conditions. PAX4 is a major transcriptional regulator of β-cell development, phenotype 
and function [513], promotes cellular survival by protecting against stress-induced 
apoptosis [513, 514] and prevents β- to α-cell transdifferentiation through inhibiting 
glucagon expression [515], whereas HNF4A functions to regulate insulin gene expression 
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[339]. Downregulation of FOXA1, FOXO1 and MAFA additionally has potential to 
disrupt β-cell function. FOXA1 acts in combination with FOXA2 to regulate insulin 
secretion and carbohydrate metabolism [516] and MAFA mediates GSIS [517], with loss 
of function disrupting mature β-cell identity [103]. Moreover, FOXO1 is essential for β-
cells to increase insulin secretion to compensate for increased peripheral insulin 
resistance [518] and regulates expression of NEUROD1 and MAFA to protect against 
oxidative damage [108].  
Tightly maintained zinc homeostasis is required for cellular signalling, differentiation and 
proliferation [519]. We have previously shown that lowered cellular zinc negatively 
impacts MIN6 cell survival and intracellular signalling (chapters 4 [405] and 5). The 
changes to transcription factor expression observed in ZnT8 haploinsufficient cells 
suggest that ZnT8 downregulation has potential to impact β-cell survival. We 
demonstrated that ZnT8 haploinsufficiency lowers proliferation of MIN6 cells and 
increases apoptosis only in adequate zinc culture, possibly due to toxicity resulting from 
a reduced zinc storage capacity. The lowered proliferation may be promoted by reduced 
MAPK signalling. MAPK cascades are activated by physiological concentrations of Zn2+ 
[520, 521] to regulate gene expression, mitosis, differentiation, metabolism and 
programmed cell death [522]. We further observed downregulation of mRNA for Stat3 
following zinc depletion, which may contribute to the reduced β-cell survival. STAT3 is 
activated by cytokines and non-receptor tyrosine kinases to mediate β-cell function, 
proliferation and survival [523-526] and maintains the β-cell steady state through 
regulating cell cycle progression [527]. STAT3 activity is linked to cellular zinc 
homeostasis through inducing transcription of ZIP6 and ZIP10 [207, 316]. However, mice 
harbouring β-cell-specific STAT3 ablation (PDX-1-Cre transgene inactivation) do not 
develop glucose intolerances, suggesting STAT3 may be dispensable for β-cell function 
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[528]. It should be acknowledged that a recent study reported CRISPR/Cas9 genome 
editing induces a p53-driven DNA damage response and cell cycle arrest in immortalised 
human retinal pigment epithelial cells; it is therefore conceivable that decreased MIN6 
cell proliferation may be secondary to the technique rather than consequential of 
transporter knockdown [529]. However, the use of sham-CRISPR cells as controls 
reduces the likelihood for this explanation.  
Contradictive to our results, previous studies suggest that loss-of-function ZnT8 variants 
are protective against Type 2 Diabetes in human [271] and that the most common loss-
of-function variant R138X elevates insulin secretion in response to high glucose [280]. 
Moreover, another study reported that lowered β-cell zinc consequential to reduced ZnT8 
activity is protective for β-cell function and increases cellular proliferation via insulin-
stimulated AKT activation [229]. ZnT8 loss-of-function variants may induce additional 
function(s) in β-cells, and/or may be coordinated differently with ZIP transporters than 
haploinsufficient genotypes, therefore inducing differing phenotypes. Alternatively, 
species-specific differences in the function of ZnT8 may exist, preventing us from 
replicating this observation in a rodent model. Our ZnT8 haploinsufficient MIN6 cells 
likely represent the downregulated ZnT8 phenotype of β-cells in response to stresses 
negatively impacting β-cell function [179, 186, 227]. 
Inadequate insulin secretion in response to elevated concentrations of glucose is a 
hallmark of β-cell failure and diabetic onset. The insulin secretory pathway is tightly 
controlled by temporal expression of multiple transcription factors and may therefore be 
impacted by the changes in expression consequential to ZnT8 abundance. In ZnT8 
haploinsufficient MIN6 cells, we recorded lowered mRNA expression for Ins1 compared 
to control cells, indicating reduced ZnT8 abundance may prevent cells mounting 
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appropriate secretory responses. However, we did not observe any differences in basal or 
KCl-stimulated insulin release, which is contradictive of a previous study exploring ZnT8 
knockdown in MIN6 cells [229]. In mouse, ZnT8 ablation has been reported to either 
negatively impact [201, 202] or have no effect [274] on glucose tolerance, nevertheless 
circulating insulin is generally lowered in ZnT8 null animals [277]. However, as 
previously noted (chapter 5, section 5.5.1), stimulation of MIN6 cells with KCl may not 
replicate differences in the secretory response that exist following glucose stimulation. 
6.5.3. ZnT8-ZIP coregulation by PDX-1 
The transcription factor PDX-1 is largely confined to β-cells in the mature pancreas [91]. 
PDX-1 regulates β-cell-specific roles of widely expressed genes, and mediates zinc 
homeostasis by promoting expression of ZnT8 [200]. We demonstrate that PDX-1 may 
bind genomic enhancers for ZIP6 and ZIP9 and could therefore co-regulate ZIP6 and 
ZIP9 alongside ZnT8 [200]. However, mechanistic investigations, such as reporter gene 
and promoter bashing assays, are required before conclusions can be drawn. Following 
PDX-1 overexpression in MIN6 cells, we further observed upregulation of mRNA for 
additional ZIP paralogues and MTF1. PDX-1 mediates expression of thousands of genes 
in β-cells with roles in almost all areas of β-cell function, including metabolism, gene 
expression and cellular survival [509]. ZIP abundance may be regulated by PDX-1-
induced expression of a SLC39A-targeting transcription factors or via another mechanism 
functioning to maintain β-cell homeostasis. MTF1 is the main transactivator of MT1 and 
MT2 expression [162, 163]; upregulation of MTF1 but not MT1 or MT2 in cells 
overexpressing PDX-1 suggests that PDX-1 might prime the β-cell zinc response, 
possibly to induce more potent responses following addition of zinc or further stimuli, 
which is consistent with our previous observations that PDX-1 primes the β-cell ZIP/zinc 
response to cytokines (chapter 3 [404]).  
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If PDX-1 is found to transcriptionally regulate ZIP6 and/or ZIP9 in addition to ZnT8, 
PDX-1 could be key for understanding zinc trafficking in β-cells. PDX-1 portrays critical 
regulatory roles during development of the endocrine pancreas [100] and is important for 
mediating a diverse range of functions in mature β-cells including cellular survival [101], 
identity [91], action of GLP-1 [530] and ER stress susceptibility [531], many of which 
are additionally regulated by zinc and its transporters [218, 519, 532, 533]. Our data 
would implicate a role of zinc for β-cell dysfunction in patients with MODY4, which 
arises from inactivating PDX-1 mutations [4]. Taken with our previous data, these results 
may suggest ZnT8 is transcriptionally coregulated with ZIP6 and ZIP9 by PDX-1 to 
maintain adequate zinc uptake into the cytosol, and that expression of ZIP8 and ZIP14 
are altered by ZnT8 activity to rapidly adapt cytosolic zinc flux following ZnT8 
downregulation. ZIP6, ZIP8, ZIP9 and ZIP14 have all previously been identified as 
important candidates for regulating β-cell function [192, 404] and may function 
cooperatively to fine-tune β-cell zinc homeostasis and endocrine function.  
6.6. Conclusion 
In this study we explored the impact of loss of ZnT8 abundance for the phenotype of 
MIN6 cells following zinc depletion. ZnT8 haploinsufficient MIN6 cells exhibited 
downregulation of ZIP8 and ZIP14 and decreased β-cell zinc uptake and accumulation. 
Moreover, loss of ZnT8 abundance altered expression of key β-cell transcription factors 
in MIN6 cells and reduced cellular survival via MAPK cascades, consistent with the 
destructive role of stress-induced ZnT8 suppression [179, 186, 227] but contradictive of 
the protective effects induced by loss-of-function ZnT8 variants [271]. The existence of 
differing pathways associated with loss of ZnT8 abundance in mature cells compared to 
expression of a truncated protein probably explain this variation. We additionally showed 
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that PDX-1 may transcriptionally co-regulate ZIP6 and ZIP9 alongside ZnT8. PDX-1-
induced β-cell dysfunction could therefore, at least in part, be driven by zinc deregulation. 
Overall, we demonstrate coordinated ZnT8-ZIP zinc trafficking is important for β-cell 
zinc homeostasis and that ZnT8 haploinsufficiency impacts β-cell phenotype and reduces 













7. ZIP6 deficiency increases the cytosolic zinc content of 
MIN6 cells to disrupt Zn2+-responsive β-cell markers and 
cellular survival   
 
7.1. Abstract  
The zinc importer ZIP6 is highly expressed in β-cells. Whilst ZIP6 is a plasma membrane 
zinc channel, its principal role in a variety of cell types is zinc-mediated cellular 
signalling, notably to stimulate proliferation and anoikis resistance. However, the role of 
ZIP6 for maintaining β-cell phenotype and mass remains poorly described. We 
hypothesised ZIP6 is important for β-cell zinc homeostasis and that ZIP6 plays key roles 
in the adaptive response to hypozincaemia. We used CRISPR/Cas9 technology to 
generate ZIP6 knockout MIN6 cell populations and stressed cells with zinc depletion. We 
showed that ZIP6 abundance is associated with expression of multiple ZIP and ZnT 
paralogues and the zinc-responsive proteins MTF1, MT1 and MT2. ZIP6 knockout MIN6 
cells cultured with depleted zinc exhibited lowered total zinc contents compared to 
controls, suggesting ZIP6 plays a role in adapting to zinc depletion. The disrupted zinc 
phenotype was accompanied with altered expression of multiple markers for β-cell 
identity including key transcription factors and the insulin gene, with potentially 
important differences observed between cells cultured with deficient and adequate zinc. 
Moreover, ZIP6 knockout cells exhibited decreased proliferation and apoptosis, coupled 
with suppression of mTOR cascades and increased abundance of Stat3 mRNA. These 
data highlight ZIP6 as important for β-cell identity and survival and show that ZIP6 is 
critical for the cellular response to zinc depletion.  
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7.2. Introduction  
Tightly controlled zinc homeostasis is important for maintaining β-cell identity and 
survival (chapters 4 [405] and 5). In mammals, the 14 ZIP and 10 ZnT zinc transporters 
mediate cellular zinc trafficking at the plasma membrane and membranes of intracellular 
vesicles and organelles. The predominantly β-cell-specific paralogue ZnT8 facilitates 
zinc uptake into insulin secretory granules and changes to its abundance and/or activity 
disrupt β-cell zinc content and induce dysfunction associated with Type 2 Diabetes [198]. 
Stimulation of islets with high glucose induces elevations in cytosolic free Zn2+ [192], 
presumably representing increased zinc trafficking to secretory granules to replenish zinc 
lost through increased Zn2+/insulin co-exocytosis. The responsible ZIP influx transporters 
(possibly ZIP6, ZIP8, ZIP9 and ZIP14; chapter 6) must also therefore be important for 
normal β-cell zinc trafficking and function.    
ZIP6 is a member of the LIV-1 subfamily of ZIP transporters and is ubiquitously 
expressed in mammals [534]. Following translation, ZIP6 is expressed as an inactive pro-
protein at the ER and subsequent N-terminal cleavage promotes translocation of the active 
protein to the plasma membrane [204]. ZIP6 forms heteromers with the phylogenetically 
closely related LIV-1 paralogue ZIP10, which exhibit non-redundant cellular signalling 
roles compared to each homodimer alone [206]. ZIP6:ZIP10 heteromers are 
transcriptionally regulated downstream of JAK-STAT3/5 pathways involved in cellular 
survival [207, 316] and are implicated in regulating the potent kinases GSK-3α and GSK-
3β [206, 311]. ZIP6 has been strongly linked to inducing epithelial-mesenchymal 
transition for tumour cell migration via transcriptionally repressing ERK1/2-SNAIL-
SLUG signalling [320, 321] and loss of ZIP6 in the breast cancer cell line MCF-7 disturbs 
intracellular zinc to promote cellular survival during hypoxia [535]. ZIP6 additionally co-
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localises with and is evolutionarily homologous to prion proteins, although the full 
significance of this remains to be determined [536].  
Limited information is available about the role of ZIP6 in β-cells. We and others [192, 
218, 404] show that ZIP6 exhibits relatively high expression in β-cells, suggestive of a 
potential biological importance. Moreover, ZIP6 abundance may be linked to β-cell 
dysfunction since ZIP6 downregulation is observed in islets from type 2 diabetic patients 
(chapter 3 [404]). Previous studies suggest that ZIP6 is important for maintaining β-cell 
and islet zinc homeostasis [218] and that ZIP6 may function to suppress β-cell apoptosis, 
promote insulin expression and biosynthesis, and interact with GLP-1R to potentiate 
GSIS [319].  
Changes to β-cell zinc are induced by the availability of extracellular zinc and impact 
cellular signalling and survival (chapter 5). We previously demonstrated that ZIP6 
expression is supressed in the islets of some type 2 diabetic patients (chapter 3 [404]). 
Moreover, that ZIP6 is downregulated in MIN6 cells by prolonged stimulation, associated 
with decreased cellular zinc (chapter 4 [405]), and in response to high zinc (chapter 5). 
Here, we hypothesised that ZIP6 maintains β-cell phenotype and promotes survival in 
response to hypozincaemia. We aimed to generate ZIP6 knockout MIN6 cells and explore 
changes to cellular zinc, phenotype and survival following zinc depletion.  
In this chapter we used CRISPR/Cas9 technology to generate ZIP6 knockout MIN6 cells. 
We showed that ZIP6 knockout disrupts Slc39a and Slc30a expression profiles, 
upregulates mRNA abundances for Mt1, Mt2 and Mtf1, and increases cellular zinc uptake 
capacities in adequate (8µM) but not deficient (1µM) zinc culture. Furthermore, ZIP6-
induced changes to cellular zinc are coupled with differential expression of transcription 
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factors important for β-cell function and survival, lowered rates of proliferation and 
apoptosis associated with mTOR signalling and Stat3 induction, and decreased 
abundance of Ins1 mRNA. Critically, we demonstrate ZIP6 is required to maintain β-cell 
zinc content, phenotype and survival and that ZIP6 plays a small, but potentially 
significant, role in the cellular response to zinc depletion. 
7.3. Methods  
7.3.1. Cell line and culture  
MIN6 cells were cultured as described in section 2.1. For zinc depletion experiments, 
standard growth medium was replaced with growth media containing 25mM glucose and 
1μM or 8μM zinc for 48 h (section 2.2). 
7.3.2. CRISPR/Cas9 gene knockout 
ZIP6/Slc39a6 gene knockout was carried out using CRISPR/Cas9 gene technology, as 
detailed in section 2.5. Primers to assess the occurrence of genome editing were designed 
through computationally aligning ZIP6 Cas9 nickase guide sequences to the mouse 
genome assembly mm10 (forward: CTTTGGGTTACAAGCCCCCT; reverse: 
CCTAGGAGGACCAAACAGGC (Sigma Aldrich); Fig 7.1A). Seven potential Slc39a6 
knockout populations were generated by serial dilution. PCR amplifications of the Cas9-
targeted genomic loci were separated by agarose gel electrophoresis to reveal multiple 
variants shifted from the control in two of the seven colonies (clones 4 and 5; Fig 7.1B), 
consistent with editing of both Slc39a6 copy variants, which was confirmed through 




Fig 7.1. Amplification of ZIP6 CRISPR/Cas9-targeted genomic DNA. (A) Binding of 
CRISPR/Cas9 constructs to Slc39a6 genomic DNA. ZIP6 was mapped to the reverse 
strand of chromosome 18 (24,579,881-24,603,817) on mouse genome GRCm38.p6 using 
the NCBI Ensembl genome browser 92. The Cas9 nuclease binds at the sequences 
highlighted in grey. The downstream nickase construct is predicted to bind at two 
identical Slc39a6 loci in close proximity (depicted in Fig 7.2). Primers to assess 
knockdown bind at the sequences highlighted in turquoise. Red: exon 2. (B) Agarose gel 
electrophoresis showing PCR-amplified regions of Slc39a6 from clonal MIN6 cell 
populations transfected with ZIP6 CRISPR/Cas9 or control nickase constructs. The gel 
was imaged using GeneSnap software.  
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7.3.3. Gene expression analysis  
RNA was extracted from MIN6 cells, reverse transcribed to cDNA and relative 
expression assayed through qPCR. The full methodology and details of primers used are 
provided in section 2.6. All results were presented as an expression ratio compared to 
control cells except for insulin gene expression, where values for FD (Log2) in expression 
are presented.  
7.3.4. Cellular zinc parameters  
Total MIN6 cell zinc contents were determined through ICP-MS (section 2.3). The 
kinetics of zinc uptake into MIN6 cells were assessed through 65Zinc uptake assays 
(section 2.8).  
7.3.5. Cellular proliferation and apoptosis 
The rates of MIN6 cell proliferation and apoptosis were determined as described in 
sections 2.9-2.10. To investigate signalling via MAPK and mTOR signalling cascades, 
protein was extracted from cells and phosphorylation of the downstream components 
ERK1/2 (MAPK) and RPS6 (mTOR) were quantified by immunoblot (section 2.7). The 
primary and secondary antibodies used are as detailed in section 6.3.7.  
7.3.6. Insulin secretion assays  
The amounts of secreted insulin were determined through insulin secretion assays 





7.4. Results  
7.4.1. ZIP6 knockout disrupts ZIP and ZnT expression  
ZIP6 exists as homomers and heteromers with ZIP10 at the plasma membrane to facilitate 
zinc uptake into the cytosol [206]. ZIP6 expression is associated with multiple stresses 
that impact β-cell function (chapter 3-4 [404, 405]) and ZIP6 downregulation disrupts the 
cytosolic zinc content of MIN6 cells [218]. To explore which zinc transporters function 
in conjunction with ZIP6 to maintain β-cell zinc homeostasis, we examined expression 
profiles for the ZIP and ZnT paralogues in ZIP6 knockout MIN6 cells.  
We first verified loss of ZIP6 abundance in CRISPR/Cas9-treated MIN6 cells. In silico 
sequence analysis revealed that ZIP6 CRISPR clone 4 is predicted to encode both 144 
amino (protein A) and 728 amino (protein B) truncated versions of ZIP6 (wildtype: 765 
amino acids) (Fig 7.2). Protein A consists of 144 amino acids of the ZIP6 NTD so is 
unlikely to be functionally active, whereas protein B only differs from the wildtype by 
the absence of 37 amino acids from the middle of its NTD; it is therefore possible protein 
B is active. Nevertheless, we only detected background expression for Slc39a6 (9.73-fold 
depletion), suggesting genome editing probably resulted in translation of unstable mRNA, 
which was rapidly degraded, indicative of ZIP6 knockout. However, it should be noted 
that genome editing was not predicted to alter the sequence for ZIP6 variant 2 (ZIP6-204 
in Fig 7.1A), nor are our primers predicted to recognise expression of this transcript. 
However, since ZIP6 variant 1 is the predominant ZIP6 isoform expressed in islets 




Fig 7.2. Slc39a6 genome editing. Editing at Slc30a6 exon 2 for ZIP6 CRISPR clone 4. The reference sequence was downloaded from the NCBI 
Ensembl genome browser 92 and binding of the ZIP6 Cas9 nickase constructs illustrated. The region shown spans Chr18:24601196-24601346 
(mouse genome GRCm38.p6) on the negative strand. The sequences of the edited genome and protein domains of the translated proteins are 
shown.   
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ZIP6 knockout was coupled with downregulation of mRNA for Slc39a2 (2.03-fold), 
Slc39a10 (8.03-fold) and Slc39a14 (1.64-fold), and upregulation for Slc39a4 (4.58-fold) 
and Slc39a13 (2.29-fold) compared to sham-CRISPR MIN6 cells (Fig 7.3A). When we 
examined expression of the ZnT paralogues, we recorded upregulation of mRNA for 
Slc30a1 (1.92-fold), Slc30a4 (1.88-fold), Slc30a6 (1.50-fold) and Slc30a7 (1.48-fold) 





Fig 7.3. Zinc transporter expression in ZIP6 knockout MIN6 cells. mRNA expression 
for (A) Slc39a and (B) Slc30a paralogues in ZIP6 knockout MIN6 cells generated by 
CRISPR/Cas9 technology. We were unable to detect quantifiable expression for Slc39a12 
or Slc30a10. Expression is presented relative to sham-CRISPR MIN6 cells (control). Data 
were analysed using t-tests and corrected for multiple comparisons. Error bars show ± 
SEM. N=3. *p <0.05, **p<0.005, ***p<0.001, ****p<0.0001.   
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7.4.2. ZIP6 knockout increases cytosolic zinc in MIN6 cells 
Extracellular zinc depletion decreases the zinc contents of MIN6 cells but increases the 
cellular zinc uptake capacities (chapter 5), presumably as an adaptive response to prevent 
zinc depletion-induced dysfunction [183]. To examine the role of ZIP6 in MIN6 cells for 
maintaining zinc homeostasis, we explored the zinc characteristics of ZIP6 knockout 
MIN6 cells cultured with depleted and adequate zinc.  
Following culture of ZIP6 knockout MIN6 cells in zinc deficient (1µM zinc) media for 
48 h, we observed a 1.35-fold reduction in total zinc compared to sham-CRISPR controls. 
However, we did not record a difference in cellular zinc content in response to 8µM zinc 
(Fig 7.4A). In ZIP6 knockout MIN6 cells, we noted upregulation of mRNA expression 
for Mt1, Mt2 and Mtf1 following culture with both 1µM (Mt1: 3.93-fold; Mt2: 3.58-fold; 
Mtf1: 1.41-fold) and 8µM (Mt1: 2.31-fold; Mt2: 2.37-fold; Mtf1: 1.49-fold) zinc (Fig 
7.4B), suggestive of increased amounts of cytosolic free Zn2+ and activation of Zn2+-
responsive genes. To attribute these increases in mRNA abundances to cytosolic zinc 
influx, we examined the zinc uptake kinetics. We treated MIN6 cells with 1µM zinc or 
8µM zinc for 48 h and then assayed 65Zn uptake at a range of concentrations. We revealed 
pre-treatment with 8µM zinc increased zinc influx into ZIP6 knockout MIN6 cells at all 
65Zn concentrations tested compared to sham-CRISPR controls (Fig 7.4C-D). However, 





Fig 7.4. Zinc content and uptake kinetics for ZIP6 knockout MIN6 cells in response 
to zinc depletion. (A) Total cellular zinc content. Zinc content was determined through 
ICP-MS and normalised to protein. (B) mRNA expression for Mt1, Mt2 and Mtf1. 
Changes in mRNA expression were calculated through qPCR and expressed as a ratio 
relative to sham-CRISPR MIN6 cells cultured with 8µM zinc (control). (C-D) Uptake 
kinetics for zinc into cells pre-treated with (C) 1µM or (D) 8µM zinc. Red: ZIP6 knockout 
MIN6 cells; black: sham-CRISPR MIN6 cells (control). All experiments were carried out 
following culture with 1µM or 8µM zinc for 48 h. Data were analysed by 2-way ANOVA 
followed by (A-B) Tukey’s or (C-D) Sidak’s multiple comparison test. ZIP6 knockout 
MIN6 cells: ZIP6-/-. For (A) N=4 and (B-D) N=3. Error bars show ± SEM. *p <0.05, **p 
<0.005, ***p <0.001, ****p <0.0001.   
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7.4.3. ZIP6 knockout disrupts expression of important β-cell markers  
Above, we indicate that ZIP6 has pronounced effects on expression of β-cell ZIP and ZnT 
transporters and cellular zinc uptake and accumulation. Critically, total cellular zinc and 
the cellular zinc uptake capacities differed dependent on pre-treatment of ZIP6 knockout 
cells with 1µM or 8µM zinc. To assess the impact of ZIP6-induced zinc disruption for β-
cell phenotype, we examined expression of markers for β-cell identity and function 
[Foxa1, Foxa2, Foxo1, Hnf1b, Hnf4a, MafA, Mnx-1, Nkx2.2, Nkx6.1, Neurod1, Pax4, 
Pax6 and Pdx-1, many of which show Zn2+-responsive expression in β-cells (chapter 4 
[405])] following loss of ZIP6 abundance. 
ZIP6 knockout MIN6 cells cultured with either 1µM or 8µM zinc for 48 h exhibited 
upregulation of mRNA for Foxa1 (1µM: 2.38-fold; 8µM: 2.24-fold), MafA (1µM: 1.70-
fold; 8µM: 1.49-fold), Nkx6.1 (1µM: 1.56-fold; 8µM: 1.31-fold) and Pdx-1 (1µM: 1.45-
fold; 8µM: 1.39-fold) and downregulation for Hnf4a (1µM: 5.69-fold; 8µM: 4.72-fold), 
Nkx2.2 (1µM: 1.51-fold; 8µM: 1.48-fold) and Pax4 (1µM: 14.47-fold; 8µM: 13.03-fold) 
compared to sham-CRISPR controls. We additionally noted upregulation of mRNA for 
Foxo1 (1.33-fold) in ZIP6 knockout MIN6 cells cultured with 1µM zinc and Pax6 (1.55-




Fig 7.5. mRNA expression for transcription factors in ZIP6 knockout MIN6 cells. 
Expression in response to (A) 1µM or (B) 8µM extracellular zinc. Expression was 
assayed through qPCR and calculated as a ratio compared to sham-CRISPR MIN6 cells 
cultured with (A) 1µM or (B) 8µM extracellular zinc (controls). Experiments were carried 
out at 48 h. Data were analysed using t-tests and corrected for multiple comparisons. Error 
bars show ± SEM. N=3. *p <0.05, **p <0.005, ***p <0.001, ****p <0.0001. 
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7.4.4. ZIP6 knockout lowers MIN6 cell apoptosis and proliferation 
ZIP6:ZIP10 heteromers stimulate proliferation and survival of mammalian cells [206]. 
We have shown that changes to extracellular zinc decrease MIN6 cell survival (chapter 
5) and that ZIP6 abundance is associated with differential expression for multiple 
transcription factors important for β-cell phenotype, function and mass (above, section 
7.4.3). Disruption of ZIP6 expression and associated changes to MIN6 cell zinc may 
therefore impact cellular survival. We examined the survival characteristics of ZIP6 
knockout MIN6 cells and, since ZIP6 induces differences to the cellular zinc content and 
the expression profiles of β-cell markers dependent on extracellular zinc, whether these 
differ following zinc depletion.  
ZIP6 knockout MIN6 cells cultured with 1µM or 8µM zinc for 48 h exhibited lowered 
rates of proliferation (1µM: 1.35-fold; 8µM: 1.18-fold) and apoptosis (1µM: 1.62-fold; 
8µM: 1.48-fold) compared to sham-CRISPR controls (Fig 7.6A-B); this observation is 
unexpected since ZIP6 deficiency has been associated with increased cellular survival 
[535]. MAPK and mTOR signalling pathways both regulate cell cycle progression, 
proliferation and apoptosis [51, 69] (depicted in chapter 5, Fig 5.5) and can be mediated 
by zinc [313, 314]. To examine if ZIP6-induced changes to MIN6 cell survival may be 
induced via MAPK or mTOR cascades, we assessed phosphorylation of their downstream 
components ERK1/2 (at p42/p44; MAPK) and RPS6 (at Ser235/236; mTOR) (Fig 7.6C-
E). We did not observe any differences in p42/p44 ERK1/2 phosphorylation between 
ZIP6 knockout MIN6 cells and controls. However, there was an increase in Ser235/236 
RPS6 phosphorylation following loss of ZIP6 abundance (1µM zinc: 1.63-fold; 8µM 
zinc: 1.34-fold). Finally, we examined expression of the transcription factor STAT3, 
which mediates key roles in growth, survival and development [507] (depicted in chapter 
6, Fig. 6.8). Stat3 mRNA was upregulated in ZIP6 knockout MIN6 cells compared to 
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sham-CRISPR controls in response to both 1µM [1.59-fold (p=0.03, n=3)] and 8µM 







Fig 7.6. Survival of ZIP6 knockout MIN6 cells in response to zinc depletion. (A) 
MIN6 cell proliferation, determined by BrdU incorporation. (B) MIN6 cell apoptosis, 
determined by Caspase 3/7 assays. (C-E) Phosphorylation of ERK1/2 and RPS6. (C) 
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Immunoblots of p42/p44 ERK1/2, ERK1/2, Ser235/236 RPS6 and RPS6. (D-E) 
Quantification of immunoblots for (D) p42/p44 ERK1/2 vs ERK1/2 and (E) Ser235/236 
RPS6 vs RPS6. Immunoblot quantification was carried out using ImageJ software. All 
experiments were carried out following culture of cells with 1µM or 8µM zinc for 48 h. 
Data were analysed by 2-way ANOVA followed by Sidak’s multiple comparison test.  
(A-B and D-E) Results are relative to sham-CRISPR MIN6 cells cultured with 8µM zinc 
(control). ZIP6 knockout MIN6 cells: ZIP6-/-. Error bars show ± SEM. N=3. *p <0.05, 
**p <0.005.   
 
7.4.5. ZIP6 knockout alters insulin gene expression   
Zinc is reported to promote both stimulatory [219, 329] and inhibitory [424] effects on β-
cell insulin secretion. Moreover, the transcription factors impacted by ZIP6 knockout 
(above, section 7.4.3) are all involved in regulating insulin production and/or secretion. 
To explore the role of ZIP6 and ZIP6-mediated zinc disruption on β-cell insulin secretory 
function, we examined expression of the two insulin genes present in rodent (Ins1 and 
Ins2) in ZIP6 knockout MIN6 cells and insulin secretion from ZIP6 knockout MIN6 cells 
following culture with zinc depletion. We observed downregulation of Ins1 mRNA in 
ZIP6 knockout MIN6 cells compared to sham-CRISPR controls (1µM zinc: 3.24-fold; 
8µM zinc: 3.38-fold). We additionally recorded a modest 1.62-fold upregulation of Ins2 
mRNA for cells cultured with 8µM zinc (Fig 7.7A). However, we did not observe any 
differences in basal or KCl-stimulated insulin secretion from MIN6 cells dependent on 





Fig 7.7. Insulin parameters for ZIP6 knockout MIN6 cells in response to zinc 
depletion. (A) Ins1 and Ins2 mRNA expression. Expression was assayed through qPCR 
and calculated as FD (Log2) in expression compared to sham-CRISPR MIN6 cells 
cultured with 8µM zinc (control). (B) Insulin secretion from MIN6 cells following 
addition of 3mM glucose (basal) or 40mM KCl (stimulated). The amounts of secreted 
insulin were calculated through insulin secretion assays and normalised to total protein. 
All experiments were carried out following culture with 1µM or 8µM zinc for 48 h. Data 
were analysed by 2-way ANOVA followed by Tukey’s multiple comparison test. ZIP6 
knockout MIN6 cells: ZIP6-/-. Error bars show ± SEM. N=3. **p <0.005, ***p <0.001, 
****p <0.0001.  
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7.5. Discussion  
Extracellular zinc depletion reduces the total zinc content of MIN6 cells, induces changes 
to the transcriptome and decreases cellular survival (chapter 5). Previous studies by 
ourselves and others [192, 218, 404] suggest ZIP6 plays key roles in β-cell zinc uptake 
and that ZIP6 downregulation may impact intracellular zinc and induce dysfunction. 
Here, we generated and studied ZIP6 knockout MIN6 cells to explore the role of ZIP6 in 
the β-cell adaptive response to extracellular zinc depletion  
Zinc transporters are regulated at transcriptional, post-transcriptional and post-
translational levels in β-cells in response to nutrients, hormones, growth factors and 
stresses to maintain adequate supplies of zinc [147, 420]. Many ZIP and ZnT paralogues 
exhibit redundant functions [537, 538] and loss of transporters important for β-cells may 
induce differential expression and/or activities of coordinated paralogues to prevent zinc 
depletion-induced dysfunction. ZIP6 ablation was coupled with downregulation of 
mRNA encoding for ZIP2, ZIP10 and ZIP14 and upregulation for ZIP4, ZIP13, ZnT1, 
ZnT4, ZnT6 and ZnT7. Disruption of any of these transporters may alter cellular zinc 
trafficking and content. ZIP13 localises to the ER and Golgi apparatus, however the other 
disrupted ZIPs all present at the plasma membrane [147]. ZIP10 forms heteromers with 
ZIP6 to mediate proliferation [539] and act as a scaffold for GSK-3 binding [206], a 
critical regulator of proliferation and survival [540]. Interestingly, Zip10 knockdown 
induces expression of Zip6 in zebrafish embryos, presumably to compensate for loss of 
Zip10 function [206], however we did not observe the reverse in MIN6 cells. We 
previously identified ZIP14 as potentially important for β-cell zinc influx [404] and ZIP14 
null mice exhibit higher islet insulin contents than controls [541], which is not easy to 
explain but indicates that downregulation may impact insulin secretory function. 
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Upregulation of ZIP4 and ZIP13 could represent compensatory mechanisms to increase 
β-cell cytosolic free Zn2+ in the absence of ZIP6. We previously identified ZIP13, which 
fluxes zinc out of the secretory pathway [542], as potentially important for β-cell function 
[404]. ZIP4 responds to zinc deficiency to induce rapid plasma membrane ZIP4 
accumulation [543] and, although exhibiting relatively low expression in β-cells [404], 
may play important roles in β-cell zinc accumulation [219], contradictory to our 
conclusion in chapter 3 [404]. However, upregulation of ZnT1, ZnT4, ZnT6 and ZnT7 
would be predicted to lower cytosolic zinc. Aside from ZnT1, which facilitates zinc efflux 
at the plasma membrane, these paralogues reside in the membranes of intracellular 
compartments including the trans-Golgi network and vesicles (ZnT4 and ZnT6) and the 
Golgi apparatus (ZnT7) in β-cells [185, 194, 195]. Upregulation may therefore increase 
the intracellular storage of zinc to ensure adequate supplies in the absence of ZIP6.  
Changes to zinc transporter expression profiles may alter cellular function and phenotype 
through disrupting zinc accumulation and/or transporter-protein interactions involved in 
intracellular signalling. When we characterised the zinc phenotype of ZIP6 knockout 
MIN6 cells, we recorded upregulation of Mt1, Mt2 and Mtf1 mRNA, indicative of 
elevated cytosolic zinc [449], and cells exhibited higher zinc uptake capacities in adequate 
zinc culture. MTF1 responds to free Zn2+ fluctuations to mediate expression of genes 
involved in zinc homeostasis and anti-oxidative responses, including the MTs [544], 
which maintain cytosolic concentrations by zinc donation, sequestration and/or redox 
control [156]. Increases in cytosolic zinc uptake and accumulation suggest that 
predominant zinc trafficking following loss of ZIP6 may be mediated by the increased 
abundances of ZIP4 at the plasma membrane and ZIP13 at the ER and Golgi apparatus. 
However, we were unable to correlate elevated cytosolic zinc to an increase in total zinc. 
A previous study suggested simultaneous loss of ZIP6 and Golgi-localised ZIP7 is 
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required to inhibit ZnSO4
- and glucose-induced increases in cellular zinc [218]. The 
lowered total zinc content of ZIP6 knockout MIN6 cells cultured with depleted zinc 
indicates that ZIP6 is required for sufficient MIN6 cell zinc uptake in the presence of low 
extracellular zinc, such as the hypozincaemia observed in some human type 2 diabetic 
patients [140, 283, 284]. 
Zinc deficiency induces profound consequences for the β-cell transcriptome (chapter 5), 
including disruption of multiple β-cell/islet specific transcription factors (chapter 4 
[405]). In this chapter, we showed that ZIP6-induced changes to MIN6 cell zinc are 
associated with distinct expression profiles for important β-cell markers. We observed 
upregulation of mRNA for Foxa1, MafA, Nkx6.1, Pdx-1 and downregulation for Hnf4a, 
Nkx2.2 and Pax4; changes to the abundances of any of these transcription factors have 
potential to disrupt cellular function in glycaemic control. MAFA, NKX6.1 and PDX-1 
are major transcriptional regulators of β-cell development, phenotype and function [100, 
116, 517] and exhibit Zn2+-responsive expression in β-cells (chapter 4 [405]), whereas 
FOXA1 acts in combination with FOXA2 to mediate insulin secretion and carbohydrate 
metabolism [516]. HNF4A, NKX2.2 and PAX4 are all required to maintain mature β-cell 
identity and optimal insulin secretion [350, 545, 546]. HNF4A additionally regulates 
nutrient-induced insulin secretion [545] and PAX4 stimulates islet proliferation and 
survival [513]. Moreover, monogenetic mutations in HNF4A, PDX-1 and PAX4 result in 
MODY development [547]. We additionally observed upregulation of mRNA for Foxo1 
in ZIP6 knockout MIN6 cells in response to zinc depletion and Pax6 in cells cultured with 
adequate zinc. FOXO1, which is ubiquitously expressed and is a major transcriptional 
regulator of cellular survival and function, inhibits proliferation by regulating cyclin-
dependent kinase inhibitor 1B [548, 549] and can promote apoptosis [550]. PAX6 is 
required for maximum insulin production [551, 552] and upregulation is consistent with 
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the observed increase in Ins2 mRNA expression. Consequences of disruption of these 
Zn2+-responsive markers for β-cell function are discussed in more detail in chapter 4 
[405]. 
Tightly maintained zinc homeostasis is required for cellular proliferation and mass [519]. 
We demonstrate the disrupted zinc phenotype of ZIP6 knockout MIN6 cells is coupled 
with lowered rates of cellular proliferation and apoptosis. ZIP6:ZIP10 heteromers 
promote proliferation [539], however ZIP6 deficiency increases survival in response to 
hypoxia [535] and can induce ROS without triggering apoptosis [218]. Simultaneous 
reductions in proliferation and apoptosis is unusual but may be indicative of 
differentiation, which has previously been shown for adipocytes and epidermal 
keratinocyte cells [553-555] and could explain the observed changes to β-cell 
transcription factor expression. Simultaneous decreases have additionally been recorded 
for macrophages stimulated by danger signals [556] and hepatic stellate cells in response 
to TNF-α and TNF-β [557]. We observed increased RPS6 phosphorylation in ZIP6 
knockout MIN6 cells, indicative of enhanced signalling via mTOR cascades. ZIP6:ZIP10 
heteromers act as a scaffold for GSK-3 binding and inhibitory phosphorylation; loss of 
ZIP6 may increase net activation of GSK-3, which phosphorylates upstream components 
of mTOR cascades including IRS-1, IRS-2, AKT, PTEN, RICTOR, TSC1 and TSC2, to 
regulate mTOR signalling [540, 558].  
mTOR cascades promote protein synthesis and β-cell growth and secretory function via 
activation of the RPS6 kinase S6K. RPS6 is a critical component of the 40 S ribosomal 
subunit [559] and represents a point of regulatory convergence for pathways controlling 
translation initiation. RPS6 undergoes inducible phosphorylation at five C-terminal serine 
residues to mediate cell size through promoting growth and proliferation [560]. Islets 
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from RPS6P-/- mice contain less insulin compared to those from RPS6P+/+ controls and 
present with impaired glucose tolerances [63], and mice deficient for the RPS6 upstream 
kinase S6K1 present with impaired glucose homeostasis [561]. Knockout of ZIP4 in the 
mouse intestine lowers cytosolic zinc (as measured by MT expression), which decreases 
the proportion of phosphorylated RPS6 in the villus epithelium, accompanied by 
diminished mTOR activity and impaired protein synthesis [313]. Consistently, we 
showed that ZIP6 knockout enhances RPS6 phosphorylation, which may result from the 
increased cytosolic zinc and/or upregulation of ZIP4. Loss of ZIP6 could therefore be 
beneficial for insulin tolerance and β-cell growth. However, we would expect this to be 
accompanied by increased insulin synthesis, which was not the case in our ZIP6 knockout 
MIN6 cells.  
We additionally recorded upregulation of mRNA for Stat3 in ZIP6 knockout MIN6 cells. 
The role of STAT3 for regulating β-cell function, proliferation and survival is discussed 
in chapter 6 (section 6.5.2). Of potential importance, STAT3 activates ZIP6 and ZIP10 
transcription [207, 316] and STAT3 upregulation may be a compensatory response for 
loss of ZIP6. Similarly, knockdown of Zip10 in zebrafish upregulates stat3 and zip6 
mRNA [206]. STAT3 is activated by mTOR signalling [562, 563] and zinc, and has been 
specifically linked to enhanced ZIP4 signalling in pancreatic cancer [564]. Activating 
STAT3 mutations cause neonatal diabetes through premature induction of pancreatic 
differentiation [565]. However, the total β-cell mass, irrespective of cellular number and 
size, determines the insulin secretory response [63]. Larger cells may be secondary to the 
reduced metabolic state characteristic of decreased proliferation and apoptosis, and future 
work should investigate the sizes of individual ZIP6 knockout MIN6 cells compared to 
controls. As discussed in chapter 6 (section 6.5.2), it is possible that decreased 
proliferation may be secondary to the CRISPR/Cas9 genome editing technique rather than 
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transporter knockdown [529], however the use of sham-CRISPR control cells reduce this 
likelihood. 
The tightly regulated phenotype ensures β-cells mount appropriate insulin secretory 
responses to extracellular glucose. The phenotype induced in MIN6 cells by loss of ZIP6 
lowered mRNA expression for Ins1, indicative of loss of insulin secretory function and 
onset of β-cell failure. We additionally noted modest upregulation of mRNA for Ins2 in 
cells cultured with adequate zinc. Unlike in human where only one insulin gene exists, 
rodents encode two insulin paralogues, insulin 1 and insulin 2. Although mouse models 
suggest insulin 1 knockout induces insulin deficiency whereas loss of insulin 2 does not 
impact β-cell insulin content [566], the roles of each in systemic glucose regulation 
remains unclear [508]. Insulin 2 abundance may be induced to compensate for loss of 
insulin 1 and ZIP6-regulated pathways could be critical for enhancing insulin 2 
expression in hypozincaemic conditions, which would directly link the supressed ZIP6 
phenotype observed in some type 2 diabetic islets [404] to loss of insulin secretory 
function. However, we did not record any differences in basal or KCl-stimulated insulin 
release from ZIP6 knockout MIN6 cells, consistent with a previous study that showed 
simultaneous knockdown of both ZIP6 and ZIP7 is required to inhibit insulin secretion 
[218]. The role of zinc in regulating insulin secretion is discussed in more detail in chapter 
5 (section 5.5.1). However, as previously noted, stimulating cells with KCl may not 
replicate differences in the secretory response that exist following glucose stimulation.  
7.6. Conclusion 
In this study we explored the role of ZIP6 in the MIN6 cell adaptive response to 
extracellular zinc depletion. We showed that ZIP6 knockout disrupts expression of 
multiple ZIP and ZnT paralogues and MIN6 cell zinc trafficking and accumulation. Our 
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data suggest ZIP6 is required for adequate zinc uptake in response to zinc depletion and 
that loss of ZIP6 abundance disrupts regulation of the insulin gene. Moreover, ZIP6 
mediates transcription of multiple markers important for β-cell identity and regulates 
survival of MIN6 cells through activating mTOR cascades and upregulating expression 
of STAT3. Critically, our data highlight the importance of ZIP6 for β-cell identity and 















8. General Discussion 
Multiple studies have associated zinc and its transporters with development and 
progression of Type 2 Diabetes. Systemic hypozincaemia is evident in some type 2 
diabetic patients [140, 283, 284] due to reduced plasma zinc transport resulting from 
hyperglycaemia-induced HSA glycation [409], and increased urinary zinc loss [410]. 
Moreover, the R325W missense mutation in the predominantly β-cell-specific zinc 
transporter ZnT8 is associated with an odds ratio for Type 2 Diabetes predisposition of 
1.14-1.15, with a ~16.5% increase in relative risk per risk allele [243, 256-259]. However, 
the mechanism whereby ZnT8 risk variants predispose patients to Type 2 Diabetes 
remains unclear: the R325W polymorphism disrupts zinc transport into granules through 
altering ZnT8 dimer formation and stability [269] but minimal differences in glycaemic 
parameters are observed following ZnT8 knockout in mouse [198]. The relatively limited 
existing evidence further suggests that loss-of-function ZnT8 mutants induced through 
SNPs or haploinsufficiency are collectively associated with a 65% reduced risk of Type 
2 Diabetes [271]. A recent study examining the most abundant loss-of-function variant 
R138X, which encodes a premature stop codon, demonstrated that ZnT8 truncation 
increases the β-cells’ capacity to secrete insulin in high glucose conditions [280]. 
Additional studies show ZnT8-mediated granule zinc uptake is coupled with cytosolic 
free Zn2+ elevations [192], presumably representing coordinated ZIP-facilitated zinc 
influx and trafficking. Spikes in cytosolic free Zn2+ may therefore induce further 
consequences for β-cells, which have not previously been examined, suggesting cytosolic 
zinc elevations are important for β-cells aside from insulin processing in secretory 
granules. ZnT8-induced β-cell dysfunction may reflect these additional roles. Moreover, 
links between the increased requirement for β-cell zinc uptake during hyperglycaemia 
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(due to elevated Zn2+/insulin co-release), the reduced pool of available zinc present in 
hypozincaemic type 2 diabetic patients, and β-cell zinc content, phenotype and survival 
remain unexplored.  
8.1. Overview of results 
In this project we postulated that zinc uptake into insulin granules is coordinated with 
ZIP-facilitated cytosolic zinc influx and that different ZnT8 abundances and genotypes 
associated with Type 2 Diabetes interfere with ZIP-regulated zinc trafficking. We further 
hypothesized that alterations to the abundances/activities of these ZIP transporters impact 
β-cell phenotype and function. Through the research carried out during this PhD, we can 
partially accept this hypothesis. We can confirm that ZnT8-facilitated granule zinc uptake 
is associated with ZIP expression, however we are unable to comment on how this relates 
to the R325W genotype. Moreover, we can confirm that loss of ZIP6 abundance disrupts 
β-cell zinc content and phenotype and reduces cellular survival. Discussion of how we 
addressed the project aims are provided below.  
Aim 1: To identify ZIP transporters that functionally coordinate with ZnT8 to maintain 
normal zinc trafficking in β-cells and explore whether these transporters are regulated 
differently based on ZnT8 activity.  
Zinc transporters exhibit unique cell- and tissue-specific expression and responsiveness 
to tightly control zinc homeostasis [170]. We therefore first sought to identify ZIP 
paralogues important for β-cell function (Chapter 3 [404]). We hypothesised that 
important ZIP paralogues are regulated by stresses that negatively impact β-cell function 
and are associated with β-cell failure during Type 2 Diabetes. We used a systematic 
approach combined with experimental expression analysis to identify ZIP1 in rodent and 
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ZIP6, ZIP7, ZIP9, ZIP13 and ZIP14 in human and rodent as potentially biologically 
important for mediating β-cell zinc homeostasis, function and phenotype. We further 
aligned ZIP mRNA and protein sequences to show high human-rodent conservation, 
suggesting paralogues substitute functionally in both backgrounds and that the data 
generated from MIN6 cell studies during this project are likely translatable to human. The 
results from this analysis were used to focus further investigation of ZIP transporters in 
β-cells.  
ZnT8 activity is associated with increases in cytosolic free Zn2+ and Type 2 Diabetes 
development [192]. To explore ZIP transporter expression in response to ZnT8 
abundance, we hypothesised that ZnT8 functions cooperatively with ZIP transporters to 
regulate β-cell zinc homeostasis (chapter 6). Since ZnT8 abundance is lowered by 
multiple stresses that negatively impact β-cell function [179, 186, 227], we examined the 
initial and final ZIP responses to stress-induced ZnT8 downregulation. Using siRNA, we 
noted initial upregulation of ZIP14 and downregulation of ZIP1, ZIP8 and ZIP9. In the 
final state following loss of ZnT8 abundance (explored using our ZnT8 haploinsufficient 
MIN6 cell model), we demonstrated that ZIP8 and ZIP14 are downregulated. From these 
data, we concluded that ZIP8 and ZIP14 are the key paralogues mediating β-cell zinc 
trafficking to coordinate with ZnT8 activity, and that ZIP1 and ZIP9 may additionally 






Fig 8.1. Proposed sequence of changes to ZIP transporter expression following 
stress-induced ZnT8 downregulation. Red arrows: downregulation. Green arrows: 
upregulation. Zn(cyt): cytosolic zinc content. Zn(total): total zinc content. The time-points 
indicate hours post-transfection. 
 
We additionally explored transcriptional co-regulation of β-cell ZIP paralogues with 
ZnT8 by the key β-cell transcription factor PDX-1 (Chapter 6). PDX-1 regulates ZnT8 
transcription through targeting two SLC30A8 enhancers in β-cells [200] and we showed 
in our systematic review that PDX-1 abundance is associated with mRNA expression for 
multiple ZIP paralogues (chapter 3 [404]). We hypothesised that PDX-1 may be involved 
in regulating coordinated ZnT8-ZIP expression. We used bioinformatics to show that 
PDX-1 is predicted to bind enhancers for ZIP6 and ZIP9 and may therefore directly co-
regulate their expression alongside ZnT8. Using PDX-1 overexpression studies, we 
demonstrated that PDX-1 upregulates multiple ZIP paralogues including ZIP6 and ZIP9, 
indicating PDX-1 may be important for transcriptionally mediating zinc trafficking in β-
cells. However, mechanistic investigations are required to confirm these results. Taken 
together, our data indicate that ZnT8 may be transcriptionally co-regulated with ZIP6 and 
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ZIP9 by PDX-1 to maintain adequate zinc uptake into the cytosol, and that expression of 
ZIP8 and ZIP14 are altered in response to ZnT8 activity to rapidly adapt zinc influx 
following stress-induced ZnT8 downregulation. 
Aim 2: To explore the consequences of the hyperglycaemia and hypozincaemia associated 
with Type 2 Diabetes for β-cell ZIP transporter expression, zinc content and cellular 
phenotype.  
Hyperglycaemia is characteristic of all diabetic patients and is a major factor driving β-
cell dysfunction. Of importance, hyperglycaemia induces increased Zn2+/insulin co-
exocytosis [567, 568] and is associated with downregulation of ZnT8 [228]. To explore 
the consequences of hyperglycaemia for the β-cell zinc response, we postulated that ZIP 
transporters are involved in intracellular zinc homeostasis during β-cell stimulation 
(chapter 4 [405]). We further hypothesised that prolonged stimulation, representative of 
hyperglycaemia in vivo, leads to cellular zinc loss and that this may influence β-cell 
phenotype. Our data suggest that prolonged stimulation decreases the zinc content of 
MIN6 cells, associated with initial upregulation of ZIP1 protein expression following by 
transcriptional downregulation of ZIP1, ZIP6, ZIP7 and ZIP14. We further demonstrated 
that multiple markers for β-cell identity are Zn2+-responsive in a mammalian system and 
suggest that hyperglycaemia-induced downregulation of these markers and consequential 
loss of cellular phenotype may be driven by lowered cellular zinc. These data are 





Fig 8.2. Proposed sequence of changes to β-cell signalling in response to 
hyperglycaemia. Data included: ZIP transporter expression, cellular zinc content and 
expression of β-cell markers. Red arrows: downregulation. Green arrows: upregulation. 
Zn(cyt): cytosolic zinc content. Zn(total): total zinc content. The time-points indicate hours 
following stimulation of cells with KCl. 
 
The hypozincaemia present in some type 2 diabetic patients [140, 283, 284] presumably 
reduces the amounts of zinc available for uptake into β-cells. To explore the relationship 
between hypozincaemia and β-cell zinc, we hypothesised that changes to extracellular 
zinc, representing serum zinc in vivo, alter β-cell zinc content and phenotype (chapter 5). 
We showed that culture with depleted zinc decreases the zinc content of MIN6 cells but 
increases cellular zinc uptake capacities, presumably through upregulation of ZIP8 and 
ZIP14. Moreover, that depleted zinc decreases cellular survival, associated with 
decreased signalling via MAPK and mTOR cascades. These data are summarised in Fig 
8.3. In addition, through transcriptomic analysis we demonstrated that genes differentially 
expressed in MIN6 cells and islets following culture with depleted zinc are enriched for 
phosphatases and that HIF1A regulation may be a key pathway mediated by zinc 
depletion. We therefore highlighted hypozincaemia as a potential stress driving zinc 
depletion-induced β-cell dysfunction. However, our experiments explored the effects of 
short-term severe zinc depletion rather than long-term relatively mild hypozincaemia 
 231 
 
(potentially over years) of type 2 diabetic patients, and whether these results can be 
translated to physiological conditions in vivo remains to be determined.  
 
 
Fig 8.3. Proposed sequence of changes to β-cell signalling in response to 
hypozincaemia. Data included: ZIP transporter expression, cellular zinc content, cellular 
survival and expression of β-cell markers. Red arrows: downregulation. Green arrows: 
upregulation. Zn(cyt): cytosolic zinc content. Zn(extracellular): extracellular zinc content. 
Zn(total): total zinc content. The time-points indicate hours following addition of depleted 
or adequate zinc media. 
 
Aim 3: To explore the roles of highlighted ZIP transporters for the β-cell response to 
hypozincaemia.  
ZIP6 is highly expressed in β-cells [192, 218, 404] and, during this project, we linked 
decreased ZIP6 abundance to hyperglycaemia in MIN6 cells (chapter 4 [405]), PDX-1 
overexpression in INS-1 cells, and Type 2 Diabetes in human (chapter 3 [404]). ZIP6 
stimulates cellular proliferation and protects against anoikis in a number of cell types and 
contexts [206, 207] and protects against hypoxia in breast cancer cell lines [535]. We 
therefore decided to focus analysis on ZIP6. To address the role of ZIP6 in β-cells, we 
hypothesised that ZIP6 maintains β-cell phenotype and mass in response to extracellular 
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zinc depletion (chapter 7). We generated ZIP6 knockout MIN6 cells to show that ZIP6 
abundance is associated with expression of multiple ZIP and ZnT paralogues, presumably 
to maintain adequate zinc uptake. We demonstrated that loss of ZIP6 increases cytosolic 
free Zn2+ but reduces total cellular zinc only in depleted zinc culture. Whereas in response 
to adequate zinc, loss of ZIP6 increases cellular zinc uptake capacities. We further showed 
that ZIP6 is important for expression of multiple markers for β-cell identity (transcription 
factors and insulin) and cellular survival associated with mTOR signalling, which has 
previously been linked to β-cell proliferation and insulin processing [569, 570]. In a 
previous study, mTORC1/S6K cascades were determined to regulate β-cell apoptosis, 
size and autophagy, which is consistent with our data [570]. We additionally noted 
upregulation of STAT3, which induces expression of ZIP6 and ZIP10 [207, 316], and 
suggested that increases in STAT3 abundance may be compensatory for loss of 
ZIP6:ZIP10 heteromers. These data indicate that ZIP6 is important for β-cell zinc 
trafficking and phenotype and is involved in the cellular response to zinc depletion. These 
data are summarised in Fig 8.4.  
 
 
Fig 8.4. Proposed sequence of changes to β-cell signalling in ZIP6 knockout MIN6 
cells. Data included: ZIP and ZnT transporter expression, cellular zinc parameters, cell 
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survival and expression of β-cell markers. *β-cell markers include data for transcription 
factors and insulin. Data shown is in response to both deficient and adequate zinc culture. 
Orange arrows: only regulated in cells in response to depleted zinc. Blue arrows: only 
regulated in cells in response to adequate zinc. Red arrows: downregulation. Green 
arrows: upregulation. Zn(cyt): cytosolic zinc content. Zn(total): total zinc content. 
 
We concluded in chapter 6 that ZnT8 activity is associated with the abundances of ZIP8 
and ZIP14. These cells therefore represent a model for investigating the role of 
coordinated ZnT8-ZIP8-ZIP14 activity in β-cells. To examine this further, we 
hypothesised that ZnT8-ZIP coordination mediates β-cell zinc homeostasis, survival and 
phenotype in response to extracellular zinc. We showed that ZnT8 haploinsufficiency 
lowers the total zinc contents of MIN6 cells and reduces cellular zinc uptake capacities 
following culture with depleted zinc. Moreover, ZnT8 haploinsufficiency decreases 
MIN6 cell proliferation and downregulates expression of insulin 1 and multiple important 
β-cell transcription factors. This contrasts with a recent investigation that showed ZnT8 
R138X loss-of-function variants, which are protective against Type 2 Diabetes [271], 
increase the β-cell’s insulin secretory capacity [280] but is consistent with ZnT8 
suppression observed in response to stresses negatively impacting β-cell function [179, 
186, 227]. These data indicate that decreased ZnT8-ZIP8-ZIP14-facilitated zinc 
trafficking impacts β-cellular survival and phenotype aside from insulin secretion and 






Fig 8.5. Proposed sequence of changes to β-cell signalling in ZnT8 haploinsufficient 
MIN6 cells. Data included: ZIP transporter expression, cellular zinc parameters, cellular 
survival and expression of β-cell markers. *= β-cell markers include data for transcription 
factors and insulin. Data shown is in response to both deficient and adequate zinc culture. 
Orange arrows: only regulated in cells in response to depleted zinc. Blue arrows: only 
regulated in cells in response to adequate zinc. Red arrows: downregulation. Green 
arrows: upregulation. Zn(cyt): cytosolic zinc content. Zn(total): total zinc content. 
 
8.2. The importance of different β-cell ZIP transporters 
Zinc impacts almost all aspects of cellular physiology and function [130-133]. It is 
therefore unsurprising that we identified a vast range of genes, processes and pathways 
to be regulated by zinc transporter deficiency/deregulation and zinc depletion in MIN6 
cells and mouse islets. We revealed Zn2+-mediated disruption of important β-cell markers, 
cellular survival and multiple signalling pathways (chapters 4 [405] and 5-7). This may 
simply reflect that Zn2+ binds ~10% of the genome [129] and changing the amount of 
Zn2+ available for protein binding inhibits zinc(II)-protein interactions and protein 
function. However, to target zinc dyshomeostasis it is important to understand the 
mechanism(s) driving zinc-mediated disruption; this may have differed between 
experiments and may explain the variation in our data. For example, we observed 
differences in cytosolic free Zn2+, cellular signalling pathways and transcription factor 
 235 
 
expression between ZIP6 knockout and ZnT8 haploinsufficient MIN6 cells compared to 
respective controls (chapter 6-7).  
In this study, we revealed changes to the abundances of multiple ZIP and ZnT paralogues 
in MIN6 cells in response to hyperglycaemia (chapter 4 [405]) and hypozincaemia 
(chapter 5), probably driven by differing cellular zinc demand and/or the activities of 
preferable ZIP/ZnT paralogue(s). Multiple zinc transporters undertake additional roles 
aside from zinc transport [171-173, 206, 322] and might be regarded as membrane-bound 
Zn2+ chaperones. ZIP6:ZIP10 heteromers stimulate proliferation through promoting 
phosphorylation and inhibition of GSK-3 [207] and ZnT1 inhibits L-VGCC and activates 
the RAF-1 kinase, promoting RAS/ERK signalling [571]. Moreover, proteins that dock 
in the local vicinity of specific ZIP or ZnT paralogues, such as to organelle membranes, 
may require ZIP/ZnT-protein interactions for normal function. Although there are no 
known SNPs in any ZIP paralogues that are associated with β-cell dysfunction or Type 2 
Diabetes, mutations or changes in expression of ZIP binding partners, due to pathological 
or maladaptive stimuli, or loss of transporter abundance may alter ZIP-protein 
interactions and downstream pathways. Delivery of zinc via certain transporters may 
additionally be critical for normal temporal release of free Zn2+ into the cytosol. For 
example, Golgi-localised ZIP7 is activated by CK2-regulated phosphorylation to drive 
MAPK, PI3K and mTOR growth and proliferation signalling pathways [457]. The results 
observed within this project may therefore not (entirely) stem from altered cellular zinc 
but from changes in ZIP-facilitated zinc trafficking and transporter abundances or from 
downstream effects of zinc- or ZIP-signalling. Zinc buffering by the MTs, which are 
readily induced in response to cytosolic free Zn2+ [572], may be adequate for cells to adapt 
to differences in cellular zinc.  
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Our lab has previously shown that the ZnT8 CTD interacts with PDLIM7 [573, 574], a 
scaffolding protein involved in cellular migration, signal transduction, differentiation, 
heart development, and oncogenesis [575, 576]. However, the significance of this 
interaction for β-cells is not yet known. The diabetes-associated rs13266634 
polymorphism resides within the ZnT8 CTD [235] and may disrupt this interaction and 
any downstream processes, which could include proper regulation of zinc uptake via 
ZnT8, in addition to affecting the thermostability and dimerization affinity of the 
transporter [269]. Further ZnT8 binding partners likely exist and may help explain the 
phenotypes imposed by ZnT8-R/W variants in vivo [260-263]. 
8.3. The significance of this study  
The work presented in this thesis has great significance for β-cell research because many 
stresses associated with Type 2 Diabetes disrupt ZIP transporter expression (chapter 3 
[404]) and consequential changes to zinc trafficking may contribute to the observed β-cell 
phenotype. We experimentally showed that this holds true for a model of hyperglycaemia 
(chapter 4 [405]) and hypozincaemia (chapters 5-7). Moreover, although the data is only 
preliminary, in chapter 6 we suggested that PDX-1 co-regulates ZnT8 with ZIP6 and ZIP9 
[200]; therefore, loss of PDX-1 function, such as in MODY4 [4], could result, in part, 
from zinc deregulation. In this project, we further demonstrated the vast range of genes 
exhibiting Zn2+-responsive expression in mammalian β-cells (chapters 4 [405] and 5), 
including key β-cell markers. Zinc may mediate these genes via Zn2+-responsive 
transcription factors (MTF1 [148], KLF4 [153] and ZNF658 [154]), chromatin 
stabilisation [577] or binding to zinc finger transcription factors, such as the diabetes-
associated zinc finger protein 407 [578]. If changes to gene expression alongside 
disruption of any of the above are observed in future studies, plausible explanations 
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should include changes to cellular zinc. The data presented in this project should direct 
future research to consider zinc and its transporters as factors impacting β-cell function, 
phenotype and survival alongside stimuli under investigation (such as hyperglycaemia, 
cytokines, oxidative stress), and whether targeted addition of zinc could help alleviate the 
phenotype.  
8.4. Study limitations  
First, the mouse MIN6 cell line was used throughout this study. Ideally, we would use 
human β-cells for experimentation of human disease, however this proves impossible in 
vivo due to ethical and logistical constraints and limited ex vivo since islets from otherwise 
healthy cadaver donors are prioritised for type 1 diabetic transplant patients. We tried to 
obtain but could not get access to the one described human β-cell line (EndoC-βH1 cells 
[579]). Rodent β-cells and islets differ from human in terms of cellular compositions, 
orthologue properties and gene expression profiles: the proportion of β-cells in islets is 
60-80% in mouse [425] and 50% in human [17], MT1 exists in eight functional isoforms 
in human but only one is present in mouse [160] and notable differences exist between 
human and rodent long non-coding RNA expression [580]. However, rodent models 
remain an important tool for β-cell study. We chose MIN6 cells for experimentation since 
they allow for relatively easy genomic manipulation and their popularity ensured we 
could directly compare results to previous studies. Nevertheless, MIN6 cells are not a 
pure β-cell line, instead existing as a mixture with other pancreatic endocrine cell types, 
including cells that express and secrete glucagon [581]. Immortalised cell lines exhibit 
significantly different transcriptomic profiles from their respective primary equivalents. 
MIN6 cells express increased levels of hexokinase mRNA, which leads to increased 
insulin secretion in response to sub-physiological levels of glucose, and MIN6 cells often 
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suddenly lose insulin sensitivity due to reduced expression of genes responsible for GSIS 
[582]; this occurred to our cells and we were therefore unable to use glucose as the 
stimulus during insulin secretion assays. Moreover, MIN6 cell phenotypes change with 
passage number, which can cause problems when comparing results carried out at 
different times [583]. Finally, MIN6 cells exist as a monolayer in tissue culture; our 
results may therefore not represent corresponding responses in vivo, where the islet 
structure, other endocrine cell types and additional stimuli (including hormones, integrins 
and nutrients) impact β-cell function in addition to the homologous β-cell interactions. 
This is the major limitation of this project: the conclusions were drawn from data 
generated in cell culture experiments and therefore need verification in vivo.  
Second, we used the results from our systematic review (chapter 3 [404]) to determine 
which ZIP transporters to focus analysis on during this study. This hypothesis-driven 
approach was necessary due to time and cost restraints. However, the pre-defined criteria 
may have been too restrictive, and we could have missed critical paralogues. During the 
systematic review, we did not highlight ZIP4 or ZIP8 as important for β-cells; however, 
potentially important roles of these paralogues for β-cell zinc homeostasis have been 
previously described [192, 219]. We additionally identified ZIP8 alongside ZIP14 as 
important for coordinating zinc trafficking with ZnT8 (chapter 6) and suggested ZIP4 
may be important for facilitating cellular zinc uptake in the absence of ZIP6 (chapter 7). 
However, since ZIP4 shows very low abundance in β-cells [218, 404], we sustain that we 
do not believe ZIP4 is of great importance for β-cells. Moreover, the nature of our data 
selection (from RNA-seq and microarray gene expression profiling studies) limited 
results to identifying ZIPs that respond to stimuli on a transcriptional level; we may 
therefore have missed paralogues regulated post-translationally. 
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Third, the majority of studies investigating the role of ZnT8 in β-cells are based on the 
rodent orthologue, which shows 80% amino acid conservation compared to human ZnT8 
(determined through sequence alignment using NCBI BLAST [584]). The diabetes-
associated loci at amino position 325 is not conserved between human and rodent: mouse 
ZnT8 harbours glutamine (Q) in contrast to arginine (R) or tryptophan (W) in human. 
ZnT8 rodent models may therefore not represent accurate models for the human protein. 
Although mice transgenic for human ZnT8 variants have been bred [278, 279], the full 
consequence of this polymorphism may not be observed due to continued expression of 
native mZnT8. Moreover, many rodent studies are based on absolute ZnT8 knockout 
[198], which has not been observed in human and which may explain the low apparent 
conservation of results cross-species. However, the protective effects of the ZnT8 loss-
of-function R138X variant appears conserved between human [271] and mouse, since 
R138X knock-in mice exhibit increased insulin secretion in response to high glucose 
[280]. Although we showed that the ZIP paralogues we highlighted as important for β-
cell function exhibit high human-rodent mRNA and protein similarities (chapter 3 [404]), 
species-specific differences remain, which could limit translation of the results 
throughout this thesis to human.  
Finally, when we cultured MIN6 cells in media containing differing concentrations of 
zinc, we did not determine or control for zinc buffering, which is mainly mediated by 
binding to serum in tissue culture (FBS in our experiments). The serum present in growth 
media has a relatively high affinity for Zn2+ (KD ~0.1 μmol/L [585]); zinc mainly binds 
to albumin but also to ligands such as histidine, cysteine and phosphate [455]. We can 
therefore only be confident about the total zinc content of the media and not the amount 
of zinc available for uptake. However, since we observed differences in the characteristics 
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of MIN6 cells cultured with depleted, adequate and excess zinc (chapter 5), we can be 
confident differences existed in the amounts of available zinc.  
8.5. Future directions  
Future studies should first expand on the work presented in this PhD project focusing on 
the ZIP transporters in MIN6 cells. To explore cooperation between paralogues and 
account for compensatory responses, the ZIPs of interest should be knocked out 
simultaneously and the described experiments repeated. Simultaneous knockdown of 
ZIP6 and ZIP7 with siRNA has previously been described in MIN6 cells, and results show 
an additive effect of loss of these two transporters for β-cell function  [218]. Since there 
are no known SNPs in any ZIP paralogues that impact β-cell function or predispose to 
Type 2 Diabetes, ZIP deregulation during diabetes likely arises from disruption of a co-
regulatory factor; therefore, a combination approach may be more representative of β-cell 
dysfunction in vivo.  
Second, our RNA-seq data (chapter 5) should be further investigated. The top gene hits 
should first be confirmed through qPCR and the highlighted pathways explored in the 
context of zinc depletion by functional assays. If these pathways are impacted by depleted 
zinc, they should be investigated in models for diabetes-associated β-cell dysfunction 
(such as hyperglycaemia [192], hypoxia [227] and cytokine stimulation [359]) and it 
should be determined if zinc supplementation helps restore normal signalling.  
Third, the results of this project should be explored in vivo through creation of β-cell-
specific ZIP knockout mice (ZIP1, ZIP6, ZIP7, ZIP8, ZIP9, ZIP13 and ZIP14). The β-
cell phenotypes and systemic glycaemic parameters should be described in the context of 
conditions relevant to human diabetes. Experimentation should be carried out in mice 
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with diabetic backgrounds (such as db/db), in response to high-fat and low zinc diets, 
and/or in response to disrupted ZnT8 expression (downregulated native mZnT8, mice 
transgenic for hZnT8-R/W and/or knock-in loss-of-function variants). These experiments 
will additionally be important for verifying if the phenotypes induced in MIN6 cells by 
KCl stimulation and severe short-term zinc deficiency are comparable to the milder long-
term hyperglycaemia and hypozincaemia, respectively, that are characteristic of human 
type 2 diabetic patients. The results from these experiments should indicate if our current 
data can be translated to a mammalian in vivo model. 
Finally, we should expand on our preliminary data indicating that PDX-1 co-regulates 
ZnT8-ZIP6/9 transcription via functional assays and site-directed mutagenesis of 
predicted binding loci. Additional candidates for ZnT8-ZIP or ZIP-ZIP coregulation in β-
cells should additionally be identified using the methods described for PDX-1 (ChIP-seq 
analysis and bioinformatic alignments) and the candidates functionally assessed. Any 
associations should eventually be confirmed in vivo. If experiments confirm coordinated 
ZnT8-ZIP or ZIP-ZIP activities are important for β-cell identity, function and/or survival, 
results will help identify mechanisms directly governing the dysfunction observed 
throughout this study. Such mechanisms could potentially be targeted to restore normal 
β-cell zinc homeostasis. 
Data from these described experiments could help explain β-cell failure in the context of 
polymorphisms and/or stresses that directly or indirectly alter β-cell zinc trafficking and 
homeostasis. Understanding the consequences of altered β-cell zinc may eventually help 
clinicians implement β-cell-targeted zinc supplementation therapies into personalised 
type 2 diabetic treatment plans to help suppress decline of β-cell function and mass and 
improve patient prognosis.  
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8.6. Concluding remarks 
During this PhD project, we investigated the consequences of hyperglycaemia and 
hypozincaemia for β-cell zinc and the role(s) of the ZIP transporters for maintaining β-
cell zinc homeostasis. Overall, we drew the following conclusions:  
1. ZIP1 in rodent and ZIP6, ZIP7, ZIP8, ZIP9, ZIP13 and ZIP14 in human and rodent 
may be biologically important for β-cell phenotype and function.  
2. Prolonged stimulation, representative of hyperglycaemia in vivo, and extracellular 
zinc depletion, representative of hypozincaemia in vivo, deplete MIN6 cells of 
zinc. 
3. Depletion of zinc from MIN6 cells disrupts the transcriptome (including 
expression of key β-cell markers) and decreases cellular survival. 
4. ZnT8 abundance is co-ordinated with expression of both ZIP8 and ZIP14.  
5. Both ZnT8 haploinsufficiency and loss of ZIP6 alter the MIN6 cell response to 
extracellular zinc depletion. 
Critically, this research demonstrates the importance of zinc and its transporters for β-cell 
phenotype, function and survival aside from its role in insulin granules. These results 
should guide future studies to consider zinc dyshomeostasis as a plausible explanation for 
observed declines in β-cell phenotype, function and mass.
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Appendix 5. Metal ion compositions of growth media 
 
Data shown: untreated growth media, growth media before addition of FBS, FBS before 
treatment with Chelex-100, FBS after treatment with Chelex-100, FBS after treatment 
with Chelex-100 following CaCl2, MgSO4 and KCl supplementation, and growth media 
containing supplemented FBS containing differing concentrations of ZnCl2. 
Concentrations were determined through ICP-MS. All values are an average of 5 
technical repeats and are expressed as µg/L. GF media = glucose-free media.  
 
 
Preparation 1 (August 2016 – February 2017) 
 
Sample 
Ca 44 Cu 65 Fe 56 K 39 Mg 24 Mn 55 Na 23 Ni 60 Zn 66 
(ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) 
Growth media 1355.9 0.31 5.19 7699.9 940.3 0.07 117198 0.02 4.01 
Growth media (no FBS) 1211.6 0.01 0.22 6638.6 878.2 0.01 118112 0.02 0.51 
FBS 2387.2 1.60 35.32 11888.9 1093.9 0.46 107161 0.01 24.61 
FBS (Chelex-100 treated) 118.8 1.40 33.02 10954.9 62.3 0.23 117140 0.01 4.35 
FBS + MgSO4 + CaCl2 + 
KCl 
286.7 1.35 34.29 11135.7 164.3 0.24 116476 0.01 4.61 
Media [1uM Zn] 1045.8 0.19 4.94 5868.5 551.1 0.04 113565 0.02 1.08 
Media [7.6uM Zn] 1077.3 0.21 5.33 6033.4 568.9 0.05 116987 0.02 7.59 
Media [14uM Zn] 1120.6 0.20 5.13 6273.8 589.4 0.04 121101 0.02 13.94 
Media [20uM Zn] 1140.5 0.20 5.25 6360.0 597.7 0.04 123241 0.02 20.43 
Media [42uM Zn] 1179.5 0.21 5.36 6532.7 618.7 0.05 127174 0.02 42.45 














Preparation 2 (March 2017) 
 
Sample 
Ca 44 Cu 65 Fe 56 K 39 Mg 24 Mn 55 Na 23 Ni 60 Zn 66 
(ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) 
FBS [untreated] 1050.4 1.04 19.78 4493.8 235.4 0.25 24647 0.01 16.24 
FBS [Chelex-100 treated] 52.3 0.91 18.49 3764.1 8.7 0.13 26942 0.01 2.88 
FBS +  MgSO4 + CaCl2 + 
KCl 
1967.1 1.40 33.4 15196.2 1227.1 0.19 115614 0.01 5.45 
Media [1uM zinc (1)] 1167.6 0.22 4.93 6639.7 653.1 0.03 111534 0.00 1.61 
Media [1uM zinc (2)] 1111.4 0.22 4.64 6290.6 621.0 0.03 104946 0.01 1.11 
Media [7.6uM zinc (1)] 1139.2 0.21 4.76 6415.9 640.2 0.03 107473 0.01 7.63 
Media [7.6uM zinc (2)] 1187.9 0.25 4.80 6654.1 663.2 0.03 111328 0.00 7.60 
Media [42uM zinc (1)] 1195.3 0.24 4.95 6672.2 670.8 0.04 110767 0.01 42.19 
Media [42uM zinc (2)] 1254.3 0.35 5.19 6940.2 700.5 0.04 114539 0.01 43.45 
Media [95uM zinc] 1323.2 0.60 5.45 7172.6 738.0 0.05 118392 0.01 92.35 
GF media [1uM zinc] 1314.1 0.30 5.55 7198.7 737.5 0.06 118625 0.01 1.36 
GF media [7.6uM zinc] 1296.4 0.43 5.38 7086.5 726.4 0.07 116260 0.01 7.56 




Preparation 3 (April – May 2017) 
 
Sample 
Ca 44 Cu 65 Fe 56 K 39 Mg 24 
Mn 
55 
Na 23 Ni 60 Zn 66 
(ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) 
Untreated growth media 1532.4 0.39 6.85 6936.4 798.9 0.15 138778 0.02 6.13 
FBS (Chelex-100 treated) 26.9 6.76 24.11 6131.5 2.7 0.09 142280 0.03 4.08 
FBS (Chelex-100 treated) 24.5 6.96 24.82 6161.1 2.3 0.07 142340 0.02 3.63 
FBS + MgSO4 + CaCl2 + KCl 1481.0 6.08 22.25 20405.7 948.3 0.07 126528 0.01 3.47 
FBS + MgSO4 + CaCl2 + KCl 1409.2 6.13 22.44 19421.3 890.7 0.11 123201 0.02 3.47 
DMEM [1uM zinc (1)] 1215.3 0.88 3.54 7247.8 647.6 0.06 123005 0.04 1.65 
DMEM [1uM zinc (2)] 1266.9 0.92 3.82 7523.3 681.3 0.06 128918 0.03 1.09 
DMEM [1uM zinc (3)] 1301.9 0.91 3.49 7742.4 706.1 0.04 132308 0.01 1.54 
DMEM [7.6uM zinc (1)] 1309.8 0.94 4.13 7766.2 719.2 0.10 133556 0.04 7.96 
DMEM [7.6uM zinc (2)] 1367.6 0.96 4.02 8093.2 756.2 0.08 139832 0.01 7.61 
DMEM [7.6uM zinc (3)] 1361.6 0.95 3.91 8075.3 756.3 0.05 139465 0.01 7.94 
DMEM [7.6uM zinc (4)] 1359.6 0.97 3.86 8074.7 760.1 0.04 139847 0.02 7.20 
DMEM [42uM zinc (1)] 1394.5 0.99 4.00 8352.6 786.0 0.12 143775 0.03 42.74 
DMEM [42uM zinc (2)] 1395.0 0.98 4.00 8277.6 785.4 0.06 143154 0.02 42.34 





Preparation 4 (July – September 2017) 
 
Sample 
Ca 44 Cu 65 Fe 56 K 39 Mg 24 Mn 55 Na 23 Ni 60 Zn 66 
(ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) 
FBS [untreated] 2541.8 2.20 41.18 13067.2 1099.5 0.61 123005 0.00 29.31 
FBS [Chelex-100 treated (1)] 22.2 2.05 40.24 8782.9 2.9 0.27 138920 0.00 2.81 
FBS [Chelex-100 treated (2)] 32.8 2.03 40.05 8541.7 3.2 0.28 135150 0.00 4.44 
DMEM [1uM zinc (1)] 1065.1 0.24 5.16 5603.0 547.9 0.06 121154 0.03 1.58 
DMEM [1uM zinc (2)] 1067.5 0.26 5.02 5590.0 556.9 0.06 121011 0.03 1.69 
DMEM [7.6uM zinc (1)] 1054.5 0.24 5.06 5472.7 552.8 0.06 119188 0.01 8.33 
DMEM [7.6uM zinc (2)] 1074.7 0.23 4.80 5606.4 572.1 0.05 121237 0.00 8.12 




Preparation 5 (October 2017) 
 
Sample 
Ca 44 Cu 65 Fe 56 K 39 Mg 24 Mn 55 Na 23 Ni 60 Zn 66 
(ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) (ug/L) 
FBS [untreated] 2195.5 1.64 34.05 10570.1 1127.2 0.44 106136 0.03 23.95 
FBS [Chelex-100 treated 
(1)] 
44.9 1.25 34.12 8248.7 15.3 0.02 121257 0.00 3.07 
FBS [Chelex-100 treated 
(2)] 
34.2 1.30 36.58 8495.3 9.5 0.06 124356 0.16 3.20 
DMEM [nothing added] 1156.9 0.07 0.21 4978.9 702.3 0.00 115458 0.01 0.20 
Glucose-free DMEM 
[nothing added] 
1240.2 0.08 0.05 5353.4 757.6 0.00 124209 0.02 0.43 
RPMI [nothing added] 310.4 0.08 0.09 5656.6 406.7 0.00 115742 0.02 0.31 
FBS + MgSO4 + CaCl2 + 
KCl 
2106.3 1.20 35.22 15068.8 1076.5 0.03 129292 0.04 2.81 
DMEM [1uM zinc (1)] 1358.4 0.19 5.62 6815.7 699.8 0.02 128565 0.07 0.60 
DMEM [1uM zinc (2)] 1374.2 0.19 5.62 6865.5 713.3 0.01 130284 0.01 0.53 
DMEM [8uM zinc (1)] 1386.4 0.20 5.63 6903.6 727.4 0.01 130447 0.04 8.06 
DMEM [8uM zinc (2)] 1391.0 0.20 5.64 6874.1 725.7 0.02 129357 0.04 7.98 
Glucose-free DMEM 
[1uM zinc] 
1362.4 0.20 5.43 6771.4 723.8 0.01 127223 0.05 0.78 
Glucose-free DMEM 
[8uM zinc] 
1386.4 0.20 5.57 6823.1 732.0 0.01 128762 0.05 8.55 
RPMI [1uM Zn] 489.2 0.14 3.86 6448.5 418.4 0.02 116164 0.04 0.47 








Appendix 6. Targeting of primers to mouse Slc39a isoforms. Predicted using Primer BLAST [506]. 
 
Transcript RefSeq ID Description  
SLC39A1 NM_013901.2  Slc39a1 
SLC39A2 NM_001039676.2  Slc39a2 
SLC39A3 NM_134135.1 Slc39a3 
SLC39A4 NM_028064.2 Slc39a4 
SLC39A5 
NM_028051.3 Slc39a5 transcript variant 1 
NM_028092.3  Slc39a5 transcript variant 2 
NM_001136237.1 Slc39a5 transcript variant 3 
SLC39A6 NM_139143.3 Slc39a6 
SLC39A7 
NM_008202.2 Slc39a7 transcript variant 1 
NM_001077709.1  Slc39a7 transcript variant 2 
SLC39A8 
NM_001135150.1 Slc39a8 transcript variant 1 
NM_001135149.1 Slc39a8 transcript variant 2 
NM_026228.5 Slc39a8 transcript variant 3 
SLC39A9 NM_026244.2  Slc39a9 
SLC39A10 NM_172653.2  Slc39a10 
SLC39A11 
NM_001166503.1 Slc39a11 transcript variant 1 
NM_027216.5  Slc39a11 transcript variant 2 
SLC39A12 NM_001012305.2  Slc39a12 
SLC39A13 
NM_001290765.1 Slc39a13 transcript variant 1 
NM_026721.3  Slc39a13 transcript variant 2 
SLC39A14 
NM_001135151.1  Slc39a14 transcript variant 1 
NM_001135152.1 Slc39a14 transcript variant 2 
NM_144808.4 Slc39a14 transcript variant 3 
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Appendix 7. Targeting of primers to human SLC39A isoforms. Predicted using Primer BLAST [506].  
 
Transcript 
Targeted Not targeted 
RefSeq ID Description RefSeq ID Description 
 
SLC39A1  
NM_014437.4 SLC39A1 transcript variant 1 
NM_001271957.1 SLC39A1 transcript variant 2 
NM_001271958.1 SLC39A1 transcript variant 3 
NM_001271959.1 SLC39A1 transcript variant 4 
NM_001271960.1 SLC39A1 transcript variant 5 
NM_001271961.1 SLC39A1 transcript variant 6 
SLC39A2 
NM_014579.3 SLC39A2 transcript variant 1     
NM_001256588.1  SLC39A2 transcript variant 2     
SLC39A3 NM_144564.4 SLC39A3 transcript variant 1 NM_213568.1 SLC39A3 transcript variant 2 
SLC39A4 
NM_017767.2 SLC39A4 transcript variant 1     
NM_130849.3  SLC39A4 transcript variant 2     
SLC39A5 
NM_173596.2  SLC39A5 transcript variant 1     
NM_001135195.1  SLC39A5 transcript variant 2     
SLC39A6 
NM_012319.3  SLC39A6 transcript variant 1     
NM_001099406.1  SLC39A6 transcript variant 2     
SLC39A7 NM_006979.2 SLC39A7 transcript variant 1 
NM_001077516.1 SLC39A7 transcript variant 2 
NM_001288777.1 SLC39A7 transcript variant 3 
SLC39A8 
NM_022154.5 SLC39A8 transcript variant 1     
NM_001135146.1  SLC39A8 transcript variant 2     
NM_001135147.1 SLC39A8 transcript variant 3     
NM_001135148.1 SLC39A8 transcript variant 4     
SLC39A9 NM_018375.4 SLC39A9 transcript variant 1 NM_001252148.1 SLC39A9 transcript variant 2 
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NM_001252150.1 SLC39A9 transcript variant 3 
NM_001252151.1 SLC39A9 transcript variant 4 
NM_001252152.1 SLC39A9 transcript variant 5 
NM_001330185.1 SLC39A9 transcript variant 6 
SLC39A10 
NM_001127257.1 SLC39A10 transcript variant 1     
NM_020342.2 SLC39A10 transcript variant 2     
SLC39A11 
NM_001159770.1 SLC39A11 transcript variant 1     
NM_139177.3  SLC39A11 transcript variant 2     
NM_001352691.1  SLC39A11 transcript variant 3     
NM_001352692.1  SLC39A11 transcript variant 4     
NM_001352693.1  SLC39A11 transcript variant 5     
SLC39A12 
NM_001145195.1 SLC39A12 transcript variant 1     
NM_152725.3  SLC39A12 transcript variant 2     
NM_001282733.1  SLC39A12 transcript variant 3     
SLC39A13 
NM_001128225.2 SLC39A13 transcript variant 1     
NM_152264.4 SLC39A13 transcript variant 2     
NM_001330245.1 SLC39A13 transcript variant 4     
SLC39A14 
NM_001128431.3 SLC39A12 transcript variant 1 
NM_001135154.2 SLC39A12 transcript variant 4 
NM_015359.5 SLC39A12 transcript variant 2 
NM_001135153.2 SLC39A12 transcript variant 3 
NM_001351655.1  SLC39A12 transcript variant 5 
NM_001351657.1 SLC39A12 transcript variant 6 
NM_001351658.1  SLC39A12 transcript variant 7 
NM_001351656.1  SLC39A12 transcript variant 8 
NM_001351659.1  SLC39A12 transcript variant 9 






































Appendix 12. Genes upregulated by zinc depletion in both MIN6 cells 
and islets (p <0.05) 
Gene Symbol p-value q-value Difference Fold change 
Gm36990 0.000167 0.70930157 1.526968 2.88179558 
Casp9 0.000211 0.70930157 1.84394 3.58989095 
Pls1 0.001551 0.70930157 0.53514 1.44908275 
Gm19426 0.002214 0.70930157 1.67434 3.19173282 
Fam186a 0.0023 0.70930157 1.37954 2.60185414 
Gm6451 0.005478 0.70930157 1.31364 2.4856792 
4933407K13Rik 0.005532 0.70930157 1.526954 2.88176748 
Anks1b 0.010257 0.70930157 1.20996 2.3133122 
Ppip5k2 0.01028 0.70930157 0.825689 1.7723808 
Pctp 0.010302 0.70930157 1.37956 2.60189026 
Gm16140 0.010752 0.70930157 0.42794 1.34531124 
Mob3c 0.011446 0.70930157 1.696546 3.24123998 
Avil 0.014266 0.70930157 1.284826 2.43652651 
Abcd1 0.021673 0.70930157 1.599433 3.03024135 
Tigd2 0.025656 0.70930157 1.062552 2.08862281 
Hlf 0.027822 0.70930157 1.20998 2.31334393 
B930095G15Rik 0.028085 0.70930157 1.062583 2.08866785 
Gm15664 0.028085 0.70930157 1.06256 2.08863437 
Gm28892 0.030101 0.70930157 0.5973 1.51288255 
AC139319.1 0.032391 0.70930157 1.0649 2.09202493 
BC005624 0.037613 0.70930157 1.20995 2.31329615 
Itga2 0.040831 0.70930157 0.67708 1.59890036 
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Lcmt1 0.041302 0.70930157 1.062576 2.0886575 
Gm9115 0.046622 0.70930157 1.062578 2.08866078 
Gldc 0.047528 0.70930157 0.706361 1.63168363 
Ecd 0.047914 0.70930157 0.808016 1.75080201 
Cpb2 0.049531 0.70930157 1.115247 2.16632043 



































Appendix 13. Genes downregulated by zinc depletion in both MIN6 
cells and islets (p <0.05) 
Gene Symbol p-value q-value Difference Fold change 
Hcar2 0.001706 0.709301573 -1.15816 0.448084 
Yipf6 0.00374 0.709301573 -1.1703 0.44433 
Zfp92 0.004825 0.709301573 -1.62315 0.324625 
Rassf10 0.005292 0.709301573 -0.67744 0.625274 
4933417C20Rik 0.006045 0.709301573 -1.15636 0.448642 
Gm44442 0.012097 0.709301573 -1.28158 0.411345 
Acaa1a 0.012145 0.709301573 -0.62062 0.650391 
Vta1 0.013988 0.709301573 -1.30379 0.405062 
Ripply3 0.01402 0.709301573 -1.15639 0.448634 
Papd4 0.014635 0.709301573 -0.98677 0.504606 
H2-Q10 0.017707 0.709301573 -1.15637 0.44864 
Kdm4b 0.018123 0.709301573 -1.82885 0.28149 
Bicd1 0.020089 0.709301573 -1.42894 0.371404 
Gm26637 0.021669 0.709301573 -0.9313 0.524386 
Fbxo2 0.022091 0.709301573 -1.60615 0.328473 
Gas2l2 0.022357 0.709301573 -1.13419 0.455592 
Ift81 0.023246 0.709301573 -1.17029 0.444333 
Cpne3 0.025662 0.709301573 -1.75355 0.29657 
Idh3b 0.03045 0.709301573 -1.19209 0.437667 
Tep1 0.030841 0.709301573 -1.18997 0.438311 
Pole4 0.032652 0.709301573 -0.98678 0.504602 
Gm45081 0.035358 0.709301573 -1.47336 0.360143 
1700034H15Rik 0.036607 0.709301573 -0.59178 0.663524 
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Mrpl23 0.039678 0.709301573 -0.98678 0.504602 
Cd82 0.039691 0.709301573 -1.1342 0.455589 
Ncf1 0.041164 0.709301573 -0.62849 0.646854 
Minpp1 0.04117 0.709301573 -0.4768 0.71857 
A230057D06Rik 0.041298 0.709301573 -0.98678 0.504602 
Rps12-ps3 0.042295 0.709301573 -0.83938 0.558884 
B330016D10Rik 0.042429 0.709301573 -1.37863 0.384583 
Dennd5a 0.045699 0.709301573 -0.99439 0.501949 




































Appendix 14. Survival of MIN6 cells in response to changes in 
extracellular zinc at 48 h  
(A) MIN6 cell proliferation, calculated by BrdU incorporation. (B) MIN6 cell apoptosis, 
measured by Caspase 3/7 assays. (C) MIN6 cell oxidative stress, measured by 
dihydrofluorescin diacetate fluorescence. (D-F) Phosphorylation of RPS6 and ERK1/2. 
(D) Immunoblots for Ser235/236 RPS6, RPS6, p42/p44 ERK1/2 and ERK1/2. (E-F) 
Quantification of immunoblots for (E) Ser235/236 RPS6 vs RPS6 and (F) p42/p44 
ERK1/2 vs ERK1/2. Immunoblot quantification was carried out using ImageJ software.  
All experiments were carried out following culture of MIN6 cells with 1µM, 8µM or 
42µM zinc for 48 h. Results are relative to MIN6 cells in 8µM zinc (control). Data were 
analysed by 2-way ANOVA followed by Tukey’s multiple comparison test. Error bars 





Appendix 15. MIN6 cell insulin gene expression and insulin secretion 
in response to changes in extracellular zinc at 24 and 48 h  
(A-B) Abundance of Ins1 and Ins2 mRNA expression following culture with 1µM, 8µM 
or 42µM zinc for (A) 24 or (B) 48 h. Expression was assayed through qPCR and 
calculated as FD (Log2) relative to MIN6 cells cultured with 8µM zinc (control). (C-D) 
Insulin secretion from MIN6 cells in response to 3mM glucose (basal) or 40mM KCl 
(stimulated) following culture with 1µM, 8µM or 42µM zinc for (C) 24 or (D) 48 h. The 
amounts of secreted insulin were calculated through insulin secretion assays and 
normalised to total protein. Data were analysed by 2-way ANOVA followed by Tukey’s 
multiple comparison test. Error bars show ± SEM. N=3. 
 
